WO2022263927A2 - Plasmalogen derivatives and uses thereof - Google Patents
Plasmalogen derivatives and uses thereof Download PDFInfo
- Publication number
- WO2022263927A2 WO2022263927A2 PCT/IB2022/000336 IB2022000336W WO2022263927A2 WO 2022263927 A2 WO2022263927 A2 WO 2022263927A2 IB 2022000336 W IB2022000336 W IB 2022000336W WO 2022263927 A2 WO2022263927 A2 WO 2022263927A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- tautomer
- solvate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 415
- 150000003839 salts Chemical class 0.000 claims abstract description 217
- 239000012453 solvate Substances 0.000 claims abstract description 183
- 239000013078 crystal Substances 0.000 claims abstract description 179
- 239000000651 prodrug Substances 0.000 claims abstract description 168
- 229940002612 prodrug Drugs 0.000 claims abstract description 168
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 123
- 201000010099 disease Diseases 0.000 claims abstract description 95
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 62
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 22
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 22
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 16
- 208000016361 genetic disease Diseases 0.000 claims abstract description 16
- 208000019693 Lung disease Diseases 0.000 claims abstract description 14
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 13
- 208000017520 skin disease Diseases 0.000 claims abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 11
- 208000019423 liver disease Diseases 0.000 claims abstract description 11
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 11
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 10
- 230000002062 proliferating effect Effects 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 208000014951 hematologic disease Diseases 0.000 claims abstract description 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 208000019229 Spleen disease Diseases 0.000 claims abstract description 8
- 208000027140 splenic disease Diseases 0.000 claims abstract description 8
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 7
- 208000026278 immune system disease Diseases 0.000 claims abstract description 7
- 208000012268 mitochondrial disease Diseases 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 184
- 239000001257 hydrogen Substances 0.000 claims description 184
- 125000000217 alkyl group Chemical group 0.000 claims description 161
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 145
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 126
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 118
- 125000003342 alkenyl group Chemical group 0.000 claims description 117
- -1 ethylene, propylene Chemical group 0.000 claims description 111
- 125000004432 carbon atom Chemical group C* 0.000 claims description 95
- 125000000623 heterocyclic group Chemical group 0.000 claims description 86
- 229910052736 halogen Inorganic materials 0.000 claims description 66
- 150000002367 halogens Chemical group 0.000 claims description 65
- 229910052799 carbon Inorganic materials 0.000 claims description 61
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 57
- 125000001188 haloalkyl group Chemical group 0.000 claims description 51
- 229910052731 fluorine Inorganic materials 0.000 claims description 43
- 239000011737 fluorine Substances 0.000 claims description 43
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 39
- 229910052805 deuterium Inorganic materials 0.000 claims description 39
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 125000002947 alkylene group Chemical group 0.000 claims description 30
- 208000035475 disorder Diseases 0.000 claims description 28
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 26
- 206010012289 Dementia Diseases 0.000 claims description 25
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 23
- 125000001153 fluoro group Chemical group F* 0.000 claims description 23
- 125000002619 bicyclic group Chemical group 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 208000018737 Parkinson disease Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims description 12
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 12
- 210000003169 central nervous system Anatomy 0.000 claims description 12
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 10
- 201000004810 Vascular dementia Diseases 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 201000002832 Lewy body dementia Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims description 5
- 201000004525 Zellweger Syndrome Diseases 0.000 claims description 5
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 210000000133 brain stem Anatomy 0.000 claims description 5
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 208000020547 Peroxisomal disease Diseases 0.000 claims description 3
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 3
- 108700011014 Congenital Deficiency of Pulmonary Surfactant Protein B Proteins 0.000 claims description 2
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 13
- 150000004677 hydrates Chemical class 0.000 abstract description 9
- 230000008499 blood brain barrier function Effects 0.000 abstract description 8
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 8
- 210000004155 blood-retinal barrier Anatomy 0.000 abstract description 7
- 230000004378 blood-retinal barrier Effects 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 3
- 125000000304 alkynyl group Chemical group 0.000 description 65
- 235000013350 formula milk Nutrition 0.000 description 61
- 150000001721 carbon Chemical group 0.000 description 47
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 41
- 206010028980 Neoplasm Diseases 0.000 description 35
- 229910052757 nitrogen Inorganic materials 0.000 description 31
- 125000005842 heteroatom Chemical group 0.000 description 29
- 125000001424 substituent group Chemical group 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 25
- 125000004433 nitrogen atom Chemical group N* 0.000 description 23
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 22
- 230000036407 pain Effects 0.000 description 22
- 239000002253 acid Substances 0.000 description 20
- 125000002950 monocyclic group Chemical group 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 125000004431 deuterium atom Chemical group 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 229910052717 sulfur Chemical group 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 125000004404 heteroalkyl group Chemical group 0.000 description 13
- 239000001301 oxygen Chemical group 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000011593 sulfur Chemical group 0.000 description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 125000004991 fluoroalkenyl group Chemical group 0.000 description 11
- 125000000262 haloalkenyl group Chemical group 0.000 description 11
- 125000004430 oxygen atom Chemical group O* 0.000 description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 208000006673 asthma Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 9
- 201000004624 Dermatitis Diseases 0.000 description 9
- 208000001089 Multiple system atrophy Diseases 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 201000006417 multiple sclerosis Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- 208000011231 Crohn disease Diseases 0.000 description 8
- 208000007465 Giant cell arteritis Diseases 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 208000023105 Huntington disease Diseases 0.000 description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 7
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000004968 inflammatory condition Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 206010043207 temporal arteritis Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 6
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical group C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 6
- 208000007502 anemia Diseases 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 206010006451 bronchitis Diseases 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 6
- 201000005962 mycosis fungoides Diseases 0.000 description 6
- 150000002829 nitrogen Chemical group 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 208000020925 Bipolar disease Diseases 0.000 description 5
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- 206010027145 Melanocytic naevus Diseases 0.000 description 5
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 5
- 229910002651 NO3 Inorganic materials 0.000 description 5
- 208000009905 Neurofibromatoses Diseases 0.000 description 5
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 5
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 208000005587 Refsum Disease Diseases 0.000 description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 201000001981 dermatomyositis Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 201000004931 neurofibromatosis Diseases 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 5
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 4
- 208000020706 Autistic disease Diseases 0.000 description 4
- 206010062804 Basal cell naevus syndrome Diseases 0.000 description 4
- 208000009137 Behcet syndrome Diseases 0.000 description 4
- 206010060999 Benign neoplasm Diseases 0.000 description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 4
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000012514 Cumulative Trauma disease Diseases 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 4
- 208000031995 Gorlin syndrome Diseases 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- 206010018634 Gouty Arthritis Diseases 0.000 description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 4
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000005615 Interstitial Cystitis Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 4
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 4
- 208000007256 Nevus Diseases 0.000 description 4
- 206010053854 Opsoclonus myoclonus Diseases 0.000 description 4
- 206010031127 Orthostatic hypotension Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000024777 Prion disease Diseases 0.000 description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 229940050390 benzoate Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 4
- 229940043264 dodecyl sulfate Drugs 0.000 description 4
- 206010013663 drug dependence Diseases 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 208000008384 ileus Diseases 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 208000005264 motor neuron disease Diseases 0.000 description 4
- 206010028537 myelofibrosis Diseases 0.000 description 4
- 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 208000022821 personality disease Diseases 0.000 description 4
- 208000005987 polymyositis Diseases 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical group [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 3
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010000591 Acrochordon Diseases 0.000 description 3
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- 201000003076 Angiosarcoma Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010006811 Bursitis Diseases 0.000 description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 206010012426 Dermal cyst Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 3
- 208000010305 Epidermal Cyst Diseases 0.000 description 3
- 208000007985 Erythema Infectiosum Diseases 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 206010016936 Folliculitis Diseases 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- 208000024412 Friedreich ataxia Diseases 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 description 3
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 206010023347 Keratoacanthoma Diseases 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- 208000006136 Leigh Disease Diseases 0.000 description 3
- 208000017507 Leigh syndrome Diseases 0.000 description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 description 3
- 206010024612 Lipoma Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000026072 Motor neurone disease Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 208000001294 Nociceptive Pain Diseases 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 206010037549 Purpura Diseases 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 206010043255 Tendonitis Diseases 0.000 description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 208000018839 Wilson disease Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 description 3
- 208000030597 adult Refsum disease Diseases 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 125000003725 azepanyl group Chemical group 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 208000002458 carcinoid tumor Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 208000007784 diverticulitis Diseases 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 208000025750 heavy chain disease Diseases 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 208000003906 hydrocephalus Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 description 3
- 208000037244 polycythemia vera Diseases 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 208000003476 primary myelofibrosis Diseases 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 208000002574 reactive arthritis Diseases 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- 201000004415 tendinitis Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
- 208000009999 tuberous sclerosis Diseases 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 3
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2
- 201000011374 Alagille syndrome Diseases 0.000 description 2
- 206010001557 Albinism Diseases 0.000 description 2
- 208000036022 Alpers' disease Diseases 0.000 description 2
- 208000006503 Amebic Liver Abscess Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010002941 Apallic syndrome Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 206010073360 Appendix cancer Diseases 0.000 description 2
- 206010003101 Arnold-Chiari Malformation Diseases 0.000 description 2
- 206010003267 Arthritis reactive Diseases 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 2
- 206010003402 Arthropod sting Diseases 0.000 description 2
- 208000033116 Asbestos intoxication Diseases 0.000 description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 2
- 206010004265 Benign familial pemphigus Diseases 0.000 description 2
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 201000004085 CLL/SLL Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 201000006867 Charcot-Marie-Tooth disease type 4 Diseases 0.000 description 2
- 208000015321 Chiari malformation Diseases 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 2
- 206010009895 Colitis ischaemic Diseases 0.000 description 2
- 206010056979 Colitis microscopic Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000012609 Cowden disease Diseases 0.000 description 2
- 201000002847 Cowden syndrome Diseases 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 2
- 206010014190 Eczema asteatotic Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000005866 Exanthema Subitum Diseases 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- 208000037574 Familial benign chronic pemphigus Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical class NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000001034 Frostbite Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 208000015872 Gaucher disease Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- 208000027655 Hailey-Hailey disease Diseases 0.000 description 2
- 208000002125 Hemangioendothelioma Diseases 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 206010019629 Hepatic adenoma Diseases 0.000 description 2
- 206010063741 Hepatic amoebiasis Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 2
- 206010063491 Herpes zoster oticus Diseases 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010021750 Infantile Spasms Diseases 0.000 description 2
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- 208000028226 Krabbe disease Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 2
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000000185 Localized scleroderma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 2
- 208000012583 Menkes disease Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 201000002983 Mobius syndrome Diseases 0.000 description 2
- 206010069681 Monomelic amyotrophy Diseases 0.000 description 2
- 206010027982 Morphoea Diseases 0.000 description 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 2
- 208000003926 Myelitis Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000010316 Myotonia congenita Diseases 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical class CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- 208000018909 Neonatal adrenoleukodystrophy Diseases 0.000 description 2
- 201000009053 Neurodermatitis Diseases 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 201000004602 Peliosis Hepatis Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
- 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 2
- 206010036186 Porphyria non-acute Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 206010054048 Postoperative ileus Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- 201000007981 Reye syndrome Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000021235 Schilder disease Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 201000003696 Sotos syndrome Diseases 0.000 description 2
- 201000010829 Spina bifida Diseases 0.000 description 2
- 208000006097 Spinal Dysraphism Diseases 0.000 description 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 206010042658 Sweat gland tumour Diseases 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000034799 Tauopathies Diseases 0.000 description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 201000003379 Townes-Brocks syndrome Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047141 Vasodilatation Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 201000006791 West syndrome Diseases 0.000 description 2
- 206010049644 Williams syndrome Diseases 0.000 description 2
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 206010001689 alkaptonuria Diseases 0.000 description 2
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 201000003465 angular cheilitis Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 208000021780 appendiceal neoplasm Diseases 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 206010003441 asbestosis Diseases 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 206010005159 blepharospasm Diseases 0.000 description 2
- 230000000744 blepharospasm Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000006431 brachial plexus neuropathy Diseases 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
- 208000007287 cheilitis Diseases 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 229910052729 chemical element Inorganic materials 0.000 description 2
- 208000010575 cherry hemangioma Diseases 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 208000008609 collagenous colitis Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
- 125000004976 cyclobutylene group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004956 cyclohexylene group Chemical group 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004979 cyclopentylene group Chemical group 0.000 description 2
- 125000004980 cyclopropylene group Chemical group 0.000 description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 description 2
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 201000008243 diversion colitis Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010013932 dyslexia Diseases 0.000 description 2
- 208000002169 ectodermal dysplasia Diseases 0.000 description 2
- 206010057271 eosinophilic colitis Diseases 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 201000001561 eosinophilic gastritis Diseases 0.000 description 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 2
- 201000006517 essential tremor Diseases 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 208000002980 facial hemiatrophy Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 201000011349 geniculate herpes zoster Diseases 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 201000010118 hypomelanosis of Ito Diseases 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000027138 indeterminate colitis Diseases 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 229940099584 lactobionate Drugs 0.000 description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 206010024217 lentigo Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000028454 lice infestation Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229960001078 lithium Drugs 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 208000004341 lymphocytic colitis Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 201000005545 motor peripheral neuropathy Diseases 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 201000010193 neural tube defect Diseases 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 206010033898 parapsoriasis Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 2
- 208000005026 persistent vegetative state Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229940075930 picrate Drugs 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 208000003619 porokeratosis Diseases 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 201000007271 pre-malignant neoplasm Diseases 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical class CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical class [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 208000001381 pseudotumor cerebri Diseases 0.000 description 2
- 201000010914 pustulosis of palm and sole Diseases 0.000 description 2
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- 201000003385 seborrheic keratosis Diseases 0.000 description 2
- 208000002477 septooptic dysplasia Diseases 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000000195 skin tag Diseases 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 208000002419 toxicodendron dermatitis Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 125000002348 vinylic group Chemical group 0.000 description 2
- DFNJPPOAVCXQQQ-UHFFFAOYSA-N (1,1,1-trichloro-2-methylpropan-2-yl) carbamate Chemical compound ClC(Cl)(Cl)C(C)(C)OC(N)=O DFNJPPOAVCXQQQ-UHFFFAOYSA-N 0.000 description 1
- AXTXAVIVKGDCLE-UHFFFAOYSA-N (1,1-dibromo-2-methylpropan-2-yl) carbamate Chemical compound BrC(Br)C(C)(C)OC(N)=O AXTXAVIVKGDCLE-UHFFFAOYSA-N 0.000 description 1
- AFCTUKSQTSHXEZ-UHFFFAOYSA-N (1-cyano-2-methylpropan-2-yl) carbamate Chemical compound N#CCC(C)(C)OC(N)=O AFCTUKSQTSHXEZ-UHFFFAOYSA-N 0.000 description 1
- FTVXFBJENACRRL-UHFFFAOYSA-N (1-hydroxypiperidin-2-yl) carbamate Chemical compound NC(=O)OC1CCCCN1O FTVXFBJENACRRL-UHFFFAOYSA-N 0.000 description 1
- KLWCNEYVHPBUNM-UHFFFAOYSA-N (1-methylcyclobutyl) carbamate Chemical compound NC(=O)OC1(C)CCC1 KLWCNEYVHPBUNM-UHFFFAOYSA-N 0.000 description 1
- AKIHTGIGOHBKGE-UHFFFAOYSA-N (1-methylcyclohexyl) carbamate Chemical compound NC(=O)OC1(C)CCCCC1 AKIHTGIGOHBKGE-UHFFFAOYSA-N 0.000 description 1
- ZLIHDHDAJVINAN-UHFFFAOYSA-N (2,4,6-trimethyl-3-pyridin-2-ylphenyl)methanimine Chemical compound CC1=C(C=N)C(C)=CC(C)=C1C1=CC=CC=N1 ZLIHDHDAJVINAN-UHFFFAOYSA-N 0.000 description 1
- KJOPTLWVYZCJBX-UHFFFAOYSA-N (2,4,6-trimethylphenyl)methyl carbamate Chemical compound CC1=CC(C)=C(COC(N)=O)C(C)=C1 KJOPTLWVYZCJBX-UHFFFAOYSA-N 0.000 description 1
- IUZVXNNZBSTDJT-UHFFFAOYSA-N (2,4,6-tritert-butylphenyl) carbamate Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=C(OC(N)=O)C(C(C)(C)C)=C1 IUZVXNNZBSTDJT-UHFFFAOYSA-N 0.000 description 1
- LZZRHUUMSXNYBI-UHFFFAOYSA-N (2,4-dichlorophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Cl)C=C1Cl LZZRHUUMSXNYBI-UHFFFAOYSA-N 0.000 description 1
- LEDMDNAHWYVAPC-UHFFFAOYSA-N (2-carbamoylphenyl)methyl benzoate Chemical compound NC(=O)C1=CC=CC=C1COC(=O)C1=CC=CC=C1 LEDMDNAHWYVAPC-UHFFFAOYSA-N 0.000 description 1
- SWHAGWLVMRLFKO-UHFFFAOYSA-N (2-nitrophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1[N+]([O-])=O SWHAGWLVMRLFKO-UHFFFAOYSA-N 0.000 description 1
- PMIODTBPFKLUMF-UHFFFAOYSA-N (2-nitrophenyl)methyl hydrogen carbonate Chemical compound OC(=O)OCC1=CC=CC=C1[N+]([O-])=O PMIODTBPFKLUMF-UHFFFAOYSA-N 0.000 description 1
- ZTESKPLFUKCHOF-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methyl hydrogen carbonate Chemical compound COC1=CC=C(COC(O)=O)C=C1OC ZTESKPLFUKCHOF-UHFFFAOYSA-N 0.000 description 1
- HIPYHINICCKLGX-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methyl carbamate Chemical compound COC1=CC(COC(N)=O)=CC(OC)=C1 HIPYHINICCKLGX-UHFFFAOYSA-N 0.000 description 1
- YVOBGLMMNWZYCL-UHFFFAOYSA-N (3-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=CC([N+]([O-])=O)=C1 YVOBGLMMNWZYCL-UHFFFAOYSA-N 0.000 description 1
- AWOKSNNHYRGYIA-UHFFFAOYSA-N (4,5-dimethoxy-2-nitrophenyl)methyl carbamate Chemical compound COC1=CC(COC(N)=O)=C([N+]([O-])=O)C=C1OC AWOKSNNHYRGYIA-UHFFFAOYSA-N 0.000 description 1
- XHTUZBFAOYRMHI-UHFFFAOYSA-N (4-bromophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Br)C=C1 XHTUZBFAOYRMHI-UHFFFAOYSA-N 0.000 description 1
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- HIIOEWGKFCWTJU-UHFFFAOYSA-N (4-chlorophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(Cl)C=C1 HIIOEWGKFCWTJU-UHFFFAOYSA-N 0.000 description 1
- NULWVEYYQSYAHP-UHFFFAOYSA-N (4-cyanophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(C#N)C=C1 NULWVEYYQSYAHP-UHFFFAOYSA-N 0.000 description 1
- IERCGNSLWQVTPC-UHFFFAOYSA-N (4-decoxyphenyl)methyl carbamate Chemical compound CCCCCCCCCCOC1=CC=C(COC(N)=O)C=C1 IERCGNSLWQVTPC-UHFFFAOYSA-N 0.000 description 1
- QXENIPSNYCZWNY-UHFFFAOYSA-N (4-methoxyphenyl)-diphenylmethanamine Chemical compound C1=CC(OC)=CC=C1C(N)(C=1C=CC=CC=1)C1=CC=CC=C1 QXENIPSNYCZWNY-UHFFFAOYSA-N 0.000 description 1
- OKLFHGKWEQKSDZ-UHFFFAOYSA-N (4-methoxyphenyl)methanimine Chemical compound COC1=CC=C(C=N)C=C1 OKLFHGKWEQKSDZ-UHFFFAOYSA-N 0.000 description 1
- SDEOSHAQCMPJIJ-UHFFFAOYSA-N (4-methoxyphenyl)methyl carbamate Chemical compound COC1=CC=C(COC(N)=O)C=C1 SDEOSHAQCMPJIJ-UHFFFAOYSA-N 0.000 description 1
- HZFLPRPFCHEBPQ-UHFFFAOYSA-N (4-methoxyphenyl)methyl hydrogen carbonate Chemical compound COC1=CC=C(COC(O)=O)C=C1 HZFLPRPFCHEBPQ-UHFFFAOYSA-N 0.000 description 1
- WNNZAHBBDIVWBB-UHFFFAOYSA-N (4-methylsulfanylphenyl) carbamate Chemical compound CSC1=CC=C(OC(N)=O)C=C1 WNNZAHBBDIVWBB-UHFFFAOYSA-N 0.000 description 1
- RZTAQRMRWPYVRR-UHFFFAOYSA-N (4-methylsulfinylphenyl)methyl carbamate Chemical compound CS(=O)C1=CC=C(COC(N)=O)C=C1 RZTAQRMRWPYVRR-UHFFFAOYSA-N 0.000 description 1
- LRJOVUGHUMSKFA-UHFFFAOYSA-N (4-nitrophenyl)methanimine Chemical compound [O-][N+](=O)C1=CC=C(C=N)C=C1 LRJOVUGHUMSKFA-UHFFFAOYSA-N 0.000 description 1
- HQNKOEZESXBYJA-UHFFFAOYSA-N (4-phenyldiazenylphenyl)methyl carbamate Chemical compound C1=CC(COC(=O)N)=CC=C1N=NC1=CC=CC=C1 HQNKOEZESXBYJA-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 description 1
- RASLWNGTMHFPIQ-AATRIKPKSA-N (e)-3-(2-nitrophenyl)prop-2-enamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1[N+]([O-])=O RASLWNGTMHFPIQ-AATRIKPKSA-N 0.000 description 1
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GLUABPSZMHYCNO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,2-b]pyrrole Chemical compound N1CCC2NCCC21 GLUABPSZMHYCNO-UHFFFAOYSA-N 0.000 description 1
- 125000005904 1,2,3,4-tetrahydro-1,6-naphthyridinyl group Chemical group 0.000 description 1
- TTXKLVVJWALEOY-UHFFFAOYSA-N 1,2-benzoxazol-5-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=C2ON=CC2=C1 TTXKLVVJWALEOY-UHFFFAOYSA-N 0.000 description 1
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 1
- 125000005895 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl group Chemical group 0.000 description 1
- FJANNOJSTOGZHK-UHFFFAOYSA-N 1-adamantyl carbamate Chemical compound C1C(C2)CC3CC2CC1(OC(=O)N)C3 FJANNOJSTOGZHK-UHFFFAOYSA-N 0.000 description 1
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
- XIUQHVQLGXTGGN-UHFFFAOYSA-N 1-cyclopropylethyl carbamate Chemical compound NC(=O)OC(C)C1CC1 XIUQHVQLGXTGGN-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000005894 1H-benzo[e][1,4]diazepinyl group Chemical group 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical class OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical class NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- XNMOEWPBTNQAQB-UHFFFAOYSA-N 2,2,5,7,8-pentamethyl-3,4-dihydrochromene-6-sulfonamide Chemical compound C1CC(C)(C)OC2=C1C(C)=C(S(N)(=O)=O)C(C)=C2C XNMOEWPBTNQAQB-UHFFFAOYSA-N 0.000 description 1
- 125000005899 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl group Chemical group 0.000 description 1
- 125000005900 2,3-dihydrofuro[2,3-b]pyridinyl group Chemical group 0.000 description 1
- PXVUDLXXKGSXHH-UHFFFAOYSA-N 2,4,6-trimethoxybenzenesulfonamide Chemical compound COC1=CC(OC)=C(S(N)(=O)=O)C(OC)=C1 PXVUDLXXKGSXHH-UHFFFAOYSA-N 0.000 description 1
- YECJUZIGFPJWGQ-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonamide Chemical compound CC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 YECJUZIGFPJWGQ-UHFFFAOYSA-N 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- YJRISODHEYGPEL-UHFFFAOYSA-N 2,6-dimethoxy-4-methylbenzenesulfonamide Chemical compound COC1=CC(C)=CC(OC)=C1S(N)(=O)=O YJRISODHEYGPEL-UHFFFAOYSA-N 0.000 description 1
- DWKLSWPFGOTZII-UHFFFAOYSA-N 2-(1-adamantyl)propan-2-yl carbamate Chemical compound C1C(C2)CC3CC2CC1(C(C)(OC(N)=O)C)C3 DWKLSWPFGOTZII-UHFFFAOYSA-N 0.000 description 1
- YURLCYGZYWDCHL-UHFFFAOYSA-N 2-(2,6-dichloro-4-methylphenoxy)acetic acid Chemical compound CC1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 YURLCYGZYWDCHL-UHFFFAOYSA-N 0.000 description 1
- DVCVYHFEWYAJCP-UHFFFAOYSA-N 2-(2-nitrophenoxy)acetamide Chemical compound NC(=O)COC1=CC=CC=C1[N+]([O-])=O DVCVYHFEWYAJCP-UHFFFAOYSA-N 0.000 description 1
- XHNQIEUUMIBVBX-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)propan-2-yl carbamate Chemical compound COC1=CC(OC)=CC(C(C)(C)OC(N)=O)=C1 XHNQIEUUMIBVBX-UHFFFAOYSA-N 0.000 description 1
- KPJXVLVCTUUFBA-UHFFFAOYSA-N 2-(3,5-ditert-butylphenyl)propan-2-yl carbamate Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C(C)(C)OC(N)=O)=C1 KPJXVLVCTUUFBA-UHFFFAOYSA-N 0.000 description 1
- JTQUNAJHSFYGSN-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonylethyl carbamate Chemical compound CC1=CC=C(S(=O)(=O)CCOC(N)=O)C=C1 JTQUNAJHSFYGSN-UHFFFAOYSA-N 0.000 description 1
- RHTMIQNZSGHFCN-UHFFFAOYSA-N 2-(4-phenyldiazenylphenyl)propan-2-yl carbamate Chemical compound C1=CC(C(C)(OC(N)=O)C)=CC=C1N=NC1=CC=CC=C1 RHTMIQNZSGHFCN-UHFFFAOYSA-N 0.000 description 1
- KXKIBGGGFMXVBJ-UHFFFAOYSA-N 2-(4-phenylphenyl)propan-2-yl carbamate Chemical compound C1=CC(C(C)(OC(N)=O)C)=CC=C1C1=CC=CC=C1 KXKIBGGGFMXVBJ-UHFFFAOYSA-N 0.000 description 1
- FGJAPOYTPXTLPY-UHFFFAOYSA-N 2-(benzylideneamino)-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1N=CC1=CC=CC=C1 FGJAPOYTPXTLPY-UHFFFAOYSA-N 0.000 description 1
- TYYAMZMDZWXHHA-UHFFFAOYSA-N 2-(dibromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(Br)Br TYYAMZMDZWXHHA-UHFFFAOYSA-N 0.000 description 1
- NEESBXODYBPTFM-UHFFFAOYSA-N 2-(methylsulfanylmethoxy)ethyl hydrogen carbonate Chemical compound CSCOCCOC(O)=O NEESBXODYBPTFM-UHFFFAOYSA-N 0.000 description 1
- JGYNXZIYXGSEJH-UHFFFAOYSA-N 2-(methylsulfanylmethoxymethyl)benzoic acid Chemical compound CSCOCC1=CC=CC=C1C(O)=O JGYNXZIYXGSEJH-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- QXQMENSTZKYZCE-UHFFFAOYSA-N 2-[2,4-bis(2-methylbutan-2-yl)phenoxy]acetic acid Chemical compound CCC(C)(C)C1=CC=C(OCC(O)=O)C(C(C)(C)CC)=C1 QXQMENSTZKYZCE-UHFFFAOYSA-N 0.000 description 1
- XTRFZKJEMAVUIK-UHFFFAOYSA-N 2-[2,6-dichloro-4-(2,4,4-trimethylpentan-2-yl)phenoxy]acetic acid Chemical compound CC(C)(C)CC(C)(C)C1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 XTRFZKJEMAVUIK-UHFFFAOYSA-N 0.000 description 1
- UJRMHFPTLFNSTA-UHFFFAOYSA-N 2-chloro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)O)C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-N 0.000 description 1
- SHHKMWMIKILKQW-UHFFFAOYSA-N 2-formylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=O SHHKMWMIKILKQW-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-M 2-iodobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-M 0.000 description 1
- UYCIUCIKUGYNBR-UHFFFAOYSA-N 2-iodoethyl carbamate Chemical compound NC(=O)OCCI UYCIUCIKUGYNBR-UHFFFAOYSA-N 0.000 description 1
- LPUAWADEOBHDIP-UHFFFAOYSA-N 2-methyl-2-(2-nitrophenoxy)propanamide Chemical compound NC(=O)C(C)(C)OC1=CC=CC=C1[N+]([O-])=O LPUAWADEOBHDIP-UHFFFAOYSA-N 0.000 description 1
- OBEJXZIQPCOKSK-UHFFFAOYSA-N 2-methyl-2-(2-phenyldiazenylphenoxy)propanamide Chemical compound NC(=O)C(C)(C)OC1=CC=CC=C1N=NC1=CC=CC=C1 OBEJXZIQPCOKSK-UHFFFAOYSA-N 0.000 description 1
- SDJNOBUNFYNROE-UHFFFAOYSA-N 2-methylbut-3-yn-2-yl carbamate Chemical compound C#CC(C)(C)OC(N)=O SDJNOBUNFYNROE-UHFFFAOYSA-N 0.000 description 1
- AUQKXXDHDKEBEY-UHFFFAOYSA-N 2-methylbutan-2-yl carbamate Chemical compound CCC(C)(C)OC(N)=O AUQKXXDHDKEBEY-UHFFFAOYSA-N 0.000 description 1
- BRUZQRBVNRKLJG-UHFFFAOYSA-N 2-methylpropyl carbamate Chemical compound CC(C)COC(N)=O BRUZQRBVNRKLJG-UHFFFAOYSA-N 0.000 description 1
- OWXVECVXBTWHPP-UHFFFAOYSA-N 2-methylsulfanylethyl carbamate Chemical compound CSCCOC(N)=O OWXVECVXBTWHPP-UHFFFAOYSA-N 0.000 description 1
- IXTODZAWAAKENF-UHFFFAOYSA-N 2-methylsulfonylethyl carbamate Chemical compound CS(=O)(=O)CCOC(N)=O IXTODZAWAAKENF-UHFFFAOYSA-N 0.000 description 1
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
- MUAUTBNKPSNTFM-UHFFFAOYSA-N 2-phenylethyl carbamate Chemical compound NC(=O)OCCC1=CC=CC=C1 MUAUTBNKPSNTFM-UHFFFAOYSA-N 0.000 description 1
- UCZSGRLQZLKLCQ-UHFFFAOYSA-N 2-phenylpropan-2-yl carbamate Chemical compound NC(=O)OC(C)(C)C1=CC=CC=C1 UCZSGRLQZLKLCQ-UHFFFAOYSA-N 0.000 description 1
- FCOXSVSQGYUZTB-UHFFFAOYSA-N 2-phosphanylethyl carbamate Chemical compound NC(=O)OCCP FCOXSVSQGYUZTB-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- WYECGUSLBPACPT-UHFFFAOYSA-N 2-pyridin-4-ylpropan-2-yl carbamate Chemical compound NC(=O)OC(C)(C)C1=CC=NC=C1 WYECGUSLBPACPT-UHFFFAOYSA-N 0.000 description 1
- MZASHBBAFBWNFL-UHFFFAOYSA-N 2-trimethylsilylethanesulfonamide Chemical compound C[Si](C)(C)CCS(N)(=O)=O MZASHBBAFBWNFL-UHFFFAOYSA-N 0.000 description 1
- XSXPJNJLDYOPTF-UHFFFAOYSA-N 2-trimethylsilylethoxymethanamine Chemical compound C[Si](C)(C)CCOCN XSXPJNJLDYOPTF-UHFFFAOYSA-N 0.000 description 1
- QWYTUBPAXJYCTH-UHFFFAOYSA-N 2-trimethylsilylethyl carbamate Chemical compound C[Si](C)(C)CCOC(N)=O QWYTUBPAXJYCTH-UHFFFAOYSA-N 0.000 description 1
- LDZNCSVWVMBVST-UHFFFAOYSA-N 2-trimethylsilylethyl hydrogen carbonate Chemical compound C[Si](C)(C)CCOC(O)=O LDZNCSVWVMBVST-UHFFFAOYSA-N 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- KADQHJDUFKAUEB-UHFFFAOYSA-N 3-(2-nitrophenyl)propanamide Chemical compound NC(=O)CCC1=CC=CC=C1[N+]([O-])=O KADQHJDUFKAUEB-UHFFFAOYSA-N 0.000 description 1
- OEHZEBOCZWCVMK-UHFFFAOYSA-N 3-(4-hydroxyphenyl)propanamide Chemical compound NC(=O)CCC1=CC=C(O)C=C1 OEHZEBOCZWCVMK-UHFFFAOYSA-N 0.000 description 1
- NRZLJLXOGSCRAO-UHFFFAOYSA-N 3-(4-nitrophenyl)prop-2-enyl carbamate Chemical compound NC(=O)OCC=CC1=CC=C([N+]([O-])=O)C=C1 NRZLJLXOGSCRAO-UHFFFAOYSA-N 0.000 description 1
- MTZNODTZOSBYJW-UHFFFAOYSA-N 3-amino-5,5-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CC(N)=CC(=O)C1 MTZNODTZOSBYJW-UHFFFAOYSA-N 0.000 description 1
- SCLGGNBFBLJQFU-UHFFFAOYSA-N 3-aminopropyl acetate Chemical compound CC(=O)OCCCN SCLGGNBFBLJQFU-UHFFFAOYSA-N 0.000 description 1
- UVODFYVXDPJZFJ-UHFFFAOYSA-N 3-methyl-3-nitrobutanamide Chemical compound [O-][N+](=O)C(C)(C)CC(N)=O UVODFYVXDPJZFJ-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical class NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- 125000005901 4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridinyl group Chemical group 0.000 description 1
- 125000005902 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl group Chemical group 0.000 description 1
- 125000005903 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl group Chemical group 0.000 description 1
- UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5h-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
- NDRAHSMAGKWWFZ-UHFFFAOYSA-N 4-(methylsulfanylmethoxy)butanoic acid Chemical compound CSCOCCCC(O)=O NDRAHSMAGKWWFZ-UHFFFAOYSA-N 0.000 description 1
- BLEFBWAGWNSEGB-UHFFFAOYSA-N 4-[(4,8-dimethoxynaphthalen-1-yl)methyl]benzenesulfonamide Chemical compound C12=C(OC)C=CC=C2C(OC)=CC=C1CC1=CC=C(S(N)(=O)=O)C=C1 BLEFBWAGWNSEGB-UHFFFAOYSA-N 0.000 description 1
- WAGMYTXJRVPMGW-UHFFFAOYSA-N 4-azidobutanoic acid Chemical compound OC(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-N 0.000 description 1
- QPSBONMVNZJUMM-UHFFFAOYSA-N 4-chloro-2-methanimidoylphenol Chemical compound OC1=CC=C(Cl)C=C1C=N QPSBONMVNZJUMM-UHFFFAOYSA-N 0.000 description 1
- XYOXIERJKILWCG-UHFFFAOYSA-N 4-chlorobutanamide Chemical compound NC(=O)CCCCl XYOXIERJKILWCG-UHFFFAOYSA-N 0.000 description 1
- UHAAUDAFKLCPEA-UHFFFAOYSA-N 4-methoxy-2,3,5,6-tetramethylbenzenesulfonamide Chemical compound COC1=C(C)C(C)=C(S(N)(=O)=O)C(C)=C1C UHAAUDAFKLCPEA-UHFFFAOYSA-N 0.000 description 1
- RVZNHBVRNJINRI-UHFFFAOYSA-N 4-methoxy-2,3,6-trimethylbenzenesulfonamide Chemical compound COC1=CC(C)=C(S(N)(=O)=O)C(C)=C1C RVZNHBVRNJINRI-UHFFFAOYSA-N 0.000 description 1
- ZJJLGMUSGUYZQP-UHFFFAOYSA-N 4-methoxy-2,6-dimethylbenzenesulfonamide Chemical compound COC1=CC(C)=C(S(N)(=O)=O)C(C)=C1 ZJJLGMUSGUYZQP-UHFFFAOYSA-N 0.000 description 1
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- KHKJLJHJTQRHSA-UHFFFAOYSA-N 4-methyl-4-nitropentanoic acid Chemical compound [O-][N+](=O)C(C)(C)CCC(O)=O KHKJLJHJTQRHSA-UHFFFAOYSA-N 0.000 description 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-M 4-phenylbenzoate Chemical compound C1=CC(C(=O)[O-])=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-M 0.000 description 1
- 125000005896 5,6-dihydro-4H-furo[3,2-b]pyrrolyl group Chemical group 0.000 description 1
- 125000005898 5,7-dihydro-4H-thieno[2,3-c]pyranyl group Chemical group 0.000 description 1
- 125000005897 6,7-dihydro-5H-furo[3,2-b]pyranyl group Chemical group 0.000 description 1
- QXPJDKVEHRKBOE-UHFFFAOYSA-N 9-phenyl-9h-fluoren-1-amine Chemical compound C1=2C(N)=CC=CC=2C2=CC=CC=C2C1C1=CC=CC=C1 QXPJDKVEHRKBOE-UHFFFAOYSA-N 0.000 description 1
- GDXXYJRQFQZYNL-UHFFFAOYSA-N 9h-fluoren-1-ylmethyl carbamate Chemical compound C1C2=CC=CC=C2C2=C1C(COC(=O)N)=CC=C2 GDXXYJRQFQZYNL-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
- 208000002618 Aarskog syndrome Diseases 0.000 description 1
- 208000033745 Aarskog-Scott syndrome Diseases 0.000 description 1
- 206010063429 Aase syndrome Diseases 0.000 description 1
- 201000004770 Ablepharon macrostomia syndrome Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010064171 Acquired digital fibrokeratoma Diseases 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 201000004625 Acrodermatitis Diseases 0.000 description 1
- 206010056951 Actinic cheilitis Diseases 0.000 description 1
- 206010068388 Actinic elastosis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 1
- 102100031260 Acyl-coenzyme A thioesterase THEM4 Human genes 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 208000002485 Adiposis dolorosa Diseases 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 201000002882 Agraphia Diseases 0.000 description 1
- 208000024341 Aicardi syndrome Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010060937 Amniotic cavity infection Diseases 0.000 description 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
- 208000008789 Anetoderma Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- 208000009594 Animal Hepatitis Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 208000022316 Arachnoid cyst Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003487 Aspergilloma Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010053622 Asplenia Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010059099 Atrophie blanche Diseases 0.000 description 1
- 206010066406 Atrophoderma of Pasini and Pierini Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000023268 Becker naevus Diseases 0.000 description 1
- 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000005080 Benign Migratory Glossitis Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 206010004485 Berylliosis Diseases 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 208000003609 Bile Duct Adenoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 206010006074 Brachial plexus injury Diseases 0.000 description 1
- 206010071443 Brachioradial pruritus Diseases 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000021465 Brief psychotic disease Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010006491 Brown-Sequard syndrome Diseases 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 208000006448 Buruli Ulcer Diseases 0.000 description 1
- 208000023081 Buruli ulcer disease Diseases 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 208000016560 COFS syndrome Diseases 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008513 Child maltreatment syndrome Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000008158 Chorioamnionitis Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000023355 Chronic beryllium disease Diseases 0.000 description 1
- 206010072726 Chronic pigmented purpura Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 208000010200 Cockayne syndrome Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010067248 Congenital naevus Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 206010067380 Costello Syndrome Diseases 0.000 description 1
- 206010011219 Costochondritis Diseases 0.000 description 1
- 208000001727 Craniofrontonasal dysplasia Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000009283 Craniosynostoses Diseases 0.000 description 1
- 206010049889 Craniosynostosis Diseases 0.000 description 1
- 208000001819 Crigler-Najjar Syndrome Diseases 0.000 description 1
- 206010011659 Cutaneous amyloidosis Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010051651 Dermatitis papillaris capillitii Diseases 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010051153 Diabetic gastroparesis Diseases 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000017754 Disseminated superficial actinic porokeratosis Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000001925 Dubowitz syndrome Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 201000002650 Ellis-van Creveld syndrome Diseases 0.000 description 1
- 206010014567 Empty Sella Syndrome Diseases 0.000 description 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
- 208000002403 Encephalocele Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000027004 Eosinophilic disease Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 208000032541 Epidermal naevus Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015152 Erythema Ab Igne Diseases 0.000 description 1
- 206010015153 Erythema annulare Diseases 0.000 description 1
- 206010055035 Erythema dyschromicum perstans Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010056274 Erythema toxicum neonatorum Diseases 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000007348 Experimental Liver Cirrhosis Diseases 0.000 description 1
- 208000001384 Facial Dermatoses Diseases 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 206010067141 Faciodigitogenital dysplasia Diseases 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- 208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 208000004057 Focal Nodular Hyperplasia Diseases 0.000 description 1
- 201000008251 Focal dermal hypoplasia Diseases 0.000 description 1
- 208000003794 Follicular Mucinosis Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010061958 Food Intolerance Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000007223 Gerstmann syndrome Diseases 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 206010053842 Gianotti-Crosti syndrome Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018381 Glomus tumour Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 201000004299 Goldberg-Shprintzen syndrome Diseases 0.000 description 1
- 201000005708 Granuloma Annulare Diseases 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000009396 Group II Malformations of Cortical Development Diseases 0.000 description 1
- 208000007698 Gyrate Atrophy Diseases 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 206010019043 Hair follicle tumour benign Diseases 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 206010019463 Hemihypertrophy Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000004751 Hepatic Echinococcosis Diseases 0.000 description 1
- 206010019646 Hepatic cyst Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019713 Hepatic vein thrombosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000003591 Hepatoerythropoietic Porphyria Diseases 0.000 description 1
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000016619 Histrionic personality disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000638510 Homo sapiens Acyl-coenzyme A thioesterase THEM4 Proteins 0.000 description 1
- 101000581514 Homo sapiens Membrane-bound transcription factor site-2 protease Proteins 0.000 description 1
- 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010050909 Hyperkeratosis follicularis et parafollicularis Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010068489 Idiopathic guttate hypomelanosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000008498 Infantile Refsum disease Diseases 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- 206010068331 Inflammatory pseudotumour Diseases 0.000 description 1
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 1
- 206010022158 Injury to brachial plexus due to birth trauma Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000010809 Ito hypomelanosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 201000008645 Joubert syndrome Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 208000002838 Juvenile Xanthogranuloma Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 1
- 208000007367 Kabuki syndrome Diseases 0.000 description 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 208000024502 Keratosis follicularis spinulosa decalvans Diseases 0.000 description 1
- 206010066295 Keratosis pilaris Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 208000006541 Klippel-Feil syndrome Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 206010024436 Lichen spinulosus Diseases 0.000 description 1
- 206010066945 Lichen striatus Diseases 0.000 description 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 206010048911 Lissencephaly Diseases 0.000 description 1
- 206010024648 Livedo reticularis Diseases 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 201000000251 Locked-in syndrome Diseases 0.000 description 1
- 208000030549 Loose anagen syndrome Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000023071 Majocchi granuloma Diseases 0.000 description 1
- 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000003863 Marijuana Abuse Diseases 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000005767 Megalencephaly Diseases 0.000 description 1
- 241000510097 Megalonaias nervosa Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102100027382 Membrane-bound transcription factor site-2 protease Human genes 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 206010027802 Moebius II syndrome Diseases 0.000 description 1
- 208000034167 Moebius syndrome Diseases 0.000 description 1
- 201000009139 Mongolian Spot Diseases 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000009433 Moyamoya Disease Diseases 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- 208000003423 Mucocele Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 201000005979 Muir-Torre Syndrome Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 206010066289 Mycobacterium ulcerans infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000012905 Myotonic disease Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 206010067193 Naevus flammeus Diseases 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- 206010058455 Nail pigmentation Diseases 0.000 description 1
- 208000027120 Narcissistic personality disease Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010056969 Necrobiosis lipoidica diabeticorum Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 208000032452 Nevus, Epithelioid and Spindle Cell Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 206010072643 Notalgia paraesthetica Diseases 0.000 description 1
- 208000020265 O'Sullivan-McLeod syndrome Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 201000010394 Ochronosis Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000006187 Onycholysis Diseases 0.000 description 1
- 206010057342 Onychophagia Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000017459 Paget disease of the penis Diseases 0.000 description 1
- 208000025610 Paget disease of the vulva Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000030601 Parasitic Liver disease Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000517307 Pediculus humanus Species 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 208000004843 Pendred Syndrome Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010069447 Pitted keratolysis Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 208000007720 Plasma Cell Granuloma Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010057041 Poikiloderma Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 206010066100 Polymorphic eruption of pregnancy Diseases 0.000 description 1
- 206010036087 Polymorphic light eruption Diseases 0.000 description 1
- 206010036172 Porencephaly Diseases 0.000 description 1
- 206010036182 Porphyria acute Diseases 0.000 description 1
- 208000006787 Port-Wine Stain Diseases 0.000 description 1
- 206010048591 Post thrombotic syndrome Diseases 0.000 description 1
- 206010052469 Postictal paralysis Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000032758 Precursor T-lymphoblastic lymphoma/leukaemia Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 208000021974 Pruritic urticarial papules and plaques of pregnancy Diseases 0.000 description 1
- 206010052276 Pseudodementia Diseases 0.000 description 1
- 208000001818 Pseudofolliculitis barbae Diseases 0.000 description 1
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 1
- 201000003699 Punctate palmoplantar keratoderma Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037649 Pyogenic granuloma Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 208000032831 Ramsay Hunt syndrome Diseases 0.000 description 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038584 Repetitive strain injury Diseases 0.000 description 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038903 Retinal vascular occlusion Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 208000009921 Rheumatoid Nodule Diseases 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 208000000729 Schizencephaly Diseases 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 208000006938 Schwannomatosis Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000002108 Shaken Baby Syndrome Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 208000028810 Shared psychotic disease Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000517830 Solenopsis geminata Species 0.000 description 1
- 206010064387 Sotos' syndrome Diseases 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 208000003589 Spider Bites Diseases 0.000 description 1
- 206010041519 Spider naevus Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000001163 Tangier disease Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010043870 Tinea infections Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010043949 Tongue discolouration Diseases 0.000 description 1
- 206010043957 Tongue geographic Diseases 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 241000746998 Tragus Species 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 206010051446 Transient acantholytic dermatosis Diseases 0.000 description 1
- 206010072688 Transient neonatal pustular melanosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 206010044522 Traumatic haematoma Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010053419 Trichophytic granuloma Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241001584775 Tunga penetrans Species 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000037084 Viral Human Hepatitis Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000026724 Waardenburg syndrome Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 201000003790 Weaver syndrome Diseases 0.000 description 1
- 201000011032 Werner Syndrome Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 206010048211 Xanthelasma Diseases 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- CLPYVPMXLNNKLB-UHFFFAOYSA-N [(2-nitrophenyl)-phenylmethyl] carbamate Chemical compound C=1C=CC=C([N+]([O-])=O)C=1C(OC(=O)N)C1=CC=CC=C1 CLPYVPMXLNNKLB-UHFFFAOYSA-N 0.000 description 1
- LXKLUWFIBVXFGX-QPJJXVBHSA-N [(e)-3-phenylprop-2-enyl] carbamate Chemical compound NC(=O)OC\C=C\C1=CC=CC=C1 LXKLUWFIBVXFGX-QPJJXVBHSA-N 0.000 description 1
- MQLDYIKXBMSDCL-UHFFFAOYSA-N [2,4-bis(methylsulfanyl)phenyl] carbamate Chemical compound CSC1=CC=C(OC(N)=O)C(SC)=C1 MQLDYIKXBMSDCL-UHFFFAOYSA-N 0.000 description 1
- OJUHIDQVEFLXSE-UHFFFAOYSA-N [2-(4-methoxyphenyl)-2-oxoethyl] carbamate Chemical compound COC1=CC=C(C(=O)COC(N)=O)C=C1 OJUHIDQVEFLXSE-UHFFFAOYSA-N 0.000 description 1
- XSXGGUVGOHDUPF-UHFFFAOYSA-N [4-(carbamoyloxymethyl)phenyl]boronic acid Chemical compound NC(=O)OCC1=CC=C(B(O)O)C=C1 XSXGGUVGOHDUPF-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010059394 acanthoma Diseases 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 206010000596 acrodermatitis enteropathica Diseases 0.000 description 1
- 201000007047 acrodysostosis Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 201000010275 acute porphyria Diseases 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005585 adamantoate group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000010640 alopecia mucinosa Diseases 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 208000025751 alpha chain disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000011916 alternating hemiplegia Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 201000009431 angiokeratoma Diseases 0.000 description 1
- 208000000252 angiomatosis Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- DQEFBVRIBYYPLE-UHFFFAOYSA-N anthracen-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)=C(C=CC=C3)C3=CC2=C1 DQEFBVRIBYYPLE-UHFFFAOYSA-N 0.000 description 1
- FKFZOFZWJNHJDE-UHFFFAOYSA-N anthracene-9-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=C(C=CC=C3)C3=CC2=C1 FKFZOFZWJNHJDE-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 208000037908 antibody-mediated disorder Diseases 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010002963 aplasia cutis congenita Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000031116 aquarium granuloma Diseases 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 206010003074 arachnoiditis Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 208000031375 autosomal dominant myotonia congenita Diseases 0.000 description 1
- 208000021033 autosomal dominant polycystic liver disease Diseases 0.000 description 1
- 208000022804 avoidant personality disease Diseases 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- DUXANUSOCMOJSI-UHFFFAOYSA-N benzhydryl carbamate Chemical compound C=1C=CC=CC=1C(OC(=O)N)C1=CC=CC=C1 DUXANUSOCMOJSI-UHFFFAOYSA-N 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- KVPFKMBYCSISTN-UHFFFAOYSA-N benzylsulfanylformic acid Chemical compound OC(=O)SCC1=CC=CC=C1 KVPFKMBYCSISTN-UHFFFAOYSA-N 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 208000037512 bile duct cyst Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- IEPBPSSCIZTJIF-UHFFFAOYSA-N bis(2,2,2-trichloroethyl) carbonate Chemical compound ClC(Cl)(Cl)COC(=O)OCC(Cl)(Cl)Cl IEPBPSSCIZTJIF-UHFFFAOYSA-N 0.000 description 1
- UXXXZMDJQLPQPH-UHFFFAOYSA-N bis(2-methylpropyl) carbonate Chemical compound CC(C)COC(=O)OCC(C)C UXXXZMDJQLPQPH-UHFFFAOYSA-N 0.000 description 1
- HROGQYMZWGPHIB-UHFFFAOYSA-N bis(4-methoxyphenyl)methanamine Chemical compound C1=CC(OC)=CC=C1C(N)C1=CC=C(OC)C=C1 HROGQYMZWGPHIB-UHFFFAOYSA-N 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 1
- JZUVESQYEHERMD-UHFFFAOYSA-N bis[(4-nitrophenyl)methyl] carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 JZUVESQYEHERMD-UHFFFAOYSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000007047 blue nevus Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000005200 bronchus cancer Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 230000035571 calor Effects 0.000 description 1
- 201000001843 cannabis dependence Diseases 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000022667 central centrifugal cicatricial alopecia Diseases 0.000 description 1
- 208000009885 central pontine myelinolysis Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001173 choledochal cyst Diseases 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 201000003652 craniofrontonasal syndrome Diseases 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- LWABFMLTBBNLTA-UHFFFAOYSA-N cyclobutyl carbamate Chemical compound NC(=O)OC1CCC1 LWABFMLTBBNLTA-UHFFFAOYSA-N 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- NNGAQKAUYDTUQR-UHFFFAOYSA-N cyclohexanimine Chemical compound N=C1CCCCC1 NNGAQKAUYDTUQR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical compound NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- UWYRVVJXSNXVAI-UHFFFAOYSA-N cyclopropylmethyl carbamate Chemical compound NC(=O)OCC1CC1 UWYRVVJXSNXVAI-UHFFFAOYSA-N 0.000 description 1
- KATXJJSCAPBIOB-UHFFFAOYSA-N cyclotetradecane Chemical compound C1CCCCCCCCCCCCC1 KATXJJSCAPBIOB-UHFFFAOYSA-N 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- UEVXKGPJXXDGCX-UHFFFAOYSA-N cyclotridecane Chemical compound C1CCCCCCCCCCCC1 UEVXKGPJXXDGCX-UHFFFAOYSA-N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 201000004400 dacryoadenitis Diseases 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000005892 decahydro-1,8-naphthyridinyl group Chemical group 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 125000005891 decahydronaphthyridinyl group Chemical group 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- 208000030964 dependent personality disease Diseases 0.000 description 1
- 201000010307 dermatosis papulosa nigra Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 201000009803 desquamative interstitial pneumonia Diseases 0.000 description 1
- 201000007394 diastrophic dysplasia Diseases 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- SEBARIVPCNBHKO-UHFFFAOYSA-N dipyridin-2-ylmethyl carbamate Chemical compound C=1C=CC=NC=1C(OC(=O)N)C1=CC=CC=N1 SEBARIVPCNBHKO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 230000035620 dolor Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000009743 drug hypersensitivity syndrome Diseases 0.000 description 1
- 208000022143 drug rash with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 201000008865 drug-induced hepatitis Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010058319 dysgraphia Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 208000006065 elastosis perforans serpiginosa Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000011025 embryonal testis carcinoma Diseases 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000017338 epidermoid cysts Diseases 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 208000004000 erythrasma Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000011384 erythromelalgia Diseases 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 208000012043 faciodigitogenital syndrome Diseases 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 208000002026 familial multiple nevi flammei Diseases 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000003645 female-pattern hair loss Effects 0.000 description 1
- 208000004967 femoral neuropathy Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- RGEAONPOJJBMHO-UHFFFAOYSA-N furan-2-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=CO1 RGEAONPOJJBMHO-UHFFFAOYSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000003860 geographic tongue Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 208000005594 glucose-galactose malabsorption Diseases 0.000 description 1
- 208000015362 glutaric aciduria Diseases 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 201000007192 granulomatous hepatitis Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000006138 hallucinogen dependence Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000033552 hepatic porphyria Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000006341 heptafluoro n-propyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 208000006634 hidrocystoma Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 208000009624 holoprosencephaly Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000009075 hydranencephaly Diseases 0.000 description 1
- HSNUXDIQZKIQRR-UHFFFAOYSA-N hydroxy-imino-bis(phenylmethoxy)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1COP(=O)(N)OCC1=CC=CC=C1 HSNUXDIQZKIQRR-UHFFFAOYSA-N 0.000 description 1
- QWMUDOFWQWBHFI-UHFFFAOYSA-N hydroxy-imino-diphenoxy-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1OP(=O)(N)OC1=CC=CC=C1 QWMUDOFWQWBHFI-UHFFFAOYSA-N 0.000 description 1
- RIGIWEGXTTUCIQ-UHFFFAOYSA-N hydroxy-imino-diphenyl-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(=O)(N)C1=CC=CC=C1 RIGIWEGXTTUCIQ-UHFFFAOYSA-N 0.000 description 1
- 206010066130 hyper-IgM syndrome Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 1
- 229960002993 ingenol mebutate Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000024710 intermittent asthma Diseases 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 208000013049 isolated hemihyperplasia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000004343 lateral medullary syndrome Diseases 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 208000015413 lichen amyloidosis Diseases 0.000 description 1
- 206010024428 lichen nitidus Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000022742 linear and whorled nevoid hypermelanosis Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000005592 lipodermatosclerosis Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 208000014817 lissencephaly spectrum disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 208000010085 loose anagen hair syndrome Diseases 0.000 description 1
- 231100000875 loss of motor control Toxicity 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000032184 meralgia paresthetica Diseases 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 208000020140 mesenchymal hamartoma Diseases 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- NYEBKUUITGFJAK-UHFFFAOYSA-N methylsulfanylmethanethioic s-acid Chemical compound CSC(O)=S NYEBKUUITGFJAK-UHFFFAOYSA-N 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 201000005935 monilethrix Diseases 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000026114 mu chain disease Diseases 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 1
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000006387 myelophthisic anemia Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001016 myotrophic effect Effects 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000005893 naphthalimidyl group Chemical group 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 201000008043 necrobiosis lipoidica Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 201000009494 neurilemmomatosis Diseases 0.000 description 1
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 206010069732 neurotrophic keratopathy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000024645 nevus of Ito Diseases 0.000 description 1
- 208000004942 nevus of Ota Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 201000010192 nonsyndromic congenital nail disorder 1 Diseases 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
- 208000014055 occupational lung disease Diseases 0.000 description 1
- 208000029347 ochronosis disease Diseases 0.000 description 1
- 125000005889 octahydrochromenyl group Chemical group 0.000 description 1
- 125000005890 octahydroisochromenyl group Chemical group 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 206010030306 omphalitis Diseases 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 208000024196 oppositional defiant disease Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000011029 ovarian embryonal carcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 208000005877 painful neuropathy Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 208000027838 paramyotonia congenita of Von Eulenburg Diseases 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 208000020930 peroxisome biogenesis disorder 1B Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 208000001095 pilomatrixoma Diseases 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 206010035111 pityriasis alba Diseases 0.000 description 1
- 206010035114 pityriasis rosea Diseases 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 208000028589 polycystic liver disease Diseases 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 208000013802 porokeratosis of Mibelli Diseases 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 208000014670 posterior cortical atrophy Diseases 0.000 description 1
- 208000037955 postinfectious encephalomyelitis Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- 208000001282 primary progressive aphasia Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 208000015412 proliferating trichilemmal cyst Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
- ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000017940 prurigo nodularis Diseases 0.000 description 1
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
- 208000030390 pulmonic stenosis Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- RWUGBYOALBYTGU-UHFFFAOYSA-N pyridin-4-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=NC=C1 RWUGBYOALBYTGU-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- FLCPORVHXQFBHT-UHFFFAOYSA-N quinolin-8-yl carbamate Chemical compound C1=CN=C2C(OC(=O)N)=CC=CC2=C1 FLCPORVHXQFBHT-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 208000015670 renal artery disease Diseases 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 208000021569 rheumatoid lung disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000036185 rubor Effects 0.000 description 1
- YBKWIGSMABMNJZ-UHFFFAOYSA-N s-(2,3,4,5,6-pentachlorophenyl)thiohydroxylamine Chemical compound NSC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl YBKWIGSMABMNJZ-UHFFFAOYSA-N 0.000 description 1
- RTKRAORYZUBVGQ-UHFFFAOYSA-N s-(2,4-dinitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O RTKRAORYZUBVGQ-UHFFFAOYSA-N 0.000 description 1
- LOVVSIULYJABJF-UHFFFAOYSA-N s-(2-nitrophenyl)thiohydroxylamine Chemical compound NSC1=CC=CC=C1[N+]([O-])=O LOVVSIULYJABJF-UHFFFAOYSA-N 0.000 description 1
- BDEZGPKAMAVGBE-UHFFFAOYSA-N s-(3-nitropyridin-2-yl)thiohydroxylamine Chemical compound NSC1=NC=CC=C1[N+]([O-])=O BDEZGPKAMAVGBE-UHFFFAOYSA-N 0.000 description 1
- DAXSYWBYJZACTA-UHFFFAOYSA-N s-(4-methoxy-2-nitrophenyl)thiohydroxylamine Chemical compound COC1=CC=C(SN)C([N+]([O-])=O)=C1 DAXSYWBYJZACTA-UHFFFAOYSA-N 0.000 description 1
- LOFZYSZWOLKUGE-UHFFFAOYSA-N s-benzyl carbamothioate Chemical compound NC(=O)SCC1=CC=CC=C1 LOFZYSZWOLKUGE-UHFFFAOYSA-N 0.000 description 1
- MAGSSGQAJNNDLU-UHFFFAOYSA-N s-phenylthiohydroxylamine Chemical compound NSC1=CC=CC=C1 MAGSSGQAJNNDLU-UHFFFAOYSA-N 0.000 description 1
- PIDYQAYNSQSDQY-UHFFFAOYSA-N s-tritylthiohydroxylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SN)C1=CC=CC=C1 PIDYQAYNSQSDQY-UHFFFAOYSA-N 0.000 description 1
- BPELEZSCHIEMAE-UHFFFAOYSA-N salicylaldehyde imine Chemical compound OC1=CC=CC=C1C=N BPELEZSCHIEMAE-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical group 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 208000014956 scrotum Paget disease Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 201000005574 senile angioma Diseases 0.000 description 1
- 208000025874 separation anxiety disease Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 208000031162 sideroblastic anemia Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 208000011584 spitz nevus Diseases 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 206010048905 steatocystoma multiplex Diseases 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000037946 swimming pool granuloma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 208000004022 syringoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000001297 telogen effluvium Diseases 0.000 description 1
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 206010062123 testicular embryonal carcinoma Diseases 0.000 description 1
- 201000006361 tethered spinal cord syndrome Diseases 0.000 description 1
- 125000005887 tetrahydrobenzofuranyl group Chemical group 0.000 description 1
- 125000005886 tetrahydrobenzothienyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
- 201000007420 thrombocytopenia-absent radius syndrome Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 208000023628 trichilemmal cyst Diseases 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000000866 velocardiofacial syndrome Diseases 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 208000028010 vulval Paget disease Diseases 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- Plasmalogens are ether phospholipids that comprise a vinyl ether moiety at the sn1 or sn2 position. In mammals, the vinyl ether moiety is typically incorporated at the sn1 position, while the sn2 substituent usually comprises an unsaturated fatty acid residue.
- Plasmalogens are found throughout various human tissues, including the nervous, immune, and cardiovascular systems. Changes to lipid metabolism are associated with the onset and pathology of various diseases, including, but not limited to, neurological diseases, cardiovascular diseases, metabolic diseases, liver diseases, and cancer. There is a particular need for compounds that cross the blood-brain barrier so that the compounds can exert their activity in the central nervous system (CNS). Despite efforts towards understanding transport across the blood-brain barrier and blood-retinal barriers, efficient delivery directly into the CNS has remained a major challenge in developing potential therapeutics.
- CNS central nervous system
- Impairment to the biosynthetic pathway of ether lipids may have deleterious downstream effects in subjects with various diseases (e.g., liver diseases, neurological diseases, ophthalmic diseases, metabolic disorders, mitochondrial diseases, cardiovascular diseases, infectious diseases, pulmonary diseases, skin diseases, genetic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, hematological diseases, painful conditions, psychiatric disorders, immune disorders, and spleen diseases).
- Ether lipids and, in particular, plasmalogen ether species are negatively associated with neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, some genetic diseases, such as Zellweger syndrome, and pulmonary diseases, such as neonatal respiratory distress syndrome.
- Plasmalogen deficiency is also linked to defects in peroxisome functions and associated disorders. Accordingly, plasmalogen replacement therapy may be used to increase plasmalogen levels in deficient patients. This therapeutic approach may correct various issues, including issues associated with neurological function. Without
- plasmalogen species disclosed herein may be effectively transported by Mfsd2a and achieve improved blood-brain barrier and/or blood-retinal barrier permeability. Additionally, compounds comprising a vinyl ether moiety do not require metabolic conversion and may therefore be effective at low doses. [0004]
- the present disclosure relates in part to new compounds that can be transported across the blood-brain barrier or blood-retinal barrier, such as by Mfsd2a, and compositions, kits, and methods of using and preparing such compounds.
- the compounds provided herein are transported by Mfsd2a and can therefore be used for the treatment and/or prevention of diseases (e.g., liver diseases, neurological diseases, ophthalmic diseases, metabolic disorders, mitochondrial diseases, cardiovascular diseases, infectious diseases, pulmonary diseases, skin diseases, genetic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, hematological diseases, painful conditions, psychiatric disorders, immune disorders, and spleen diseases).
- diseases e.g., liver diseases, neurological diseases, ophthalmic diseases, metabolic disorders, mitochondrial diseases, cardiovascular diseases, infectious diseases, pulmonary diseases, skin diseases, genetic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, hematological diseases, painful conditions, psychiatric disorders, immune disorders, and spleen diseases).
- the present disclosure also provides methods of using the compounds and compositions provided herein, e.g., for treating and/or preventing a disease, disorder, or condition (e.g., a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition, a psychiatric disorder, an immune disorder, or a spleen disease) in a subject.
- a disease, disorder, or condition e.g., a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition
- the disease is a genetic disease. In some embodiments, the disease is an ophthalmic disease.
- the present disclosure provides kits comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co- crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof.
- the disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, wherein R 1 , R 2 , L 1 , and X are as defined herein.
- the compound is of Formula (I-A): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , L 1 and L 2 are as defined herein.
- the compound is of Formula (I-A-i): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and L 2 are as defined herein.
- the compound is of Formula (I-A-ii): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1 , R 2 , L 1 , and L 2 are as defined herein.
- the compound is of Formula (I-A-iii): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1 , R 2 , L 1 , and L 2 are as defined herein.
- the compound is of Formula (I-B): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1 , R 2 , R 3 , R 4 , L 1 , and L 2 are as defined herein.
- the compound is of Formula (I-C): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1 , R 2 , R 6 , R 7 , R 8 , R 9 , R 10 , and X are as defined herein.
- the disclosure provides compounds of Formula (II): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrug thereof, wherein R 1' , R 2' , R 3' , R 4' , X, Y, Z, *, and n are as defined herein.
- the compound is of Formula (II-A): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1' , R 2" , R 3' , R 4' , X, Y, Z, *, and n are as defined herein.
- the compound is of Formula (II-B): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1' , R 2' , R 3' , R 4' , Y, Z, and n are as defined herein.
- the compound is of Formula (II-C): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1' , R 2' , R 3' , R 4' , X, Z, and n are as defined herein.
- the compound is of Formula (II-D): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R 1' , R 2' , R 3' , R 4' , X, Y, and n are as defined herein.
- compositions comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; and a pharmaceutically acceptable carrier and/or excipient.
- the composition is a pharmaceutical composition.
- the pharmaceutical composition further comprises an additional pharmaceutical agent.
- a pharmaceutical composition provided herein is formulated for oral administration.
- the composition is a nutraceutical composition
- a nutraceutical composition comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co- crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; and a nutraceutically acceptable carrier and/or excipient.
- a nutraceutical composition provided herein is formulated for oral administration.
- the present disclosure provides methods for treating and/or preventing a disease, disorder, or condition in a subject comprising administering to the subject an effective amount of a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a pharmaceutical composition thereof.
- the disease is a neurological disease.
- the disease is a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition, a psychiatric disorder, an immune disorder, or a spleen disease.
- the disease is a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition, a psychiatric disorder, an immune disorder, or a spleen disease.
- the disease is a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease,
- the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington’s disease, amyotrophic lateral sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV-related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supran
- the disease is dementia, Alzheimer’s disease, other Parkinson’s disease, Huntington’s disease, a prion disease, amyotrophic lateral sclerosis, or multiple sclerosis.
- the disease is dementia, or Alzheimer’s disease.
- the disease is dementia.
- the disease is Alzheimer’s disease.
- the disease is Parkinson’s disease.
- the method comprises administering to a subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the method comprises contacting a cell, tissue, or biological sample with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the method is an in vitro method.
- the method is an in vivo method.
- the method comprises administering to a subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the method comprises contacting a cell, tissue, or biological sample with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the method is an in vitro method. In some embodiments, the method is an in vivo method. In some embodiments, the method is an ex vivo method. [0024] In another aspect, provided herein is a method of increasing plasmalogen levels in a subject, biological sample, tissue, or cell, comprising administering to the subject or contacting the biological sample, tissue, or cell with compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a method of increasing plasmalogen levels in the brain or central nervous system of a subject comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the present disclosure provides a kit comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co- crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; or a composition provided herein; and instructions for using the compound, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, prodrug, or composition thereof.
- Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers.
- the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
- Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw–Hill, NY, 1962); and Wilen, S.H., Tables of Resolving Agents and Optical Resolutions p.268 (E.L. Eliel, Ed., Univ.
- formulae and structures depicted herein include compounds that do not include isotopically enriched atoms, and also include compounds that include isotopically enriched atoms.
- compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, replacement of 19 F with 18 F, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of the disclosure. Such compounds are useful, for example, as analytical tools or probes in biological assays.
- isotopes refers to variants of a particular chemical element such that, while all isotopes of a given element share the same number of protons in each atom of the element, those isotopes differ in the number of neutrons.
- isotopes refers to variants of a particular chemical element such that, while all isotopes of a given element share the same number of protons in each atom of the element, those isotopes differ in the number of neutrons.
- C1-6 alkyl encompasses, C1, C2, C3, C4, C5, C6, C1–6, C1–5, C 1–4 , C 1–3 , C 1–2 , C 2–6 , C 2–5 , C 2–4 , C 2–3 , C 3–6 , C 3–5 , C 3–4 , C 4–6 , C 4–5 , and C 5–6 alkyl.
- aliphatic refers to alkyl, alkenyl, alkynyl, and carbocyclic groups.
- heteroaliphatic refers to heteroalkyl, heteroalkenyl, heteroalkynyl, and heterocyclic groups.
- alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1–20 alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C1–12 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C 1–10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C1–9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C1–8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C1–7 alkyl”).
- an alkyl group has 1 to 6 carbon atoms (“C 1–6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1–5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1–4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1–3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C 1–2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C 1 alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”).
- C1–6 alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C 4 ) (e.g., n-butyl, tert-butyl, sec-butyl, isobutyl), pentyl (C 5 ) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tert-amyl), and hexyl (C6) (e.g., n-hexyl).
- C1–6 alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C 4 ) (e.g., n-butyl, tert-butyl, sec-buty
- alkyl groups include n-heptyl (C7), n-octyl (C8), n-dodecyl (C12), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents (e.g., halogen, such as F).
- substituents e.g., halogen, such as F
- the alkyl group is an unsubstituted C 1–12 alkyl (such as unsubstituted C 1–6 alkyl, e.g., ⁇ CH 3 (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g., unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (i-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n-butyl (n-Bu), unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted sec-butyl (sec-Bu or s-Bu), unsubstituted isobutyl (i-Bu)).
- the alkyl group is a substituted C 1–12 alkyl (such as
- haloalkyl is a substituted alkyl group, wherein one or more of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo.
- Perhaloalkyl is a subset of haloalkyl, and refers to an alkyl group wherein all of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo.
- the haloalkyl moiety has 1 to 20 carbon atoms (“C 1–20 haloalkyl”).
- the haloalkyl moiety has 1 to 10 carbon atoms (“C1–10 haloalkyl”).
- the haloalkyl moiety has 1 to 9 carbon atoms (“C1–9 haloalkyl”).
- the haloalkyl moiety has 1 to 8 carbon atoms (“C 1–8 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 7 carbon atoms (“C 1–7 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 6 carbon atoms (“C1–6 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 5 carbon atoms (“C1–5 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 4 carbon atoms (“C 1–4 haloalkyl”).
- the haloalkyl moiety has 1 to 3 carbon atoms (“C1–3 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 2 carbon atoms (“C1–2 haloalkyl”). In some embodiments, all of the haloalkyl hydrogen atoms are independently replaced with fluoro to provide a “perfluoroalkyl” group. In some embodiments, all of the haloalkyl hydrogen atoms are independently replaced with chloro to provide a “perchloroalkyl” group.
- haloalkyl groups include –CHF 2 , ⁇ CH 2 F, ⁇ CF 3 , ⁇ CH 2 CF 3 , ⁇ CF 2 CF 3 , ⁇ CF 2 CF 2 CF 3 , ⁇ CCl 3 , ⁇ CFCl 2 , ⁇ CF 2 Cl, and the like.
- alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 1 to 20 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 1 to 20 carbon atoms (“C1-20 alkenyl”).
- an alkenyl group has 1 to 12 carbon atoms (“C1–12 alkenyl”). In some embodiments, an alkenyl group has 1 to 11 carbon atoms (“C1–11 alkenyl”). In some embodiments, an alkenyl group has 1 to 10 carbon atoms (“C 1–10 alkenyl”). In some embodiments, an alkenyl group has 1 to 9 carbon atoms (“C1–9 alkenyl”). In some embodiments, an alkenyl group has 1 to 8 carbon atoms (“C1–8 alkenyl”). In some embodiments, an alkenyl group has 1 to 7 carbon atoms (“C 1–7 alkenyl”).
- an alkenyl group has 1 to 6 carbon atoms (“C 1–6 alkenyl”). In some embodiments, an alkenyl group has 1 to 5 carbon atoms (“C1–5 alkenyl”). In some embodiments, an alkenyl group has 1 to 4 carbon atoms (“C1–4 alkenyl”). In some embodiments, an alkenyl group has 1 to 3 carbon atoms (“C 1–3 alkenyl”). In some
- an alkenyl group has 1 to 2 carbon atoms (“C 1–2 alkenyl”). In some embodiments, an alkenyl group has 1 carbon atom (“C1 alkenyl”). The one or more carbon- carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C 1–4 alkenyl groups include methylidenyl (C 1 ), ethenyl (C 2 ), 1-propenyl (C 3 ), 2- propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like.
- C1–6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C 5 ), hexenyl (C 6 ), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C 1-20 alkenyl.
- the alkenyl group is a substituted C1-20 alkenyl.
- the term “alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 1 to 20 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) (“C1-20 alkynyl”).
- an alkynyl group has 1 to 10 carbon atoms (“C1-10 alkynyl”).
- an alkynyl group has 1 to 9 carbon atoms (“C 1-9 alkynyl”). In some embodiments, an alkynyl group has 1 to 8 carbon atoms (“C 1- 8 alkynyl”). In some embodiments, an alkynyl group has 1 to 7 carbon atoms (“C1-7 alkynyl”). In some embodiments, an alkynyl group has 1 to 6 carbon atoms (“C1-6 alkynyl”). In some embodiments, an alkynyl group has 1 to 5 carbon atoms (“C 1-5 alkynyl”). In some embodiments, an alkynyl group has 1 to 4 carbon atoms (“C 1-4 alkynyl”).
- an alkynyl group has 1 to 3 carbon atoms (“C1-3 alkynyl”). In some embodiments, an alkynyl group has 1 to 2 carbon atoms (“C 1-2 alkynyl”). In some embodiments, an alkynyl group has 1 carbon atom (“C 1 alkynyl”).
- the one or more carbon- carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).
- C1-4 alkynyl groups include, without limitation, methylidynyl (C1), ethynyl (C2), 1-propynyl (C 3 ), 2-propynyl (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ), and the like.
- C1-6 alkenyl groups include the aforementioned C2-4 alkynyl groups as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C 8 ), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted
- alkynyl with one or more substituents.
- the alkynyl group is an unsubstituted C1-20 alkynyl.
- the alkynyl group is a substituted C1-20 alkynyl.
- carbocyclyl or “carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 14 ring carbon atoms (“C3-14 carbocyclyl”) and zero heteroatoms in the non-aromatic ring system.
- a carbocyclyl group has 3 to 14 ring carbon atoms (“C 3-14 carbocyclyl”).
- a carbocyclyl group has 3 to 13 ring carbon atoms (“C3-13 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 12 ring carbon atoms (“C3-12 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 11 ring carbon atoms (“C 3-11 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 10 ring carbon atoms (“C 3-10 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C3-8 carbocyclyl”).
- a carbocyclyl group has 3 to 7 ring carbon atoms (“C3-7 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms (“C4-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms (“C5-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 carbocyclyl”).
- Exemplary C3-6 carbocyclyl groups include cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
- Exemplary C 3-8 carbocyclyl groups include the aforementioned C 3-6 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like.
- Exemplary C3-10 carbocyclyl groups include the aforementioned C 3-8 carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like.
- Exemplary C3-8 carbocyclyl groups include the aforementioned C 3-10 carbocyclyl groups as well as cycloundecyl (C11), spiro[5.5]undecanyl (C11), cyclododecyl (C12), cyclododecenyl (C12), cyclotridecane (C13), cyclotetradecane (C14), and the like.
- the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds.
- “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one
- each instance of a carbocyclyl group is independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents.
- the carbocyclyl group is an unsubstituted C3-14 carbocyclyl.
- the carbocyclyl group is a substituted C 3-14 carbocyclyl.
- “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 14 ring carbon atoms (“C3-14 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 10 ring carbon atoms (“C 3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 4 to 6 ring carbon atoms (“C4-6 cycloalkyl”).
- a cycloalkyl group has 5 to 6 ring carbon atoms (“C 5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10 cycloalkyl”). Examples of C5-6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-6 cycloalkyl groups include the aforementioned C 5-6 cycloalkyl groups as well as cyclopropyl (C 3 ) and cyclobutyl (C4).
- C3-8 cycloalkyl groups include the aforementioned C3-6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8).
- each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents.
- the cycloalkyl group is an unsubstituted C3-14 cycloalkyl.
- the cycloalkyl group is a substituted C3-14 cycloalkyl.
- the term “heterocyclyl” or “heterocyclic” refers to a radical of a 3- to 14-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3–14 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
- a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon- carbon double or triple bonds.
- heterocyclyl polycyclic ring systems can include one or more
- Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system.
- each instance of heterocyclyl is independently unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents.
- the heterocyclyl group is an unsubstituted 3–14 membered heterocyclyl.
- the heterocyclyl group is a substituted 3–14 membered heterocyclyl.
- the heterocyclyl is substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, wherein 1, 2, or 3 atoms in the heterocyclic ring system are independently oxygen, nitrogen, or sulfur, as valency permits.
- a heterocyclyl group is a 5–10 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–10 membered heterocyclyl”).
- a heterocyclyl group is a 5–8 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heterocyclyl”).
- a heterocyclyl group is a 5–6 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heterocyclyl”).
- the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
- Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include azirdinyl, oxiranyl, and thiiranyl.
- Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include azetidinyl, oxetanyl, and thietanyl.
- Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5- dione.
- Exemplary 5-membered heterocyclyl groups containing 2 heteroatoms include dioxolanyl, oxathiolanyl and dithiolanyl.
- Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include azirdinyl, oxiranyl, and thiiranyl.
- heteroatoms containing 3 heteroatoms include triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6- membered heterocyclyl groups containing 1 heteroatom include piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
- Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include piperazinyl, morpholinyl, dithianyl, and dioxanyl.
- Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include triazinyl.
- Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include azepanyl, oxepanyl and thiepanyl.
- Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include azocanyl, oxecanyl and thiocanyl.
- Exemplary bicyclic heterocyclyl groups include indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetra- hydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl,
- alkylene is the divalent moiety of alkyl
- alkenylene is the divalent moiety of alkenyl
- alkynylene is the divalent moiety of alkynyl
- heteroalkylene is the divalent moiety of heteroalkyl
- heteroalkenylene is the divalent moiety of heteroalkenyl
- heteroalkynylene is the divalent moiety of heteroalkynyl
- carbocyclylene is the divalent moiety of carbocyclyl
- heterocyclylene is the divalent moiety of heterocyclyl
- arylene is the divalent moiety of aryl
- heteroarylene is the divalent moiety of heteroaryl.
- a group is optionally substituted unless expressly provided otherwise.
- the term “optionally substituted” refers to being substituted or unsubstituted.
- alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted.
- Optionally substituted refers to a group which is substituted or unsubstituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” heteroalkenyl, “substituted” or “unsubstituted” heteroalkynyl, “substituted” or “unsubstituted” carbocyclyl,
- substituted or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group).
- substituted means that at least one hydrogen present on a group is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
- a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
- substituted is contemplated to include substitution with all permissible substituents of organic compounds, and includes any of the substituents described herein that results in the formation of a stable compound.
- the present disclosure contemplates any and all such combinations in order to arrive at a stable compound.
- heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
- each instance of R aa is independently selected from C 1–20 alkyl, C 1–20 perhaloalkyl, C1–20 alkenyl, C1–20 alkynyl, heteroC1–20 alkyl, heteroC1–20alkenyl, heteroC1–20alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5- 14 membered heteroaryl, or two R aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups; each instance of R bb is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups; each instance of R
- each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, ⁇ OR aa , ⁇ SR aa , ⁇ N(R bb )2, –CN, –SCN, or –NO2.
- each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen moieties) or unsubstituted C 1–10 alkyl, ⁇ OR aa , ⁇ SR aa , ⁇ N(R bb )2, –CN, –SCN, or –NO2, wherein R aa is hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1–10 alkyl, an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl) when attached to an oxygen atom, or a sulfur protecting group (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine-s
- the molecular weight of a carbon atom substituent is lower than 250, lower than 200, lower than 150, lower than 100, or lower than 50 g/mol.
- a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, nitrogen, and/or silicon atoms.
- a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, and/or nitrogen atoms. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, and/or iodine atoms. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, and/or chlorine atoms. [0048]
- the term “halo” or “halogen” refers to fluorine (fluoro, ⁇ F), chlorine (chloro, ⁇ Cl), bromine (bromo, ⁇ Br), or iodine (iodo, ⁇ I).
- amino refers to the group ⁇ NH 2 .
- substituted amino by extension, refers to a monosubstituted amino, a disubstituted amino, or a trisubstituted amino. In certain embodiments, the “substituted amino” is a monosubstituted amino or a disubstituted amino group.
- Exemplary acyl groups include
- aldehydes ⁇ CHO
- carboxylic acids ⁇ CO 2 H
- carboxylic acids ⁇ CO2H
- aldehydes – CHO
- esters ⁇ CO2R aa
- Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms.
- each nitrogen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C 1-6 alkyl or a nitrogen protecting group.
- the substituent present on the nitrogen atom is a nitrogen protecting group (also referred to herein as an “amino protecting group”).
- Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
- the nitrogen protecting group does not form a urea with the nitrogen to which it is attached.
- each nitrogen protecting group is independently selected from the group consisting of formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3- phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o- nitrophenoxyacetamide, acetoacetamide, (N’-dithiobenzyloxyacylamino)acetamide, 3-(p- hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o- nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4- chlorobutanamide, 3-methyl-3-nitrobutanamide, o-
- each nitrogen protecting group is independently selected from the group consisting of methyl carbamate, ethyl carbamate, 9- fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7- dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10- tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-
- each nitrogen protecting group is independently selected from the group consisting of p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6- trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4- methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms),
- Ts p-toluenesulfonamide
- each nitrogen protecting group is independently selected from the group consisting of phenothiazinyl-(10)-acyl derivatives, N’-p-toluenesulfonylaminoacyl derivatives, N’-phenylaminothioacyl derivatives, N-benzoylphenylalanyl derivatives, N- acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N- dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4- tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5- triazacyclohexan-2-one, 5-substituted 1,3-d
- Dpp diphenylphosphinamide
- Mpt dimethylthiophosphinamide
- two instances of a nitrogen protecting group together with the nitrogen atoms to which the nitrogen protecting groups are attached are N,N’-isopropylidenediamine.
- at least one nitrogen protecting group is Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts.
- each oxygen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl or an oxygen protecting group.
- the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as a “hydroxyl protecting group”).
- oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
- the oxygen protecting group, together with the oxygen atom to which the oxygen protecting group is attached is selected from the group consisting of
- At least one oxygen protecting group is silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl.
- the molecular weight of a substituent is lower than 250, lower than 200, lower than 150, lower than 100, or lower than 50 g/mol.
- a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, nitrogen, and/or silicon atoms.
- a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, and/or nitrogen atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, and/or iodine atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, and/or chlorine atoms. In certain embodiments, a substituent comprises 0, 1, 2, or 3 hydrogen bond donors. In certain embodiments, a substituent comprises 0, 1, 2, or 3 hydrogen bond acceptors.
- At least one instance refers to 1, 2, 3, 4, or more instances, but also encompasses a range, e.g., for example, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 4, from 2 to 3, or from 3 to 4 instances, inclusive.
- the disclosure is not intended to be limited in any manner by the above exemplary listing of substituents. Additional terms may be defined in other sections of this disclosure.
- salt refers to any and all salts, and encompasses pharmaceutically acceptable salts. Salts include ionic compounds that result from the neutralization reaction of an acid and a base. A salt is composed of one or more cations (positively charged ions) and one or more anions (negative ions) so that the salt is electrically neutral (without a net charge). Salts of the compounds of this disclosure include those derived from inorganic and organic acids and bases.
- acid addition salts are salts of an amino group formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2– naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1–4 alkyl) 4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
- pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
- Pharmaceutically acceptable salts of the compounds of this disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic
- acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N + (C 1-4 alkyl) 4 ⁇ salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
- the pharmaceutically acceptable salt is an alkali metal salt.
- the pharmaceutically acceptable salt is a nontoxic ammonium, quaternary ammonium, or amine cation.
- solvate refers to forms of the compound, or a salt thereof, that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding.
- Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like.
- the compounds described herein may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates.
- the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid.
- “Solvate” encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, and methanolates.
- the term “stoichiometric solvate” refers to a solvate, which comprises a compound (e.g., a compound disclosed herein) and a solvent, wherein the solvent molecules are an integral part of the crystal lattice, in which they interact strongly with the compound and each other. The removal of the solvent molecules will cause instability of the crystal network,
- non-stoichiometric solvate refers to a solvate, which comprises a compound (e.g., a compound disclosed herein) and a solvent, wherein the solvent content may vary without major changes in the crystal structure. The amount of solvent in the crystal lattice only depends on the partial pressure of solvent in the surrounding atmosphere. In the fully solvated state, non-stoichiometric solvates may, but not necessarily have to, show an integer molar ratio of solvent to the compound.
- hydrate refers to a compound that is associated with water. Typically, the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate.
- a hydrate of a compound may be represented, for example, by the general formula R ⁇ x H 2 O, wherein R is the compound, and x is a number greater than 0.
- a given compound may form more than one type of hydrate, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5 H2O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H2O) and hexahydrates (R ⁇ 6 H2O)).
- tautomers or “tautomeric” refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa).
- the exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base.
- Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(a different enamine) tautomerizations.
- isomers compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”.
- stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”.
- enantiomers When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
- An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or ( ⁇ )-isomers respectively).
- a chiral compound can exist as either individual enantiomer or as a mixture thereof.
- a mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
- the term “co-crystal” refers to a crystalline structure comprising at least two different components (e.g., a compound disclosed herein and an acid), wherein each of the components is independently an atom, ion, or molecule. In certain embodiments, none of the components is a solvent. In certain embodiments, at least one of the components is a solvent.
- a co-crystal of a compound disclosed herein and an acid is different from a salt formed from a compound disclosed herein and the acid.
- a compound disclosed herein is complexed with the acid in a way that proton transfer (e.g., a complete proton transfer) from the acid to a compound disclosed herein easily occurs at room temperature.
- a compound disclosed herein is complexed with the acid in a way that proton transfer from the acid to a compound disclosed herein does not easily occur at room temperature.
- Co-crystals may be useful to improve the properties (e.g., solubility, stability, and ease of formulation) of a compound disclosed herein.
- polymorph refers to a crystalline form of a compound (or a salt, hydrate, or solvate thereof). All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate.
- Various polymorphs of a compound can be prepared by crystallization under different conditions.
- prodrugs refers to compounds that have cleavable groups and become by solvolysis or under physiological conditions the compounds described herein, which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like. Other derivatives of the
- Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds described herein are particular prodrugs.
- double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
- Glycerol is prochiral with respect to reactions of the two primary alcohols. In substituted derivatives, such as plasmalogens, stereospecific numbering (sn) is used.
- the hydroxyl group of the second carbon of glycerol (sn2) is on the left on a Fischer projection, the sn1 carbon at the top, and the sn3 carbon at the bottom.
- the spatial configuration (D or L) of the glycero-molecule is identified by the residues on the positions sn1 and sn3.
- the term “plasmalogen” refers to vinyl ether phospholipids comprising a vinyl ether moiety at the 1-position, an ester moiety at the 2-position, and a head group (e.g., a phosphate head group) at the 3-position of a glycerol backbone.
- Plasmalogens include plasmenylcholines and plasmenylethalomines.
- the term “plasmalogen species” refers to both plasmalogens and plasmalogen derivatives.
- the vinyl ether moiety is a saturated or unsaturated aliphatic group (e.g., C16:0, C18:0, or C18:1).
- the acyl group is a saturated or unsaturated fatty acid (e.g., docosahexaenoic acid or arachidonic acid).
- the vinyl ether moiety is at the sn1 position.
- the phosphate head group is at the sn3 position.
- a “subject” to which administration is contemplated refers to a human (i.e., male or female of any age group, e.g., pediatric subject (e.g., infant, child, or adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) or non-human animal.
- the non-human animal is a mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog), or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or
- the non-human animal is a fish, reptile, or amphibian.
- the non-human animal may be a male or female at any stage of development.
- the non-human animal may be a transgenic animal or genetically engineered animal.
- patient refers to a human subject in need of treatment of a disease.
- tissue sample refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise).
- tissue samples such as tissue sections and needle biopsies of a tissue
- cell samples e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection) or samples of cells obtained by microdissection
- samples of whole organisms such as samples of yeasts or bacteria
- cell fractions, fragments or organelles such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise.
- tissue refers to any biological tissue of a subject (including a group of cells, a body part, or an organ) or a part thereof, including blood and/or lymph vessels.
- the tissue is a biological tissue which is the object to which a compound, particle, and/or composition of the invention is delivered.
- a tissue may be an abnormal or unhealthy tissue, which may need to be treated.
- a tissue may also be a normal or healthy tissue that is under a higher than normal risk of becoming abnormal or unhealthy, which may need to be prevented.
- the term “administer,” “administering,” or “administration” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a composition thereof, in or on a subject.
- treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease described herein.
- treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed.
- treatment may be administered in the absence of signs or symptoms of the disease.
- treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of exposure to a pathogen). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
- condition “disease,” and “disorder” are used interchangeably.
- an “effective amount” of a compound described herein refers to an amount sufficient to elicit the desired biological response.
- An effective amount of a compound described herein may vary depending on such factors as the desired biological endpoint, severity of side effects, disease, or disorder, the identity, pharmacokinetics, and pharmacodynamics of the particular compound, the condition being treated, the mode, route, and desired or required frequency of administration, the species, age and health or general condition of the subject.
- an effective amount is a therapeutically effective amount.
- an effective amount is a prophylactic treatment.
- an effective amount is the amount of a compound described herein in a single dose.
- an effective amount is the combined amounts of a compound described herein in multiple doses.
- the desired dosage is delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
- the desired dosage is delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
- an effective amount of a compound for administration one or more times a day to a 70 kg adult human comprises about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosage form.
- the compounds of the present disclosure may be administered orally or parenterally at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and more preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
- dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult.
- the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
- a “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition.
- a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition.
- the term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and/or enhances the therapeutic efficacy of another therapeutic agent.
- a therapeutically effective amount is an amount sufficient for transport via Mfsd2a in a subject.
- a therapeutically effective amount is an amount sufficient for treating a disease, disorder, or condition in a subject. In certain embodiments, a therapeutically effective amount is an amount sufficient for treating a neurological disease in a subject. In certain embodiments, a therapeutically effective amount is an amount sufficient for transport via Mfsd2a and treating a disease, disorder, or condition in a subject. In certain embodiments, a therapeutically effective amount is an amount sufficient for transport via Mfsd2a and treating a neurological disease in a subject. [0094] A “prophylactically effective amount” of a compound described herein is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence.
- a prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition.
- the term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
- a prophylactically effective amount is an amount sufficient for transport via Mfsd2a in a subject.
- a prophylactically effective amount is an amount sufficient for preventing a disease, disorder, or condition in a subject.
- a prophylactically effective amount is an amount sufficient for preventing a neurological disease in a subject.
- a prophylactically effective amount is an amount sufficient for transport via Mfsd2a and preventing a disease, disorder, or condition in a subject. In certain embodiments, a prophylactically effective amount is an amount sufficient for transport via Mfsd2a and preventing a neurological disease in a subject.
- the term “prevent,” “preventing,” or “prevention” refers to a prophylactic treatment of a subject who is not and was not with a disease but is at risk of developing the disease or who was with a disease, is not with the disease, but is at risk of regression of the disease. In
- the subject is at a higher risk of developing the disease or at a higher risk of regression of the disease than an average healthy member of a population.
- the term “neurological disease” refers to any disease of the nervous system, including diseases that involve the central nervous system (brain, brainstem and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both central and peripheral nervous system).
- Neurodegenerative diseases refer to a type of neurological disease marked by the loss of nerve cells, including, but not limited to, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, tauopathies (including frontotemporal dementia), and Huntington’s disease.
- neurological diseases include, but are not limited to, headache, stupor and coma, dementia, seizure, sleep disorders, trauma, infections, neoplasms, neuro-ophthalmology, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of peripheral nerves, muscle and neuromuscular junctions.
- Neurological disorders also include synuclienopathies. Synuclienopathies include, but are not limited to Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.
- Addiction and mental illness include, but are not limited to, bipolar disorder and schizophrenia, are also included in the definition of neurological diseases.
- neurological diseases include acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers’ disease; alternating hemiplegia; Alzheimer’s disease; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Arnold-Chiari malformation; arteriovenous malformation; Asperger syndrome; ataxia telangiectasia; attention deficit hyperactivity disorder; autism; autonomic dysfunction; back pain; Batten disease; Behcet’s disease; Bell’s palsy; benign essential blepharospasm; benign focal; amyotrophy; benign intracranial hypertension; Binswanger’s disease; blepharospasm; Bloch
- Jakob disease Jakob disease; cumulative trauma disorders; Cushing’s syndrome; cytomegalic inclusion body disease (CIBD); cytomegalovirus infection; dancing eyes-dancing feet syndrome; Dandy-Walker syndrome; Dawson disease; De Morsier’s syndrome; Dejerine-Klumpke palsy; dementia; dermatomyositis; diabetic neuropathy; diffuse sclerosis; dysautonomia; dysgraphia; dyslexia; dystonias; early infantile epileptic encephalopathy; empty sella syndrome; encephalitis; encephaloceles; encephalotrigeminal angiomatosis; epilepsy; Erb’s palsy; essential tremor; Fabry’s disease; Fahr’s syndrome; fainting; familial spastic paralysis; febrile seizures; Fisher syndrome; Friedreich’s ataxia; frontotemporal dementia and other “tauopathies”; Gaucher’s disease; Gerstmann’s syndrome; giant cell arteritis;
- dementia is used herein to indicate both cognitive impairment per se, as well as pathologies causing cognitive impairment.
- dementia is caused by one or more neurological disorders.
- Dementia includes, but is not limited to, dementia associated with Alzheimer’s disease, dementia with Lewy bodies, frontotemporal lobe dementia, vascular induced dementia (e.g., multi-infarct dementia), anoxic event induced
- dementia e.g., cardiac arrest
- trauma to the brain induced dementia e.g., dementia pugilistica
- dementia resulting from exposure to an infectious agent e.g., Creutzfeldt-Jakob Disease
- toxic agent e.g., alcohol-induced dementia
- autism multiple sclerosis
- Parkinson's disease bipolar disorder
- ischemia ischemia
- Huntington's chorea major depressive disorder
- amnesia anxiety disorder
- traumatic brain injury obsessive compulsive disorder
- schizophrenia mental retardation, and/or epilepsy.
- metabolic disorder refers to any disorder that involves an alteration in the normal metabolism of carbohydrates, lipids, proteins, nucleic acids, or a combination thereof.
- a metabolic disorder is associated with either a deficiency or excess in a metabolic pathway resulting in an imbalance in metabolism of nucleic acids, proteins, lipids, and/or carbohydrates.
- Factors affecting metabolism include, and are not limited to, the endocrine (hormonal) control system (e.g., the insulin pathway, the enteroendocrine hormones including GLP-1, PYY or the like), the neural control system (e.g., GLP-1 in the brain), or the like.
- metabolic disorders include, but are not limited to, diabetes (e.g., Type I diabetes, Type II diabetes, gestational diabetes), hyperglycemia, hyperinsulinemia, insulin resistance, and obesity.
- diabetes e.g., Type I diabetes, Type II diabetes, gestational diabetes
- hyperglycemia hyperinsulinemia
- insulin resistance e.g., obesity
- obesity e.g., diabetes e.g., diabetes, diabetes, diabetes, diabetes, Type I diabetes, Type II diabetes, gestational diabetes
- hyperglycemia e.g., hyperglycemia, hyperinsulinemia, insulin resistance, and obesity.
- diabetes e.g., Type I diabetes, Type II diabetes, gestational diabetes
- hyperglycemia e.g., hyperinsulinemia
- hyperinsulinemia e.g., insulin resistance to obesity
- obesity e.g., diabetes e.g., diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes,
- Cardiovascular diseases include, but are not limited to, angina, arrhythmia, congenital heart disease, coronary artery disease, heart attack, heart failure, dilated cardiomyopathy, hypertrophic cardiomyopathy, mitral regurgitation, mitral valve prolapse, pulmonary stenosis, aortic stenosis, atrial fibrillation, rheumatic heart disease, radiation heart disease, peripheral artery disease, aneurysm, renal artery disease, Raynaud’s disease, peripheral venous disease, ischemic stroke, transient ischemic attack, venous blood clots, blood clotting disorders, or Buerger’s disease, cerebrovascular disease, deep vein thrombosis, pulmonary embolism, hypertension, circulatory shock, myocardial reperfusion injury, and atherosclerosis.
- a proliferative disease refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990).
- a proliferative disease is associated with one or more of: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g.,
- proliferative diseases include cancers (i.e., “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.
- malignant neoplasms a malignant neoplasms
- benign neoplasms a benign neoplasms
- angiogenesis a renin-like reonucleic acid
- inflammatory diseases a malignant neoplasms
- autoimmune diseases include cancers (i.e., “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.
- angiogenesis refers to the physiological process through which new blood vessels form from pre-existing vessels.
- Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development. Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. In some embodiments, angiogenesis is chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF).
- VEGF growth factors
- neoplasm refers to abnormal (e.g., excessive or insufficient) angiogenesis that amounts to and/or is associated with a disease.
- neoplasm and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue.
- a neoplasm or tumor is “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis.
- a “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin.
- a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites.
- Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias.
- certain “benign” tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor’s neoplastic cells, and these tumors are referred to as “pre-malignant neoplasms.”
- An exemplary pre-malignant neoplasm is a teratoma.
- a “malignant neoplasm” is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue.
- a malignant neoplasm generally has the capacity to metastasize to distant sites.
- cancer refers to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue and is typically identifiable by the presence of a “secondary tumor” or “secondary cell mass” of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located.
- a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.
- cancer refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues.
- Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), med
- marginal zone B-cell lymphomas e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenström’s macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T-lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T
- Wilms tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a.
- HCC hepatocellular cancer
- lung cancer e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung
- myelofibrosis MF
- chronic idiopathic myelofibrosis chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)
- neuroblastoma e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis
- neuroendocrine cancer e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor
- osteosarcoma e.g.,bone cancer
- ovarian cancer e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma
- papillary adenocarcinoma pancreatic cancer
- pancreatic cancer e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors
- liver disease or “hepatic disease” refers to damage to or a disease of the liver.
- liver disease examples include intrahepatic cholestasis (e.g., alagille syndrome, biliary liver cirrhosis), fatty liver (e.g., alcoholic fatty liver, Reye’s syndrome), hepatic vein thrombosis, hepatolenticular degeneration (i.e., Wilson's disease), hepatomegaly, liver abscess (e.g., amebic liver abscess), liver cirrhosis (e.g., alcoholic, biliary, and experimental liver cirrhosis), alcoholic liver diseases (e.g., fatty liver, hepatitis, cirrhosis), parasitic liver disease (e.g., hepatic echinococcosis, fascioliasis, amebic liver abscess), jaundice (e.g., hemolytic, hepatocellular, cholestatic jaundice), cholestasis, portal hypertension, liver en
- ophthalmic disease includes diseases of the eye and ocular appendages.
- an ophthalmic disease may affect the eyelids, tear organ, cornea, iris, pupil, lens, retina, or sclera.
- the ophthalmic disease or disorder is
- lung disease or “pulmonary disease” refers to a disease of the lung.
- lung diseases include, but are not limited to, bronchiectasis, bronchitis, bronchopulmonary dysplasia, interstitial lung disease, occupational lung disease, emphysema, cystic fibrosis, acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, bronchopulmonary dysplasia, asthma (e.g., intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma), chronic bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, interstitial lung disease, sarcoidosis, asbestosis, aspergilloma, aspergillosis, pneumonia (e.g., lobar pneumonia, multilobar pneumonia, bronchial pneumonia, interstitial pneumonia), pulmonary fibrosis, pulmonary tub
- genetic disease refers to a disease caused by one or more abnormalities in the genome of a subject, such as a disease that is present from birth of the subject.
- a genetic disease is heritable and is passed down from the parents’ genes.
- a genetic disease is caused by mutations or changes of the DNAs and/or RNAs of the subject. In such cases, the genetic disease will be heritable if it occurs in the germline.
- Exemplary genetic diseases include, but are not limited to, Aarskog-Scott syndrome, Aase syndrome, achondroplasia, acrodysostosis, addiction, adreno- leukodystrophy, albinism, ablepharon-macrostomia syndrome, alagille syndrome, alkaptonuria, alpha-1 antitrypsin deficiency, Alport’s syndrome, Alzheimer’s disease, asthma, autoimmune polyglandular syndrome, androgen insensitivity syndrome, Angelman syndrome, ataxia, ataxia telangiectasia, atherosclerosis, attention deficit hyperactivity disorder (ADHD), autism, baldness, Batten disease, Beckwith-Wiedemann syndrome, Best disease, bipolar disorder, brachydactyl), breast cancer, Burkitt lymphoma, chronic myeloid leukemia, Charcot-Marie-Tooth disease, Crohn’s disease, cleft lip, Cockayne syndrome, Coffin Lowry syndrome, colon cancer, congenital adrenal
- inflammatory disease and “inflammatory condition” are used interchangeably herein, and refer to a disease or condition caused by, resulting from, or resulting in inflammation.
- Inflammatory diseases and conditions include those diseases, disorders or conditions that are characterized by signs of pain (dolor, from the generation of noxious substances and the stimulation of nerves), heat (calor, from vasodilatation), redness (rubor, from vasodilatation and increased blood flow), swelling (tumor, from excessive inflow or restricted outflow of fluid), and/or loss of function (functio laesa, which can be partial or complete, temporary or permanent.
- Inflammation takes on many forms and includes, but is not limited to, acute, adhesive, atrophic, catarrhal, chronic, cirrhotic, diffuse,
- inflammatory disease may also refer to a dysregulated inflammatory reaction that causes an exaggerated response by macrophages, granulocytes, and/or T-lymphocytes leading to abnormal tissue damage and/or cell death.
- An inflammatory disease can be either an acute or chronic inflammatory condition and can result from infections or non-infectious causes.
- Inflammatory diseases include, without limitation, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthrosteitis, rheumatoid arthritis, inflammatory arthritis, Sjogren’s syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g., Type I), myasthenia gravis, Hashimoto’s thyroiditis, Graves’ disease, Goodpasture’s disease, mixed connective tissue disease,
- An ocular inflammatory disease includes, but is not limited to, post-surgical inflammation.
- Additional exemplary inflammatory conditions include, but are not limited to, inflammation associated with acne, anemia (e.g., aplastic anemia, haemolytic autoimmune anaemia), asthma, arteritis (e.g., polyarteritis, temporal arteritis, periarteritis nodosa, Takayasu's arteritis), arthritis (e.g., crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis and Reiter's arthritis), ankylosing spondylitis, amylosis, amyotrophic lateral sclerosis, autoimmune diseases, allergies or allergic reactions, atherosclerosis, bronchitis, bursitis, chronic prostatitis, conjunctivitis, Chagas disease, chronic
- the inflammatory disorder is selected from arthritis (e.g., rheumatoid arthritis), inflammatory bowel disease, inflammatory bowel syndrome, asthma, psoriasis, endometriosis, interstitial cystitis and prostatistis.
- arthritis e.g., rheumatoid arthritis
- inflammatory bowel disease e.g., inflammatory bowel syndrome
- asthma e.g., psoriasis
- endometriosis e.g., endometriosis
- interstitial cystitis e.g., interstitial cystitis and prostatistis.
- the inflammatory condition is an acute inflammatory condition (e.g., for example,
- the inflammatory condition is a chronic inflammatory condition (e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease).
- the compounds may also be useful in treating inflammation associated with trauma and non-inflammatory myalgia.
- the compounds disclosed herein may also be useful in treating inflammation associated with cancer.
- An “autoimmune disease” refers to a disease arising from an inappropriate immune response of the body of a subject against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells.
- this is restricted to certain organs (e.g., in autoimmune thyroiditis) or involve a particular tissue in different places (e.g., Goodpasture’s disease which may affect the basement membrane in both the lung and kidney).
- the treatment of autoimmune diseases is typically with immunosuppression, e.g., medications which decrease the immune response.
- Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture’s syndrome, necrotizing vasculitis, lymphadenitis, peri- arteritis nodosa, systemic lupus erythematosis, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosis, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis/polymyositis, anti-phospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener’s granulomatosis, microscopic polyangiitis), uveitis, Sjogren’s syndrome, Crohn’s disease, Reiter’s syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barré syndrome, Hashimoto’s thyroiditis, and cardio
- a “hematological disease” includes a disease which affects a hematopoietic cell or tissue.
- Hematological diseases include diseases associated with aberrant hematological content and/or function. Examples of hematological diseases include diseases resulting from bone marrow irradiation or chemotherapy treatments for cancer, diseases such as pernicious anemia, hemorrhagic anemia, hemolytic anemia, aplastic anemia, sickle cell anemia, sideroblastic anemia, anemia associated with chronic infections such as malaria, trypanosomiasis, HTV, hepatitis virus or other viruses, myelophthisic anemias caused by marrow deficiencies, renal failure resulting from anemia, anemia, polycythemia, infectious mononucleosis (EVI), acute non-lymphocytic leukemia (ANLL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute myelomonocytic leukemia (AMMoL),
- transfusion reactions and erythroblastosis mechanical trauma to red blood cells such as micro-angiopathic hemolytic anemias, thrombotic thrombocytopenic purpura and disseminated intravascular coagulation, infections by parasites such as Plasmodium, chemical injuries from, e.g., lead poisoning, and hypersplenism.
- a “painful condition” includes, but is not limited to, neuropathic pain (e.g., peripheral neuropathic pain), central pain, deafferentiation pain, chronic pain (e.g., chronic nociceptive pain, and other forms of chronic pain such as post–operative pain, e.g., pain arising after hip, knee, or other replacement surgery), pre–operative pain, stimulus of nociceptive receptors (nociceptive pain), acute pain (e.g., phantom and transient acute pain), noninflammatory pain, inflammatory pain, pain associated with cancer, wound pain, burn pain, postoperative pain, pain associated with medical procedures, pain resulting from pruritus, painful bladder syndrome, pain associated with premenstrual dysphoric disorder and/or premenstrual syndrome, pain associated with chronic fatigue syndrome, pain associated with pre–term labor, pain associated with withdrawl symptoms from drug addiction, joint pain, arthritic pain (e.g., pain associated with crystalline arthritis, osteoarthritis, psoriatic arthritis, g
- One or more of the painful conditions contemplated herein can comprise mixtures of various types of pain provided above and herein (e.g., nociceptive pain, inflammatory pain, neuropathic pain, etc.). In some embodiments, a particular pain can dominate. In other embodiments, the painful condition comprises two or more types of pains without one dominating. A skilled clinician can determine the dosage to achieve a therapeutically effective amount for a particular subject based on the painful condition.
- the term “psychiatric disorder” refers to a disease of the mind and includes diseases and disorders listed in the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV), published by the American Psychiatric Association, Washington D. C. (1994).
- Psychiatric disorders include, but are not limited to, anxiety disorders (e.g., acute stress disorder agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, and specific phobia), childhood disorders, (e.g., attention-deficit/hyperactivity disorder, conduct disorder, and oppositional defiant disorder), eating disorders (e.g., anorexia nervosa and bulimia nervosa), mood disorders (e.g., depression, bipolar disorder, cyclothymic disorder, dysthymic disorder, and major depressive disorder), personality disorders (e.g., antisocial
- anxiety disorders e.g., acute stress disorder agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, and specific phobia
- childhood disorders e.g., attention-deficit/hyperactivity disorder, conduct disorder, and oppositional
- personality disorder avoidant personality disorder, borderline personality disorder, dependent personality disorder, histrionic personality disorder, narcissistic personality disorder, obsessive-compulsive personality disorder, paranoid personality disorder, schizoid personality disorder, and schizotypal personality disorder), psychotic disorders (e.g., brief psychotic disorder, delusional disorder, schizoaffective disorder, schizophreniform disorder, schizophrenia, and shared psychotic disorder), substance-related disorders (e.g., alcohol dependence, amphetamine dependence, cannabis dependence, cocaine dependence, hallucinogen dependence, inhalant dependence, nicotine dependence, opioid dependence, phencyclidine dependence, and sedative dependence), adjustment disorder, autism, delirium, dementia, multi-infarct dementia, learning and memory disorders (e.g., amnesia and age- related memory loss), and Tourette’s disorder.
- psychotic disorders e.g., brief psychotic disorder, delusional disorder, schizoaffective disorder, schizophreniform disorder, schizophrenia, and shared
- Immune disorders include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren’s syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet’s disease, haemolytic autoimmune anaemias, multiple sclerosis, amyotrophic lateral sclerosis, amylosis, acute painful shoulder, psoriatic, and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin condition (e.g., psoriasis, eczema, burns, dermatitis, pruritus (itch)), enuresis, eosinophilic disease, gastrointestinal disorder (e.g., selected from p
- An “infection” or “infectious disease” refers to an infection with a microorganism, such as a protozoa, fungus, bacteria, or virus.
- a microorganism such as a protozoa, fungus, bacteria, or virus.
- Various infections include, but are not limited to, skin infections, GI infections, urinary tract infections, genito-urinary infections, sepsis, blood infections, and systemic infections.
- mitochondria disorders related to disorders that are due to abnormal mitochondria, such as, for example, a mitochondrial genetic mutation, enzyme pathways, etc.
- disorders include, but are not limited to: loss of motor control, muscle weakness and pain, gastro-intestinal disorders and swallowing difficulties, poor growth, cardiac disease, liver disease, diabetes, respiratory complications, seizures, visual/hearing problems, lactic acidosis, developmental delays, and susceptibility to infection.
- skin condition or “skin disease” refers to a condition related to the skin.
- Exemplary skin conditions or skin diseases include, but are not limited to, but are not limited to, acanthoma fissuratum, acanthosis nigricans, accessory tragus, acne, acne excoriée, acne keloidalis nuchae, acquired digital fibrokeratoma, acrochordons, acrodermatitis enteropathica, acropustulosis of infancy, actinic cheilitis, actinic keratosis, actinic purpura, dolorosa (Dercum’s disease), albinism, alkaptonuria, allergic contact dermatitis, alopecia areata, alopecia mucinosa, androgenetic alopecia, anetoderma, angioedema, angiofibroma, angiokeratoma, angiomas, angular cheilitis, aphthous ulcer, aplasia cutis congenita, ashy dermatosis, puttotic ec
- scrotum syndrome rheumatoid nodules, rocky mountain spotted fever, rosacea, roseola infantum, sarcoidosis, scabies, scarlet fever, Schamberg’s disease, scleroderma, sebaceous cyst, sebaceous hyperplasia, seborrheic dermatitis, seborrheic keratoses, shingles, skin tags, spider angioma, spider bites, spitz nevus, sporotrichosis, squamous cell carcinoma, staphylococcal scalded skin syndrome, stasis dermatitis, steatocystoma multiplex, Stevens Johnson syndrome, stretch marks, striae, Sturge-Weber syndrome, subacute cutaneous lupus erythematosus, subungual hematoma, sweet’s syndrome, swimmer’s itch, syphilis, syringoma, systemic lupus erythe
- spleen disease refers to a disease of the spleen.
- Example of spleen diseases include, but are not limited to, splenomegaly, spleen cancer, asplenia, spleen trauma, idiopathic purpura, Felty’s syndrome, Hodgkin’s disease, and immune-mediated destruction of the spleen.
- all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” “About” and “approximately” mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements.
- the compounds provided herein may cross the blood-brain barrier and/or blood-retinal barrier and can therefore be used to treat and/or prevent diseases and conditions in a subject, such as diseases or conditions associated with plasmalogen deficiency of one or more plasmalogens, including, but not limited to, neurodegenerative diseases, genetic diseases, and pulmonary infections
- the plasmalogen deficiency may be caused by reduced synthesis (e.g., due to peroxisomal dysfunction) or transport, or by increased degradation (e.g., due to cytochrome C activity, oxidative stress, inflammation, or homeostatic conversion).
- methods of treating and/or preventing a disease, disorder, or condition in a subject comprising administering an effective amount of a compound or composition provided herein to the subject.
- the compound or composition may be administered as a monotherapy or in combination with another therapy, as described herein.
- Mfsd2a methods of transporting a compound or composition provided herein via Mfsd2a, including but not limited to transport via Mfsd2a across the blood-brain barrier or blood-retinal barrier, and methods of increasing plasmalogen levels in the brain or central nervous system of a subject.
- R 1 is optionally substituted C7-25 alkyl
- R 2 is optionally substituted
- L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene
- X is selected from R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C 1-6 alkyl, or R 5 is absent when
- L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene.
- the compound of Formula (I) is not: , or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 is optionally substituted C7-25 alkyl; R 2 is optionally substituted ;
- L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene;
- X is selected from R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C 1-6 alkyl, or R 5 is absent when L 2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene.
- the compound is of Formula (I-A): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1 is optionally substituted C 7-25 alkyl; R 2 is optionally substituted ; L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C1-6 alkyl; and L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene. [00127] In certain embodiments, the compound is of Formula (I-A): or a pharmaceutically acceptable salt thereof, wherein: R 1 is optionally substituted C7-25 alkyl; R 2 is optionally substituted ;
- L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C1-6 alkyl; and L 2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene.
- the compound is of Formula (I-A-i): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1 is optionally substituted C 7-25 alkyl; R 2 is optionally substituted R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C 1-6 alkyl; R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or C1-6 alkyl, or R 6 and R 7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or R 9 and R 10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; and
- the compound is of Formula (I-A-i): or a pharmaceutically acceptable salt thereof, wherein: R 1 is optionally substituted C 7-25 alkyl; R 2 is optionally substituted ; R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C 1-6 alkyl;
- R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or C 1-6 alkyl, or R 6 and R 7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or R 9 and R 10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; and L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene; provided that at least one of R 6 , R 7 , R 8 , R 9 , and R 10 is not hydrogen.
- the compound is of Formula (I-A-ii): -ii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1 is optionally substituted C 7-25 alkyl; R 2 is optionally substituted L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; and L 2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene.
- the compound is of Formula (I-A-ii): -ii), or a pharmaceutically acceptable salt thereof, wherein: R 1 is optionally substituted C 7-25 alkyl; R 2 is optionally substituted ; L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; and L 2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene.
- the compound is of Formula (I-A-iii): -iii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1 is optionally substituted C7-25 alkyl; R 2 is optionally substituted ; L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; and L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene.
- the compound is of Formula (I-A-iii): -iii), or a pharmaceutically acceptable salt thereof, wherein: R 1 is optionally substituted C7-25 alkyl; R 2 is optionally substituted ; L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; and L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene.
- the compound is of Formula (I-B): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1 is optionally substituted C7-25 alkyl; R 2 is optionally substituted
- L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R 3 and R 4 are each independently hydrogen or optionally substituted C1-6 alkyl; and L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene.
- the compound is of Formula (I-B): or a pharmaceutically acceptable salt thereof, wherein: R 1 is optionally substituted C7-25 alkyl; R 2 is optionally substituted ; L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R 3 and R 4 are each independently hydrogen or optionally substituted C 1-6 alkyl; and L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene.
- R 1 is optionally substituted C7-25 alkyl
- R 2 is optionally substituted
- L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene
- R 3 and R 4 are each independently hydrogen or optionally substituted C 1-6 alkyl
- L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene.
- the compound is of Formula (I-C): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1 is optionally substituted C7-25 alkyl; R 2 is optionally substituted ; X is selected from R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C1-6 alkyl, or R 5 is absent when
- L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene; and R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or C1-6 alkyl, or R 6 and R 7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or R 9 and R 10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. [00137] In some embodiments, R 1 is optionally substituted C7-25 alkyl.
- R 1 is unsubstituted C 7-25 alkyl. In some embodiments, R 1 is C 7-25 haloalkyl. In certain embodiments, R 1 is C 7-25 fluoroalkyl. In some embodiments, R 1 is C 7-25 alkyl substituted with at least one deuterium. In certain embodiments, R 1 is C7-25 alkyl substituted with at least two deuterium atoms. In some embodiments, R 1 is optionally substituted C12-20 alkyl. In certain embodiments, R 1 is unsubstituted C 12-20 alkyl. In some embodiments, R 1 is C12-20 haloalkyl. In certain embodiments, R 1 is C12-20 fluoroalkyl.
- R 1 is C12-20 alkyl substituted with at least one deuterium. In certain embodiments, R 1 is C12-20 alkyl substituted with at least two deuterium atoms. In some embodiments, R 1 is optionally substituted C14-18 alkyl. In certain embodiments, R 1 is unsubstituted C14-18 alkyl. In some embodiments, R 1 is C14-18 haloalkyl. In certain embodiments, R 1 is C14-18 fluoroalkyl. In some embodiments, R 1 is C 14-18 alkyl substituted with at least one deuterium. In certain embodiments, R 1 is C 14-18 alkyl substituted with at least two deuterium atoms.
- R 1 is optionally substituted C14 alkyl. In certain embodiments, R 1 is unsubstituted C14 alkyl. In some embodiments, R 1 is C14 haloalkyl. In certain embodiments, R 1 is C 14 fluoroalkyl. In some embodiments, R 1 is C 14 alkyl substituted with at least one deuterium. In certain embodiments, R 1 is C14 alkyl substituted with at least two deuterium atoms. In some embodiments, R 1 is optionally substituted C16 alkyl. In certain embodiments, R 1 is unsubstituted C 16 alkyl. In some embodiments, R 1 is C 16 haloalkyl.
- R 1 is C16 fluoroalkyl. In some embodiments, R 1 is C16 alkyl substituted with at least one deuterium. In certain embodiments, R 1 is C16 alkyl substituted with at least two deuterium atoms. [00138] In certain embodiments, R 1 is selected from the group consisting of ,
- R 1 is selected from . [00139] In certain embodiments, R 1 is selected from the group consisting of: . [00140] In some embodiments, R 1 is selected from the group consisting of: some embodiments, R 1 is selected from the group consisting of: . [00141] In certain embodiments, R 1 is selected from the group consisting of: ,
- R 1 is selected from . [00142] In certain embodiments, R 1 is selected from the group consisting of: . In certain embodiments, R 1 is selected from the group . [00143] In some embodiments, R 2 is optionally substituted . certain embodiments, R 2 is unsubstituted . some embodiments, R 2 is substituted with a non-aliphatic substituent. In some embodiments, R 2 is not substituted with an aliphatic substituent. In some embodiments, R 2 is not substituted with an alkyl, alkenyl, alkynyl group.
- R 2 is some embodiments, R 2 is substituted with at least one fluorine. In certain embodiments, R 2 is substituted with at least one deuterium. [00146] In certain embodiments, R 2 is selected from the group consisting of . [00147] In certain embodiments, R 1 is unsubstituted C 7-25 alkyl, and R 2 is unsubstituted . some embodiments, R 1 is C7-25 haloalkyl, and R 2 is unsubstituted . In certain embodiments, R 1 is C 7-25 fluoroalkyl, and R 2 is unsubstituted . some embodiments, R 1 is unsubstituted C12-20 alkyl, and R 2 is unsubstituted . certain embodiments, R 1 is C12- 20 haloalkyl, and R 2 is unsubstituted
- R 1 is C 12- 20 fluoroalkyl, and R 2 is unsubstituted .
- R 1 is unsubstituted C 7-25 alkyl, and R 2 is substituted with at least one fluorine.
- R 1 is C7-25 haloalkyl, and R 2 is substituted with at least one fluorine.
- R 1 is C 7-25 fluoroalkyl, and R 2 is substituted with at least one fluorine.
- R 1 is unsubstituted C12-20 alkyl, and R 2 is substituted with at least one fluorine.
- R 1 is C 12-20 haloalkyl, and R 2 is substituted with at least one fluorine. In some embodiments, R 1 is C12-20 fluoroalkyl, and R 2 is substituted with at least one fluorine. [00149] In certain embodiments, R 1 is unsubstituted C7-25 alkyl, and R 2 is substituted with at least one deuterium. In some embodiments, R 1 is C 7-25 haloalkyl, and R 2 is substituted with at least one deuterium. In certain embodiments, R 1 is C7-25 fluoroalkyl, and R 2 is substituted with at least one deuterium.
- R 1 is unsubstituted C 12-20 alkyl, and R 2 is substituted with at least one deuterium.
- R 1 is C12-20 haloalkyl, and R 2 is substituted with at least one deuterium.
- R 1 is C 12-20 fluoroalkyl, and R 2 is substituted with at least one deuterium.
- X is selected from .
- R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C 1-6 alkyl. In certain embodiments, R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C1-4 alkyl. In some embodiments, R 3 , R 4 , and R 5 are each independently hydrogen or optionally substituted C1-2 alkyl. In certain embodiments, R 3 , R 4 , and R 5 are each independently hydrogen or unsubstituted C 1-6 alkyl. In certain embodiments, R 3 , R 4 , and R 5 are each independently hydrogen or unsubstituted C1-4 alkyl.
- R 3 , R 4 , and R 5 are each independently hydrogen or unsubstituted C1-2 alkyl.
- at least one of R 3 , R 4 , and R 5 is hydrogen.
- at least two of R 3 , R 4 , and R 5 are hydrogen.
- R 3 , R 4 , and R 5 are each hydrogen.
- R 3 and R 4 are each hydrogen.
- R 3 and R 5 are each hydrogen.
- R 4 and R 5 are each hydrogen.
- at least one of R 3 , R 4 , and R 5 is unsubstituted C1-6 alkyl.
- At least one of R 3 and R 4 is optionally substituted C1-6 alkyl. In certain embodiments, at least one of R 3 and R 5 is optionally substituted C 1-6 alkyl. In some embodiments, at least one of R 4 and R 5 is optionally substituted C1-6 alkyl. In certain embodiments, R 3 and R 4 are each independently optionally substituted C1-6 alkyl. In some embodiments, R 3 and R 5 are each independently optionally substituted C 1-6 alkyl. In certain embodiments, R 4 and R 5 are each independently optionally substituted C 1-6 alkyl. In some embodiments, R 3 and R 4 are each methyl. In some embodiments, R 3 and R 5 are each methyl. In some embodiments, R 4 and R 5 are each methyl.
- R 5 is optionally substituted C 1-6 alkyl. In some embodiments, R 5 is methyl. [00154] In certain embodiments, R 3 and R 4 are hydrogen, and R 5 is unsubstituted C1-6 alkyl. In some embodiments, at least two of R 3 , R 4 , and R 5 are unsubstituted C1-6 alkyl. In some embodiments, R 3 is hydrogen, and at least one of R 4 and R 5 is unsubstituted C 1-6 alkyl. In
- R 3 , R 4 , and R 5 are each unsubstituted C 1-6 alkyl. In some embodiments, are each independently methyl, ethyl, propyl, or butyl. In certain embodiments, R 3 , R 4 , and R 5 are each methyl. In some embodiments, R 3 , R 4 , and R 5 are each ethyl. In certain embodiments, R 3 , R 4 , and R 5 are each propyl. In some embodiments, R 3 , R 4 , and R 5 are each butyl. [00155] In certain embodiments, at least one of R 3 , R 4 , and R 5 is optionally substituted C1-6 alkyl.
- R 3 and R 4 are hydrogen, and R 5 is optionally substituted C 1-6 alkyl. In some embodiments, at least two of R 3 , R 4 , and R 5 are optionally substituted C1-6 alkyl. In some embodiments, R 3 is hydrogen, and at least one of R 4 and R 5 is optionally substituted C 1-6 alkyl. In certain embodiments, R 3 is hydrogen, and R 4 is optionally substituted C 1-6 alkyl. In some embodiments, R 3 is hydrogen, and R 5 is optionally substituted C1-6 alkyl. In certain embodiments, R 3 , R 4 , and R 5 are each optionally substituted C1-6 alkyl.
- At least one of R 3 , R 4 , and R 5 is C1-6 fluoroalkyl. In some embodiments, at least one of R 3 and R 4 is C 1-6 fluoroalkyl. In certain embodiments, at least one of R 3 and R 5 is C1-6 fluoroalkyl. In some embodiments, at least one of R 4 and R 5 is C1-6 fluoroalkyl. In certain embodiments, R 5 is C1-6 fluoroalkyl. In some embodiments, R 5 is - CH 2 F, -CHF2, or -CF3. [00157] In certain embodiments, R 3 and R 4 are hydrogen, and R 5 is C1-6 fluoroalkyl.
- R 3 , R 4 , and R 5 are C 1-6 fluoroalkyl.
- R 3 is hydrogen, and at least one of R 4 and R 5 is C 1-6 fluoroalkyl.
- R 3 , R 4 , and R 5 are each C1-6 fluoroalkyl.
- at least one of R 3 , R 4 , and R 5 is - CH2F, -CHF 2 , or -CF 3 .
- at least one of R 3 and R 4 is -CH 2 F, -CHF 2 , or -CF 3 .
- At least one of R 3 and R 5 is -CH2F, -CHF2, or -CF3. In certain embodiments, at least one of R 4 and R 5 is -CH2F, -CHF2, or -CF3. In certain embodiments, at least one of R 3 , R 4 , and R 5 is -CH 2 F. In some embodiments, at least one of R 3 , R 4 , and R 5 is - CHF2. In certain embodiments, at least one of R 3 , R 4 , and R 5 is -CF3. [00158] In certain embodiments, R 3 and R 4 are joined together with the intervening atoms to form optionally substituted heterocyclyl.
- R 3 and R 4 are joined together with the intervening atoms to form substituted heterocyclyl. In certain embodiments, R 3 and R 4 are joined together with the intervening atoms to form unsubstituted heterocyclyl. In certain embodiments, R 3 and R 4 are joined together with the intervening atoms to form 3- to 7-membered optionally substituted heterocyclyl. In certain embodiments, R 3 and R 4 are
- R 3 and R 4 are joined together with the intervening atoms to form optionally substituted an aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl ring. In certain embodiments, R 3 and R 4 are joined together with the intervening atoms to form an unsubstituted aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl ring.
- R 3 and R 4 are joined together with the intervening atoms to form optionally substituted pyrrolidinyl or piperidinyl. In certain embodiments, R 3 and R 4 are joined together with the intervening atoms to form unsubstituted pyrrolidinyl or piperidinyl.
- R 1 is unsubstituted C7-25 alkyl, and at least one of R 3 , R 4 , and R 5 is hydrogen. In some embodiments, R 1 is C 7-25 haloalkyl, and at least one of R 3 , R 4 , and R 5 is hydrogen.
- R 1 is C7-25 fluoroalkyl, and at least one of R 3 , R 4 , and R 5 is hydrogen. In some embodiments, R 1 is unsubstituted C12-20 alkyl, and at least one of R 3 , R 4 , and R 5 is hydrogen. In certain embodiments, R 1 is C 12-20 haloalkyl, and at least one of R 3 , R 4 , and R 5 is hydrogen. In some embodiments, R 1 is C 12-20 fluoroalkyl, and at least one of R 3 , R 4 , and R 5 is hydrogen.
- R 1 is unsubstituted C7-25 alkyl, and at least one of R 3 , R 4 , and R 5 is optionally substituted C 1-6 alkyl. In some embodiments, R 1 is C 7-25 haloalkyl, and at
- R 3 , R 4 , and R 5 are optionally substituted C 1-6 alkyl.
- R 1 is C7-25 fluoroalkyl, and at least one of R 3 , R 4 , and R 5 is optionally substituted C1-6 alkyl.
- R 1 is unsubstituted C12-20 alkyl, and at least one of R 3 , R 4 , and R 5 is optionally substituted C 1-6 alkyl.
- R 1 is C 12-20 haloalkyl, and at least one of R 3 , R 4 , and R 5 is optionally substituted C1-6 alkyl.
- R 1 is C12-20 fluoroalkyl, and at least one of R 3 , R 4 , and R 5 is optionally substituted C1-6 alkyl .
- R 1 is unsubstituted C 7-25 alkyl, and at least one of R 3 , R 4 , and R 5 is C1-6 fluoroalkyl.
- R 1 is C7-25 haloalkyl, and at least one of R 3 , R 4 , and R 5 is C1-6 fluoroalkyl.
- R 1 is C7-25 fluoroalkyl, and at least one of R 3 , R 4 , and R 5 is C 1-6 fluoroalkyl.
- R 1 is unsubstituted C 12-20 alkyl, and at least one of R 3 , R 4 , and R 5 is C 1-6 fluoroalkyl. In certain embodiments, R 1 is C 12-20 haloalkyl, and at least one of R 3 , R 4 , and R 5 is C1-6 fluoroalkyl. In some embodiments, R 1 is C12-20 fluoroalkyl, and at least one of R 3 , R 4 , and R 5 is C1-6 fluoroalkyl . [00163] In some embodiments, L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene.
- L 1 is optionally substituted or optionally substituted carbocyclylene. In some embodiments, L 1 is optionally substituted or optionally substituted heterocyclylene. In certain embodiments, L 1 is optionally substituted carbocyclylene, or optionally substituted heterocyclylene. [00164] In some embodiments, L 1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene, wherein ** designates the point of attachment to -OC(O)R 2 . In certain embodiments, L 1 is optionally substituted or optionally substituted carbocyclylene, wherein ** designates the point of attachment to -OC(O)R 2 . In some embodiments, L 1 is optionally substituted or optionally substituted heterocyclylene, wherein ** designates the point of attachment to -
- L 1 is optionally substituted carbocyclylene, or optionally substituted heterocyclylene, wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is optionally substituted .
- L 1 is optionally substituted .
- L 1 is unsubstituted .
- L 1 is substituted .
- L 1 is substituted with one or more fluorine atoms.
- L 1 is substituted with one or more deuterium atoms.
- L 1 is substituted with one or more instances of optionally substituted C 1-6 alkyl.
- L 1 is substituted with one or more instances of unsubstituted C1-6 alkyl. In some embodiments, L 1 is substituted with one or more instances of substituted C1-6 alkyl. In some embodiments, L 1 is substituted with optionally substituted carbocyclyl. In certain embodiments, L 1 is substituted with unsubstituted carbocyclyl. In some embodiments, L 1 is substituted with substituted carbocyclyl. In some embodiments, L 1 is substituted with optionally substituted C3-6 carbocyclyl. In certain embodiments, L 1 is substituted with unsubstituted C 3-6 carbocyclyl. In some embodiments, L 1 is substituted with substituted C 3-6 carbocyclyl.
- L 1 is substituted with optionally substituted C3-4 carbocyclyl. In certain embodiments, L 1 is substituted with unsubstituted C3-4 carbocyclyl. In some embodiments, L 1 is substituted with substituted C3-4 carbocyclyl.
- L is optionally substituted , wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is optionally substituted , wherein ** designates the point of attachment to -OC(O)R 2 .
- L is unsubstituted , wherein ** designates the point of 2 1 attachment to -OC(O)R .
- L is substituted , wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is substituted with one or more fluorine atoms, wherein ** designates the point of attachment to 2 1 -OC(O)R .
- L is substituted with one or more deuterium atoms, wherein ** designates the point of attachment to -OC(O)R 2 .
- L is substituted with one or more instances of optionally substituted C1-6 alkyl, wherein ** designates the point of attachment to -OC(O)R 2 .
- L is substituted with one or more instances of unsubstituted C 1- 6 alkyl, wherein ** designates the point of attachment to -OC(O)R 2 .
- 1 L is substituted with one or more instances of substituted C 1-6 alkyl, wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is substituted with optionally substituted carbocyclyl, wherein ** designates the
- L is substituted with unsubstituted carbocyclyl, wherein ** designates the point of attachment to -OC(O)R 2 . 1 In some embodiments, L is substituted with substituted carbocyclyl, wherein ** designates the point of attachment to -OC(O)R 2 . In some embodiments, L 1 is substituted with optionally substituted C3-6 carbocyclyl, wherein ** designates 2 1 the point of attachment to -OC(O)R . In certain embodiments, L is substituted with unsubstituted C 3-6 carbocyclyl, wherein ** designates the point of attachment to - 2 1 OC(O)R .
- L is substituted with substituted C3-6 carbocyclyl, wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is substituted with optionally substituted C3-4 carbocyclyl, wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is substituted with unsubstituted C3-4 carbocyclyl, wherein ** designates the 2 1 point of attachment to -OC(O)R .
- L is substituted with substituted C 3-4 carbocyclyl, wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is optionally substituted carbocyclylene. In some embodiments, L 1 is unsubstituted carbocyclylene. In certain embodiments, L 1 is substituted carbocyclylene. In certain embodiments, L 1 is optionally substituted C3-14 carbocyclylene. In certain embodiments, L 1 is optionally substituted C 3 - 8 carbocyclylene. In certain embodiments, L 1 is C 3 - 6 carbocyclylene. In certain embodiments, L 1 is optionally substituted monocyclic carbocyclylene. In some embodiments, L 1 is unsubstituted monocyclic carbocyclylene. In certain embodiments, L 1 is substituted monocyclic carbocyclylene. In
- L 1 is optionally substituted C 3 - 14 monocyclic carbocyclylene. In certain embodiments, L 1 is optionally substituted C3-8 monocyclic carbocyclylene. In certain embodiments, L 1 is C3-6 monocyclic carbocyclylene. In certain embodiments, L 1 is optionally substituted cyclopropylene, optionally substituted cyclobutylene, optionally substituted cyclopentylene, or optionally substituted cyclohexylene. In some embodiments, L 1 is optionally substituted bicyclic carbocyclylene. In certain embodiments, L 1 is unsubstituted bicyclic carbocyclylene. In some embodiments, L 1 is substituted bicyclic carbocyclylene.
- L 1 is optionally substituted C3-14 bicyclic carbocyclylene. In certain embodiments, L 1 is optionally substituted C5-14 bicyclic carbocyclylene. In certain embodiments, L 1 is optionally substituted C 5 - 10 bicyclic carbocyclylene. [00168] In some embodiments, L 1 is optionally substituted heterocyclylene. In certain embodiments, L 1 is unsubstituted heterocyclylene. In some embodiments, L 1 is substituted heterocyclylene. In certain embodiments, L 1 is optionally substituted 3-14 membered heterocyclylene. In certain embodiments, L 1 is optionally substituted 3-8 membered heterocyclylene.
- L 1 is optionally substituted monocyclic heterocyclylene. In some embodiments, L 1 is unsubstituted monocyclic heterocyclylene. In certain embodiments, L 1 is substituted monocyclic heterocyclylene. In certain embodiments, L 1 is optionally substituted 3-14 membered monocyclic heterocyclylene. In certain embodiments, L 1 is optionally substituted 3-8 membered monocyclic heterocyclylene. In some embodiments, L 1 is optionally substituted bicyclic heterocyclylene. In certain embodiments, L 1 is unsubstituted bicyclic heterocyclylene. In some embodiments, L 1 is substituted bicyclic heterocyclylene.
- L 1 is optionally substituted 5-14 membered bicyclic heterocyclylene. In certain embodiments, L 1 is optionally substituted 5-10 membered bicyclic heterocyclylene. In certain embodiments, L 1 is heterocyclylene comprising at least one oxygen atom. In some embodiments, L 1 is heterocyclylene comprising at least one sulfur atom. In certain embodiments, L 1 is heterocyclylene comprising at least one optionally substituted nitrogen atom. In some embodiments, L 1 is heterocyclylene comprising at least one nitrogen atom substituted with hydrogen, optionally substituted C1-6 alkyl, or a nitrogen protecting group.
- L 1 is heterocyclylene comprising at least one nitrogen atom substituted with hydrogen, unsubstituted C 1-6 alkyl, or a nitrogen protecting group.
- L 1 is optionally substituted piperidinylene, optionally substituted tetrahydro-2H-pyranylene, or optionally substituted tetrahydro-2H-thiopyranylene.
- L 1 is selected from the group consisting of: , embodiments, L 1 is selected from the group consisting of: , and certain embodiments, L 1 is selected from the group consisting of:
- L 1 is selected from the group consisting of: , wherein ** designates the point of attachment to -OC(O)R 2 . In certain embodiments, L 1 is selected from the group consisting of: ,
- L 1 is selected from the group consisting of: , , , , , , , , , wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is selected from the group consisting of: , wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is selected from the group consisting of: wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is selected from the group consisting of: wherein ** designates the point of attachment to -OC(O)R 2 .
- L 1 is selected from the group consisting of: , wherein ** designates the point of attachment to -OC(O)R 2 .
- L 2 is optionally substituted C 1-10 alkylene or optionally substituted carbocyclylene. In certain embodiments, L 2 is optionally substituted C1-6 alkylene or optionally substituted carbocyclylene. In some embodiments, L 2 is optionally substituted
- L 2 is substituted with fluorine. In some embodiments, L 2 is optionally substituted C1-10 alkylene or optionally substituted C3-14 carbocyclylene. In certain embodiments, L 2 is optionally substituted C 1-6 alkylene or optionally substituted C 3-8 carbocyclylene. In some embodiments, L 2 is optionally substituted C1-4 alkylene or optionally substituted C3-8 carbocyclylene. In some embodiments, L 2 is substituted with fluorine. [00172] In some embodiments, L 2 is –(optionally substituted C 1-10 alkylene)-(optionally substituted carbocyclylene)-.
- L 2 is –(optionally substituted C1-10 alkylene)-(optionally substituted C3-14 carbocyclylene)-. In some embodiments, L 2 is – (optionally substituted C 1-6 alkylene)-(optionally substituted C 3-8 carbocyclylene)-. In some embodiments, L 2 is -(optionally substituted C 1-4 alkylene)-(optionally substituted C 3-14 carbocyclylene). In some embodiments, L 2 is –(optionally substituted C1-4 alkylene)- (optionally substituted C3-8 carbocyclylene)-. In some embodiments, L 2 is -(optionally substituted C 1 alkylene)-(optionally substituted C 3-8 carbocyclylene)-.
- L 2 is -(optionally substituted C2 alkylene)-(optionally substituted C3-8 carbocyclylene)-. In some embodiments, L 2 is -(optionally substituted C1-6 alkylene)-(optionally substituted C3-8 carbocyclylene)-(optionally substituted C 0-4 alkylene)-. In some embodiments, L 2 is - (optionally substituted C1-4 alkylene)-(optionally substituted C3-8 carbocyclylene)-(optionally substituted C0-4 alkylene)-. [00173] In certain embodiments, L 2 is optionally substituted C 1-10 alkylene. In some embodiments, L 2 is unsubstituted C 1-10 alkylene.
- L 2 is substituted C 1- 10 alkylene. In certain embodiments, L 2 is optionally substituted C1-6 alkylene. In some embodiments, L 2 is unsubstituted C1-6 alkylene. In certain embodiments, L 2 is substituted C1-6 alkylene. In certain embodiments, L 2 is optionally substituted C 1-4 alkylene. In some embodiments, L 2 is unsubstituted C1-4 alkylene. In certain embodiments, L 2 is substituted C1-4 alkylene. In some embodiments, L 2 is optionally substituted ethylene, propylene, or butylene. In certain embodiments, L 2 is optionally substituted ethylene or propylene. In some embodiments, L 2 is optionally substituted ethylene.
- L 2 is optionally substituted propylene. In some embodiments, L 2 is C1-10 alkylene substituted with fluorine. In some embodiments, L 2 is C 1-6 alkylene substituted with fluorine. In some embodiments, L 2 is C 1-4 alkylene substituted with fluorine. [00174] In certain embodiments, L 2 is optionally substituted carbocyclylene. In some embodiments, L 2 is unsubstituted carbocyclylene. In certain embodiments, L 2 is substituted carbocyclylene. In certain embodiments, L 2 is carbocyclylene substituted with fluorine. In
- L 2 is optionally substituted C 3-14 carbocyclylene. In some embodiments, L 2 is optionally substituted C3-8 carbocyclylene. In certain embodiments, L 2 is C3-6 carbocyclylene. In certain embodiments, L 2 is optionally substituted monocyclic carbocyclylene. In some embodiments, L 2 is unsubstituted monocyclic carbocyclylene. In certain embodiments, L 2 is substituted monocyclic carbocyclylene. In certain embodiments, L 2 is optionally substituted C3-14 monocyclic carbocyclylene. In certain embodiments, L 2 is optionally substituted C 3 - 8 monocyclic carbocyclylene. In certain embodiments, L 2 is C 3 - 6 monocyclic carbocyclylene.
- L 2 is optionally substituted cyclopropylene, optionally substituted cyclobutylene, optionally substituted cyclopentylene, or optionally substituted cyclohexylene.
- L 2 is optionally substituted bicyclic carbocyclylene.
- L 2 is unsubstituted bicyclic carbocyclylene.
- L 2 is substituted bicyclic carbocyclylene.
- L 2 is optionally substituted C3-14 bicyclic carbocyclylene.
- L 2 is optionally substituted C 5 - 14 bicyclic carbocyclylene.
- L 2 is optionally substituted C5-10 bicyclic carbocyclylene.
- L 2 is optionally substituted tricyclic carbocyclylene. In certain embodiments, L 2 is unsubstituted tricyclic carbocyclylene. In some embodiments, L 2 is substituted tricyclic carbocyclylene. In certain embodiments, L 2 is optionally substituted C3-14 tricyclic carbocyclylene. In certain embodiments, L 2 is optionally substituted C5-14 tricyclic carbocyclylene. In certain embodiments, L 2 is optionally substituted C 5 - 10 tricyclic carbocyclylene. , certain embodiments, L 2 is selected from the group consisting of: , some embodiments, L 2 is selected from the group consisting of:
- R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or optionally substituted C 1-6 alkyl, or R 6 and R 7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl, or R 9 and R 10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl.
- R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or C1-6 alkyl, or R 6 and R 7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl, or R 9 and R 10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl.
- R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or optionally substituted C 1-6 alkyl, or R 6 and R 7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl, or R 9 and R 10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; provided that at least one of R 6 , R 7 , R 8 , R 9 , and R 10 is not hydrogen.
- R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or C 1-6 alkyl, or R 6 and R 7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl, or R 9 and R 10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; provided that at least one of R 6 , R 7 , R 8 , R 9 , and R 10 is not hydrogen.
- R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or optionally substituted C1-6 alkyl. In certain embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, fluorine, or optionally substituted C1-6 alkyl. In some embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or unsubstituted C1-6 alkyl. In certain embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, halogen, or substituted C1-6 alkyl.
- R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen or halogen. In certain embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen or fluorine. In some embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen or optionally substituted C1-6 alkyl. In certain embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen or unsubstituted C 1-6 alkyl. In some embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently halogen or optionally substituted C1-6 alkyl.
- R 6 , R 7 , R 8 , R 9 , and R 10 are each independently halogen or optionally substituted C1-6 alkyl. In some embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently fluorine or optionally substituted C 1-6 alkyl. In some embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are each independently fluorine or unsubstituted C1-6 alkyl. In some embodiments, R 6 and R 7 are each methyl. In some embodiments, R 9 and R 10 are each methyl. [00178] In certain embodiments, at least two of R 6 , R 7 , R 8 , R 9 , and R 10 are not hydrogen.
- R 8 , R 9 , and R 10 are each hydrogen. In certain embodiments, R 6 , R 7 , and R 8 are each hydrogen. In some embodiments, R 6 , R 7 , R 8 , R 9 , and R 10 are hydrogen. [00179] In certain embodiments, at least one of R 6 , R 7 , R 8 , R 9 , and R 10 is halogen. In some embodiments, one of R 6 , R 7 , R 8 , R 9 , and R 10 is fluorine; and the others are hydrogen. In certain embodiments, R 6 is fluorine, and R 7 , R 8 , R 9 , and R 10 are hydrogen.
- R 8 is fluorine
- R 6 , R 7 , R 9 , and R 10 are hydrogen
- R 10 is fluorine
- R 6 , R 7 , R 8 , and R 9 are hydrogen.
- R 6 and R 7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl.
- R 6 and R 7 are joined together with the intervening carbon atom to form an unsubstituted carbocyclyl.
- R 6 and R 7 are joined together with the intervening carbon atom to form a substituted carbocyclyl.
- R 6 and R 7 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl, an unsubstituted cyclopentyl, an unsubstituted cyclobutyl, or an unsubstituted cyclopropyl. In some embodiments, R 6 and R 7 are joined together with the intervening carbon atom to form an unsubstituted cyclobutyl or an unsubstituted cyclopropyl. In certain embodiments, R 6 and R 7 are joined together with
- R 6 and R 7 are joined together with the intervening carbon atom to form an unsubstituted cyclopropyl.
- R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl.
- R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl.
- R 6 and R 9 are joined together with the intervening carbon atom to form an unsubstituted carbocyclyl.
- R 6 and R 9 are joined together with the intervening carbon atom to form a substituted carbocyclyl. In certain embodiments, R 6 and R 9 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl, unsubstituted cyclopentyl, unsubstituted cyclobutyl, or unsubstituted cyclopropyl. In some embodiments, R 6 and R 9 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl or unsubstituted cyclopentyl.
- R 6 and R 9 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl. In some embodiments, R 6 and R 9 are joined together with the intervening carbon atom to form an unsubstituted cyclopentyl. In certain embodiments, R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl. In some embodiments, R 6 and R 9 are joined together with the intervening carbon atoms to form an unsubstituted heterocyclyl. In certain embodiments, R 6 and R 9 are joined together with the intervening carbon atoms to form a substituted heterocyclyl.
- R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl comprising at least one oxygen atom. In certain embodiments, R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl comprising at least one sulfur atom. In some embodiments, R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl comprising at least one optionally substituted nitrogen atom. In certain embodiments, R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl comprising at least one nitrogen atom substituted with hydrogen, optionally substituted C1-6 alkyl, or a nitrogen protecting group.
- R 6 and R 9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl, comprising at least one nitrogen atom substituted with hydrogen, unsubstituted C1-6 alkyl, or a nitrogen protecting group.
- R 9 and R 10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. In certain embodiments, R 9 and R 10 are
- R 9 and R 10 are joined together with the intervening carbon atom to form an unsubstituted carbocyclyl. In some embodiments, R 9 and R 10 are joined together with the intervening carbon atom to form a substituted carbocyclyl. In certain embodiments, R 9 and R 10 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl, unsubstituted cyclopentyl, unsubstituted cyclobutyl, or unsubstituted cyclopropyl. In some embodiments, R 9 and R 10 are joined together with the intervening carbon atom to form an unsubstituted cyclobutyl or unsubstituted cyclopropyl.
- R 9 and R 10 are joined together with the intervening carbon atom to form an unsubstituted cyclobutyl. In some embodiments, R 9 and R 10 are joined together with the intervening carbon atom to form an unsubstituted cyclopropyl. [00183] In certain embodiments, the compound is: , , , , ,
- the compound is: , , , , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
- the compound is: , , , , , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
- the compound is: , , , , , or a pharmaceutically acceptable salt thereof.
- the compound is: , , , , , or a pharmaceutically acceptable salt thereof.
- the compound is: , , , , , , , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
- the compound is: , , ,
- the compound is: , , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
- the compound is: , , or a pharmaceutically acceptable salt thereof.
- the compound is: , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
- the compound is: , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
- the compound is of Formula (II): or a pharmaceutically acceptable salt thereof, wherein: R 1’ is optionally substituted C 7-25 alkyl; R 2’ is optionally substituted C7-25 alkenyl; R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-6 alkyl;
- the compound is of Formula (II-A): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1’ is optionally substituted C 7-25 alkyl; R 2” is optionally substituted ; R 3’ and R 4’ are each independently hydrogen or optionally substituted C 1-6 alkyl; n is 0, 1, 2, or 3; * designates a point of attachment at one of positions X, Y, or Z; and the other two of positions X, Y, or Z are each independently hydrogen, halogen, or C 1- 6 alkyl.
- the compound is of Formula (II-A): or a pharmaceutically acceptable salt thereof, wherein: R 1’ is optionally substituted C 7-25 alkyl; R 2” is optionally substituted R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3;
- the compound is of Formula (II-B): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1’ is optionally substituted C7-25 alkyl; R 2’ is optionally substituted C 7-25 alkenyl; R 3’ and R 4’ are each independently hydrogen or optionally substituted C 1-6 alkyl; n is 0, 1, 2, or 3; and Y and Z are each independently hydrogen, halogen, or C 1-6 alkyl.
- the compound is of Formula (II-B): or a pharmaceutically acceptable salt thereof, wherein: R 1’ is optionally substituted C7-25 alkyl; R 2’ is optionally substituted C7-25 alkenyl; R 3’ and R 4’ are each independently hydrogen or optionally substituted C 1-6 alkyl; n is 0, 1, 2, or 3; and Y and Z are each independently hydrogen, halogen, or C1-6 alkyl.
- the compound is of Formula (II-C): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1’ is optionally substituted C 7-25 alkyl; R 2’ is optionally substituted C 7-25 alkenyl; R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; and X and Z are each independently hydrogen, halogen, or C 1-6 alkyl.
- R 1’ is optionally substituted C 7-25 alkyl
- R 2’ is optionally substituted C 7-25 alkenyl
- R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-6 alkyl
- n is 0, 1, 2, or 3
- X and Z are each independently hydrogen, halogen, or C 1-6 alkyl.
- the compound is of Formula (II-C): or a pharmaceutically acceptable salt thereof, wherein: R 1’ is optionally substituted C7-25 alkyl; R 2’ is optionally substituted C 7-25 alkenyl; R 3’ and R 4’ are each independently hydrogen or optionally substituted C 1-6 alkyl; n is 0, 1, 2, or 3; and X and Z are each independently hydrogen, halogen, or C1-6 alkyl.
- the compound is of Formula (II-D): or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R 1’ is optionally substituted C 7-25 alkyl; R 2’ is optionally substituted C 7-25 alkenyl; R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; and X and Y are each independently hydrogen, halogen, or C 1-6 alkyl.
- R 1’ is optionally substituted C 7-25 alkyl
- R 2’ is optionally substituted C 7-25 alkenyl
- R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-6 alkyl
- n is 0, 1, 2, or 3
- X and Y are each independently hydrogen, halogen, or C 1-6 alkyl.
- the compound is of Formula (II-D): or a pharmaceutically acceptable salt thereof, wherein: R 1’ is optionally substituted C7-25 alkyl; R 2’ is optionally substituted C 7-25 alkenyl; R 3’ and R 4’ are each independently hydrogen or optionally substituted C 1-6 alkyl; n is 0, 1, 2, or 3; and X and Y are each independently hydrogen, halogen, or C1-6 alkyl.
- R 1’ is optionally substituted C 7-25 alkyl.
- R 1’ is unsubstituted C7-25 alkyl.
- R 1’ is C7-25 haloalkyl.
- R 1’ is C7-25 fluoroalkyl. In some embodiments, R 1’ is C7-25 alkyl substituted with at least one deuterium. In certain embodiments, R 1’ is C 7-25 alkyl substituted with at least two deuterium atoms. In some embodiments, R 1’ is optionally substituted C12-20 alkyl. In certain embodiments, R 1’ is unsubstituted C12-20 alkyl. In some embodiments, R 1’ is
- R 1’ is C 12-20 haloalkyl.
- R 1’ is C 12-20 fluoroalkyl.
- R 1’ is C12-20 alkyl substituted with at least one deuterium.
- R 1’ is C12-20 alkyl substituted with at least two deuterium atoms.
- R 1’ is optionally substituted C 14-18 alkyl.
- R 1’ is unsubstituted C 14-18 alkyl.
- R 1’ is C14-18 haloalkyl.
- R 1’ is C14-18 fluoroalkyl.
- R 1’ is C14-18 alkyl substituted with at least one deuterium.
- R 1’ is C 14-18 alkyl substituted with at least two deuterium atoms. In some embodiments, R 1’ is optionally substituted C14 alkyl. In certain embodiments, R 1’ is unsubstituted C14 alkyl. In some embodiments, R 1’ is C14 haloalkyl. In certain embodiments, R 1’ is C 14 fluoroalkyl. In some embodiments, R 1’ is C 14 alkyl substituted with at least one deuterium. In certain embodiments, R 1’ is C 14 alkyl substituted with at least two deuterium atoms. In some embodiments, R 1’ is optionally substituted C16 alkyl.
- R 1’ is unsubstituted C16 alkyl. In some embodiments, R 1’ is C16 haloalkyl. In certain embodiments, R 1’ is C 16 fluoroalkyl. In some embodiments, R 1’ is C 16 alkyl substituted with at least one deuterium. In certain embodiments, R 1’ is C16 alkyl substituted with at least two deuterium atoms. [00202] In some embodiments, R 1’ is selected from the group consisting of: . some embodiments, R 1’ is selected from ,
- R 1’ is selected from the group consisting of: .
- R 1’ is selected from the group consisting of: some embodiments, R 1’ is selected from the group consisting of: .
- R 1’ is selected from the group consisting of: .
- R 1’ is selected from the group consisting of: .
- R 1’ is selected from the group .
- R 2’ is optionally substituted C7-25 alkenyl. In certain embodiments, R 2’ is unsubstituted C7-25 alkenyl. In some embodiments, R 2’ is C7-25 haloalkenyl. In certain embodiments, R 2’ is C 7-25 fluoroalkenyl. In some embodiments, R 2’ is C 7-25 alkenyl substituted with at least one deuterium. In certain embodiments, R 2’ is C 7-25 alkenyl substituted with at least two deuterium atoms. In some embodiments, R 2’ is optionally substituted C 12-20 alkenyl.
- R 2’ is unsubstituted C 12-20 alkenyl. In some embodiments, R 2’ is C 12-20 haloalkenyl. In certain embodiments, R 2’ is C 12-20 fluoroalkenyl. In some embodiments, R 2’ is C12-20 alkenyl substituted with at least one deuterium. In certain embodiments, R 2’ is C 12-20 alkenyl substituted with at least two deuterium atoms. In some embodiments, R 2’ is optionally substituted C 14-18 alkenyl. In certain embodiments, R 2’ is unsubstituted C14-18 alkenyl. In some embodiments, R 2’ is C14-18 haloalkenyl.
- R 2’ is C14-18 fluoroalkenyl. In some embodiments, R 2’ is C14-18 alkenyl substituted with at least one deuterium. In certain embodiments, R 2’ is C 14-18 alkenyl substituted with at least two deuterium atoms. In some embodiments, R 2’ is optionally substituted C14 alkenyl. In certain embodiments, R 2’ is unsubstituted C14 alkenyl. In some embodiments, R 2’ is C 14 haloalkenyl. In certain embodiments, R 2’ is C 14 fluoroalkenyl. In some embodiments, R 2’ is C 14 alkenyl substituted with at least one deuterium.
- R 2’ is C14 alkenyl substituted with at least two deuterium atoms. In some embodiments, R 2’ is optionally substituted C 16 alkenyl. In certain embodiments, R 2’ is unsubstituted C 16 alkenyl. In some embodiments, R 2’ is C 16 haloalkenyl. In certain embodiments, R 2’ is C16 fluoroalkenyl. In some embodiments, R 2’ is C16 alkenyl substituted with at least one deuterium. In certain embodiments, R 2’ is C16 alkenyl substituted with at least two deuterium atoms.
- R 2’ is linear optionally substituted C 7-25 alkenyl. In certain embodiments, R 2’ is linear unsubstituted C7-25 alkenyl. In some embodiments, R 2’ is linear optionally substituted C12-20 alkenyl. In certain embodiments, R 2’ is linear unsubstituted C12-20 alkenyl. In some embodiments, R 2’ is linear optionally substituted C 14-18 alkenyl. In certain embodiments, R 2’ is linear unsubstituted C14-18 alkenyl. [00209] In some embodiments, R 2’ comprises cis and trans double bonds. In certain embodiments, R 2’ comprises only cis double bonds.
- R 2’ comprises only trans double bonds. [00210] In some embodiments, R 2’ comprises at least two double bonds. In certain embodiments, R 2’ comprises at least three double bonds. In some embodiments, R 2’ comprises at least four double bonds. In certain embodiments, R 2’ comprises at least five double bonds. In some embodiments, R 2’ comprises at least six double bonds. In certain embodiments, R 2’ comprises 1-8 double bonds. In some embodiments, R 2’ comprises 1-6 double bonds. In certain embodiments, R 2’ comprises 2-8 double bonds. In some embodiments, R 2’ comprises 2-6 double bonds. In certain embodiments, R 2’ comprises 1, 2, 3, 4, 5, or 6 double bonds. In some embodiments, R 2’ comprises 2, 3, 4, 5, or 6 double bonds.
- R 2’ comprises 3, 4, 5, or 6 double bonds. In certain embodiments, R 2’ comprises 3, 4, or 5 double bonds. [00211] In certain embodiments, R 2’ comprises unconjugated double bonds. In some embodiments, R 2’ comprises conjugated double bonds. In certain embodiments, R 2’ comprises both conjugated and unconjugated double bonds. [00212] In some embodiments, R 2’ is optionally substituted n embodiments, R 2’ is u nsubstituted . In certain embodiments, R 2’ is substituted . In some embodiments, substituted with a non-aliphatic substituent. In some embodiments, R 2’ is not substituted with an aliphatic substituent.
- R 2’ is not substituted with an alkyl, alkenyl, alkynyl group. In some embodiments, R 2’ is not substituted with an alkyl, alkenyl, alkynyl group at the terminal position. In some embodiments, R 2’ is substituted at a vinylic or allylic position. [00213] In some embodiments, R 2’ is substituted with deuterium,
- R 2’ is substituted with halogen or deuterium. In some embodiments, R 2’ is substituted with halogen.
- R 2’ is substituted with at least one fluorine. In certain embodiments, R 2’ is substituted with at least one deuterium. [00215] In certain embodiments, R 2’ is selected from the group consisting of . [00216] In certain embodiments, R 2’ is . [00217] In some embodiments, R 2” is optionally substituted n embodiments, R 2” is u nsubstituted . In certain embodiments, R 2” is substituted . In some embodiments, substituted with at least one fluorine. In certain embodiments, R 2” is
- R 2 is selected from the group consisting of . [00219] In certain embodiments, R 2” is . [00220] In certain embodiments, R 1’ is unsubstituted C7-25 alkyl, and R 2’ is unsubstituted C7-25 alkenyl. In some embodiments, R 1’ is C7-25 haloalkyl, and R 2’ is unsubstituted C7-25 alkenyl. In certain embodiments, R 1’ is C 7-25 fluoroalkyl, and R 2’ is unsubstituted C 7-25 alkenyl.
- R 1’ is unsubstituted C 12-20 alkyl, and R 2’ is unsubstituted C 12-20 alkenyl.
- R 1’ is C12-20 haloalkyl, and R 2’ is unsubstituted C12-20 alkenyl.
- R 1’ is C12-20 fluoroalkyl, and R 2’ is unsubstituted C12-20 alkenyl.
- R 1’ is unsubstituted C 7-25 alkyl, and R 2’ is C 7-25 haloalkenyl.
- R 1’ is C7-25 haloalkyl, and R 2’ is C7-25 haloalkenyl. In certain embodiments, R 1’ is C7-25 fluoroalkyl, and R 2’ is C7-25 haloalkenyl . In some embodiments, R 1’ is unsubstituted C 12-20 alkyl, and R 2’ is C 12-20 haloalkenyl. In certain embodiments, R 1’ is C 12- 20 haloalkyl, and R 2’ is C12-20 haloalkenyl. In some embodiments, R 1’ is C12-20 fluoroalkyl, and R 2’ is C12-20 haloalkenyl.
- R 1’ is unsubstituted C 7-25 alkyl, and R 2’ is C 7-25 fluoroalkenyl. In some embodiments, R 1’ is C 7-25 haloalkyl, and R 2’ is C 7-25 fluoroalkenyl. In certain embodiments, R 1’ is C7-25 fluoroalkyl, and R 2’ is C7-25 fluoroalkenyl. In some embodiments, R 1’ is unsubstituted C12-20 alkyl, and R 2’ is C12-20 fluoroalkenyl . In certain embodiments, R 1’ is C 12-20 haloalkyl, and R 2’ is C 12-20 fluoroalkenyl.
- R 1’ is C12-20 fluoroalkyl, and R 2’ is C12-20 fluoroalkenyl.
- R 1’ is unsubstituted C7-25 alkyl, and R 2’ is C7-25 alkenyl substituted with at least one deuterium.
- R 1’ is C 7-25 haloalkyl, and R 2’ is C7-25 alkenyl substituted with at least one deuterium.
- R 1’ is C7-25 fluoroalkyl, and R 2’ is C7-25 alkenyl substituted with at least one deuterium.
- R 1’ is unsubstituted C 12-20 alkyl, and R 2’ is C 7-25 alkenyl substituted with at least one deuterium.
- R 1’ is C12-20 haloalkyl, and R 2’ is C7-25 alkenyl substituted with at least one deuterium .
- R 1’ is C12-20 fluoroalkyl, and R 2’ is C 7-25 alkenyl substituted with at least one deuterium.
- R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-6 alkyl.
- R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-4 alkyl.
- R 3’ and R 4’ are each independently hydrogen or optionally substituted C1-2 alkyl. In certain embodiments, R 3’ and R 4’ are each independently hydrogen or unsubstituted C 1-6 alkyl. In certain embodiments, R 3’ and R 4’ are each independently hydrogen or unsubstituted C 1-4 alkyl. In some embodiments, R 3’ and R 4’ are each independently hydrogen or unsubstituted C1-2 alkyl. [00226] In some embodiments, one of R 3’ and R 4’ is hydrogen. In certain embodiments, at least one of R 3’ and R 4’ is hydrogen. In some embodiments, R 3’ and R 4’ are each hydrogen.
- R 3’ is hydrogen, and R 4’ is unsubstituted C1-6 alkyl.
- R 3’ is hydrogen, and R 4’ is methyl, ethyl, propyl, butyl, pentyl, or hexyl.
- R 3’ is hydrogen, and R 4’ is methyl, ethyl, propyl, or butyl.
- R 3’ is hydrogen, and R 4’ is methyl.
- R 3’ is hydrogen, and R 4’ is ethyl. [00227] In some embodiments, one of R 3’ and R 4’ is unsubstituted C 1-6 alkyl.
- R 3’ and R 4’ are unsubstituted C 1-6 alkyl. In some embodiments, R 3’ and R 4’ are each unsubstituted C1-6 alkyl. In some embodiments, R 3’ and R 4’ are each independently methyl, ethyl, propyl, butyl, pentyl, or hexyl. In some embodiments, R 3’ and R 4’ are each independently methyl, ethyl, propyl, or butyl. In some embodiments, R 3’ is methyl, and R 4’ is methyl, ethyl, propyl, butyl, pentyl, or hexyl.
- R 3’ is methyl
- R 4’ is methyl, ethyl, propyl, or butyl.
- R 3’ and R 4’ are each methyl.
- R 3’ and R 4’ are each ethyl.
- R 3’ and R 4’ are each propyl.
- R 3’ and R 4’ are each butyl.
- one of R 3’ and R 4’ is optionally substituted C1-6 alkyl.
- at least one of R 3’ and R 4’ is optionally substituted C 1-6 alkyl.
- R 3’ and R 4’ are each independently optionally substituted C 1-6 alkyl.
- one of R 3’ and R 4’ is C1-6 fluoroalkyl. In certain embodiments, at least one of R 3’ and R 4’ is C1-6 fluoroalkyl. In some embodiments, R 3’ and R 4’ are each C 1-6 fluoroalkyl. In some embodiments, at least one of R 3’ and R 4’ is -CH 2 F, -
- R 3’ and R 4’ are -CH 2 F. In some embodiments, at least one of R 3’ and R 4’ is -CHF2. In certain embodiments, at least one of R 3’ and R 4’ is -CF3. [00230] In some embodiments, R 3’ is hydrogen, and R 4’ is C 1-6 fluoroalkyl. In certain embodiments, R 3’ is hydrogen, and R 4’ is -CH2F, CHF2, or -CF3. In some embodiments, R 3’ is hydrogen, and R 4’ is -CH2F. In certain embodiments, R 3’ is hydrogen, and R 4’ is -CHF2. In certain embodiments, R 3’ is hydrogen, and R 4’ is -CHF2.
- R 3’ is hydrogen, and R 4’ is -CF 3 .
- R 3’ is unsubstituted C1-6 alkyl, and R 4’ is C1-6 fluoroalkyl. In certain embodiments, R 3’ is unsubstituted C1-6 alkyl, and R 4’ is -CH2F, CHF2, or -CF 3 . In some embodiments, R 3’ is unsubstituted C 1-6 alkyl, and R 4’ is -CH 2 F. In certain embodiments, R 3’ is unsubstituted C 1-6 alkyl, and R 4’ is -CHF 2 .
- R 3’ is unsubstituted C1-6 alkyl, and R 4’ is -CF3. In some embodiments, R 3’ is methyl, and R 4’ is C1-6 fluoroalkyl. In certain embodiments, R 3’ is methyl, and R 4’ is -CH2F, CHF2, or -CF3. In some embodiments, R 3’ is methyl, and R 4’ is -CH 2 F. In certain embodiments, R 3’ is methyl, and R 4’ is -CHF2. In some embodiments, R 3’ is methyl, and R 4’ is -CF3. [00232] In some embodiments, n is 0, 1, 2, or 3. In certain embodiments, n is 0, 1, or 2.
- n is 0 or 1. In certain embodiments, n is 1 or 2. In some embodiments, n is 2 or 3. In certain embodiments, n is 0. In some embodiments, n is 1. In certain embodiments, n is 2. In some embodiments, n is 3. [00233] In certain embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen, halogen, or C1-6 alkyl. [00234] In certain embodiments, * designates a point of attachment at position X. In some embodiments, * designates a point of attachment at position Y. In certain embodiments, * designates a point of attachment at position Z.
- * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen or halogen. In certain embodiments, * designates a point of attachment at position X; and Y and Z are each independently hydrogen or halogen. In some embodiments, * designates a point of attachment at position Y; and X and Z are each independently hydrogen or halogen. In certain embodiments, * designates a point of attachment at position Z; and X and Y are each independently hydrogen or halogen. [00236] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen or
- * designates a point of attachment at position X; and Y and Z are each independently hydrogen or fluorine. In some embodiments, * designates a point of attachment at position Y; and X and Z are each independently hydrogen or fluorine. In certain embodiments, * designates a point of attachment at position Z; and X and Y are each independently hydrogen or fluorine. [00237] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen or C 1-6 alkyl. In certain embodiments, * designates a point of attachment at position X; and Y and Z are each independently hydrogen or C1-6 alkyl.
- * designates a point of attachment at position Y; and X and Z are each independently hydrogen or C 1-6 alkyl. In certain embodiments, * designates a point of attachment at position Z; and X and Y are each independently hydrogen or C1-6 alkyl. [00238] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each hydrogen. In certain embodiments, * designates a point of attachment at position X; and Y and Z are each hydrogen. In some embodiments, * designates a point of attachment at position Y; and X and Z are each hydrogen.
- * designates a point of attachment at position Z; and X and Y are each hydrogen. [00239] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently halogen. In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently C1-6 alkyl. [00240] In certain embodiments, the compound is: ,
- the compound is: ,
- the compound is: , , , , , ,
- the compound is: , , , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof.
- the compound is: , , , , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof.
- compounds and generic formulae provided herein are drawn in zwitterionic form. Any compound or generic formula drawn as a zwitterion herein is understood to also encompass the corresponding non-zwitterionic form.
- compounds of Formula (I) wherein R 3 , R 4 , and R 5 (if present) are hydrogen also encompass compounds wherein X is selected from (non-zwitterionic form).
- compounds of Formula (I-A), wherein R 3 , R 4 , and R 5 are hydrogen also encompass compounds of the following formula (non-zwitterionic form): .
- compounds of Formula (II-A) wherein R 3’ and R 4’ are hydrogen (drawn in zwitterionic form herein) also encompass compounds of the following formula (non-zwitterionic form): .
- compounds of Formula (II-B) wherein R 3’ and R 4’ are hydrogen (drawn in zwitterionic form herein) also encompass compounds of the following formula (non-zwitterionic form): .
- compounds of Formula (II-C) wherein R 3’ and R 4’ are hydrogen (drawn in zwitterionic form herein) also encompass compounds of the following formula (non-zwitterionic form): .
- compounds of Formula (II-D) wherein R 3’ and R 4’ are hydrogen also encompass compounds of the following formula (non-zwitterionic form): .
- Compounds excluded by proviso in their zwitterionic form are also understood to be excluded in their non-zwitterionic form.
- compounds excluded by proviso in their non-zwitterionic form are also understood to be excluded in their zwitterionic form.
- compositions comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, and optionally a carrier and/or excipient.
- the composition is a pharmaceutical composition.
- the pharmaceutical composition described herein comprises a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, and a pharmaceutically acceptable carrier and/or excipient.
- the composition is a nutraceutical composition.
- the nutraceutical composition described herein comprises a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, and a carrier and/or excipient.
- the compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof is provided in an effective amount in the composition.
- the effective amount is a therapeutically or prophylactically effective amount.
- the effective amount is an amount effective for treating a disease, disorder, or condition in a subject in need thereof.
- the nutraceutical composition described herein comprises a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer,
- the effective amount is an amount effective for treating a liver disease, neurological disease, ophthalmic disease, metabolic disorder, mitochondrial disease, cardiovascular disease, infectious disease, pulmonary disease, skin disease, genetic disease, proliferative disease, inflammatory disease, autoimmune disease, hematological disease, painful condition, psychiatric disorder, immune disorder, or spleen disease.
- the effective amount is an amount effective for treating a neurological disease in a subject in need thereof.
- the effective amount is an amount effective for treating Alzheimer’s disease in a subject in need thereof.
- the effective amount is an amount effective for treating a genetic disease.
- the effective amount is an amount effective for treating Zellweger syndrome.
- the effective amount is an amount effective for treating a pulmonary disease. In some embodiments, the effective amount is an amount effective for treating NRDS. [00259] In some embodiments, the effective amount is an amount effective for preventing a disease, disorder, or condition in a subject in need thereof. In some embodiments, the effective amount is an amount effective for preventing a liver disease, neurological disease, ophthalmic disease, metabolic disorder, mitochondrial disease, cardiovascular disease, infectious disease, pulmonary disease, skin disease, genetic disease, proliferative disease, inflammatory disease, autoimmune disease, hematological disease, painful condition, psychiatric disorder, immune disorder, or spleen disease.
- the effective amount is an amount effective for preventing a neurological disease in a subject in need thereof. In some embodiments, the effective amount is an amount effective for preventing Alzheimer’s disease in a subject in need thereof. In some embodiments, the effective amount is an amount effective for preventing a genetic disease. In some embodiments, the effective amount is an amount effective for preventing Zellweger syndrome. In some embodiments, the effective amount is an amount effective for preventing a pulmonary disease. In some embodiments, the effective amount is an amount effective for preventing NRDS. [00260] Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology.
- Such preparatory methods include bringing the compound described herein (i.e., the “active ingredient”) into association with a carrier or excipient, and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping, and/or packaging the product into a desired single- or multi-dose unit.
- Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
- a “unit dose” is a discrete amount
- compositions comprising a predetermined amount of the active ingredient.
- the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage.
- Relative amounts of the compound of the disclosure, pharmaceutically acceptable excipient, agent, and/or any additional ingredients in a composition described herein will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
- the composition may comprise between 0.1% and 100% (w/w) agent.
- compositions used in manufacture of provided pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils.
- Excipients and accessory ingredients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents, may also be present in the composition.
- Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.
- Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross- linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
- crospovidone cross-linked poly(vinyl-pyrrolidone)
- sodium carboxymethyl starch sodium starch glycolate
- Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and
- natural emulsifiers e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, ge
- Exemplary binding agents include starch (e.g., cornstarch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum ® ), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol
- Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
- the preservative is an antioxidant.
- the preservative is a chelating agent.
- Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
- Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium
- citric acid and salts and hydrates thereof e.g., citric acid monohydrate
- fumaric acid and salts and hydrates thereof malic acid and salts and hydrates thereof
- phosphoric acid and salts and hydrates thereof tartaric acid and salts and hydrates thereof.
- antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
- Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
- Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
- Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta- carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
- Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant ® Plus, Phenonip ® , methylparaben, Germall ® 115, Germaben ® II, Neolone ® , Kathon ® , and Euxyl ® .
- Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen- free water, isotonic saline
- Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel,
- Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.
- Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate,
- the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- the compounds described herein are mixed with solubilizing agents such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.
- solubilizing agents such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.
- injectable preparations for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation can be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- a nontoxic parenterally acceptable diluent or solvent for example, as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that can be employed are water, Ringer’s solution, U.S.P., and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or
- injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the compounds described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (a) fillers or
- the dosage form may include a buffering agent.
- Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the art of pharmacology. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- coatings and shells such as enteric coatings and other coatings well known in the art of pharmacology. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- encapsulating compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type can be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight pol
- the active ingredient can be in a micro-encapsulated form with one or more excipients as noted above.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art.
- the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose, or starch.
- Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
- the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of encapsulating agents which can be used include polymeric substances and waxes. [00286] Dosage forms for topical and/or transdermal administration of a compound described herein may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and/or patches.
- the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier or excipient and/or any needed preservatives and/or buffers as can be required.
- a pharmaceutically acceptable carrier or excipient and/or any needed preservatives and/or buffers as can be required.
- the present disclosure contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body.
- dosage forms can be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium.
- the rate can be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel.
- Formulations suitable for topical administration include, but are not limited to, liquid and/or semi-liquid preparations such as liniments, lotions, oil-in-water and/or water-in-oil
- Topically administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient can be as high as the solubility limit of the active ingredient in the solvent.
- Formulations for topical administration may further comprise one or more of the additional ingredients described herein.
- Suitable devices for use in delivering injectable pharmaceutical compositions described herein include short needle devices. Injectable compositions can be administered by devices which limit the effective penetration length of a needle into the skin. Alternatively or additionally, conventional syringes can be used in the classical mantoux method of administration.
- a pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity.
- a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, or from about 1 to about 6 nanometers.
- compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder and/or using a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container.
- a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container.
- Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers.
- Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
- Low boiling propellants generally include liquid propellants having a boiling point of below 65 °F at atmospheric pressure. Generally, the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition.
- the propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
- compositions described herein formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension.
- Such formulations can be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device.
- Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative, such as methylhydroxybenzoate.
- the droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers.
- Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition described herein.
- Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
- Formulations for nasal administration may, for example, comprise from about as little as 0.1% (w/w) to as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein.
- a pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation for buccal administration.
- Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein.
- formulations for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient.
- Such powdered, aerosolized, and/or aerosolized formulations when dispersed, may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.
- a pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation for ophthalmic administration.
- Such formulations may, for example, be in the form of eye drops including, for example, a 0.1-1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid carrier or excipient.
- Such drops may further comprise buffering agents, salts, and/or one or more other of the additional
- compositions suitable for administration to humans are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.
- compositions described herein are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions described herein will be decided by a physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex, and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.
- the compounds and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intraarticular, intra- arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
- enteral e.g., oral
- parenteral intravenous, intramuscular, intraarticular, intra- arterial, intramedullary
- intrathecal subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal
- topical as by powders, ointments, creams, and/or drops
- contemplated routes are intraarticular administration, oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and/or lymph supply, and/or direct administration to an affected site.
- intraarticular administration e.g., oral administration
- intravenous administration e.g., systemic intravenous injection
- regional administration via blood and/or lymph supply e.g., direct administration to an affected site.
- direct administration e.g., systemic intravenous injection
- the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its
- the compound or pharmaceutical composition described herein is suitable for intraarticular administration.
- the compound or pharmaceutical composition described herein is suitable for intraarticular injection.
- the intraarticular injection comprises direct injection into the closed cavity of a joint.
- the joint is a knee joint, wrist joint, ankle joint, hip joint, shoulder joint, elbow joint, neck joint, spine joint, vertebral disc joints, finger joints, and toe joints.
- any two doses of the multiple doses include different or substantially the same amounts of an agent described herein.
- the frequency of administering the multiple doses to the subject or applying the multiple doses to the tissue or cell may be, in non-limiting examples, three doses a day, two doses a day, one dose a day, one dose every other day, one dose every third day, one dose every week, one dose every two weeks, one dose every three weeks, or one dose every four weeks, or even slow dose controlled delivery over a selected period of time using a drug delivery device.
- the duration between the first dose and last dose of the multiple doses is one day, two days, four days, one week, two weeks, three weeks, one month, two months, three months, four months, six months, nine months, one year, two years, three years, four years, five years, seven years, ten years, fifteen years, twenty years, or the lifetime of the subject, tissue, or cell.
- the duration between the first dose and last dose of the multiple doses is three months, six months, or one year.
- the duration between the first dose and last dose of the multiple doses is the lifetime of the subject, tissue, or cell.
- a dose (e.g., a single dose, or any dose of multiple doses) described herein includes independently between 0.1 ⁇ g and 1 ⁇ g, between 0.001 mg and 0.01 mg, between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg,
- a dose described herein includes independently between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, or between 1 g and 10 g, inclusive, of a compound described herein.
- a dose described herein includes independently between 1 mg and 3 mg, inclusive, of a compound described herein.
- a dose described herein includes independently between 3 mg and 10 mg, inclusive, of a compound described herein.
- a dose described herein includes independently between 10 mg and 30 mg, inclusive, of a compound described herein.
- a dose described herein includes independently between 30 mg and 100 mg, inclusive, of a compound described herein.
- Dose ranges as described herein provide guidance for the administration of provided compounds or compositions to an adult.
- the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
- a dose described herein is a dose to an adult human whose body weight is 70 kg.
- a compound or composition, as described herein, can be administered in combination with one or more additional pharmaceutical agents (e.g., therapeutically and/or prophylactically active agents).
- the compounds or compositions can be administered in combination with additional pharmaceutical agents that improve their activity (e.g., potency and/or efficacy), improve bioavailability, improve safety, reduce drug resistance, reduce and/or modify metabolism, inhibit excretion, and/or modify distribution in a subject or cell.
- additional pharmaceutical agents that improve their activity (e.g., potency and/or efficacy), improve bioavailability, improve safety, reduce drug resistance, reduce and/or modify metabolism, inhibit excretion, and/or modify distribution in a subject or cell.
- additional pharmaceutical agent that improve their activity (e.g., potency and/or efficacy), improve bioavailability, improve safety, reduce drug resistance, reduce and/or modify metabolism, inhibit excretion, and/or modify distribution in a subject or cell.
- the therapy employed may achieve a desired effect for the same disorder, and/or it may achieve different effects.
- a pharmaceutical composition described herein including a compound described herein and an additional pharmaceutical agent shows a synergistic effect that is absent in a pharmaceutical composition
- the compound or composition can be administered concurrently with, prior to, or subsequent to one or more additional pharmaceutical agents, which may be useful as, e.g., combination therapies.
- Pharmaceutical agents include therapeutically active agents.
- Pharmaceutical agents also include prophylactically active agents.
- Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved for
- the additional pharmaceutical agent is a pharmaceutical agent useful for treating and/or preventing a disease, disorder, or condition .
- Each additional pharmaceutical agent may be administered at a dose and/or on a time schedule determined for that pharmaceutical agent.
- the additional pharmaceutical agents may also be administered together with each other and/or with the compound or composition described herein in a single dose or composition or administered separately in different doses or compositions.
- the particular combination to employ in a regimen will take into account compatibility of the compound described herein with the additional pharmaceutical agent(s) and/or the desired therapeutic and/or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agent(s) in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
- the additional pharmaceutical agents include, but are not limited to, anti- proliferative agents, anti-cancer agents, anti-angiogenesis agents, steroidal or non-steroidal anti-inflammatory agents, immunosuppressants, anti-bacterial agents, anti-viral agents, cardiovascular agents, cholesterol-lowering agents, anti-diabetic agents, anti-allergic agents, contraceptive agents, pain-relieving agents, anesthetics, anti–coagulants, inhibitors of an enzyme, steroidal agents, steroidal or antihistamine, antigens, vaccines, antibodies, decongestant, sedatives, opioids, analgesics, anti-pyretics, hormones, and prostaglandins.
- the composition is a food product.
- the food product is any item that is to be processed, partially processed, or unprocessed for consumption by an animal.
- the food product is for consumption by a mammal.
- the food product is for consumption by a human.
- the food product is a food supplement, medical food, or infant formula.
- the food product is a food supplement.
- the food product is a medical food.
- the food product is infant formula.
- the food product is a food additive.
- the food product is a dietary supplement.
- the composition further comprises a sweetener.
- Sweeteners can be used to improve palatability and are usually classified as natural or artificial.
- a sweetener is a natural sweetener or artificial sweetener.
- Exemplary natural sweeteners include, but are not limited to, dextrose, fructose, glucose, liquid glucose, maltose, rebiana, glycyrrhizin, thaumatin, sorbitol, mannitol, isomalt, glycerol, maltitol, xylitol, and erythritol.
- Exemplary artificial sweeteners include, but are not limited to, saccharin, cyclamate, aspartame, acesulfame-K, sucralose, alitame, and neotame.
- sucralose is used as a sweetener.
- one or combination of neohespiridin dihydrochalcone, glycerol, and/or sucralose are used as sweeteners.
- the concentration of the sweetener in the composition is between 0.01% and 5%, inclusive, by weight. In some embodiments, the concentration of the sweetener in the composition is between 0.01% and 1%, inclusive, by weight.
- the concentration of the sweetener in the composition is between 0.5% and 1%, inclusive, by weight.
- the composition further comprises sucralose.
- the composition further comprises sucralose as about 0.01-0.25% based on the dry weight of all the components of the composition.
- a composition further comprises a colorant.
- a colorant can be added to enhance the aesthetic appeal of the composition, especially when formulation ingredients or drugs are presented in a non-solution form. Generally, any colorant could be added, such as for example FD&C pigments (for example, blue no1, blue no2, red no3, red no40, yellow no5, or yellow no 6).
- Exemplary colorants include, but are not limited to annatto extract, dehydrated beets (beet powder), canthaxanthin, caramel, ⁇ -apo-8'-carotenal, ⁇ - carotene, cochineal extract, carmine, sodium copper chlorophyllin, toasted partially defatted cooked cottonseed flour, ferrous gluconate, ferrous lactate, grape color extract, grape skin extract (enocianina), synthetic iron oxide, fruit juice, vegetable juice, carrot oil, paprika, paprika oleoresin, mica-based pearlescent pigments, riboflavin, saffron, spirulina extract, titanium dioxide, tomato lycopene extract; tomato lycopene concentrate, turmeric, turmeric oleoresin, alumina (dried aluminum hydroxide), calcium carbonate, potassium sodium copper chlorophyllin (chlorophyllin-copper complex), dihydroxyacetone, bismuth oxychloride, synthetic iron oxide, ferric am
- a colorant represents 0.001% to about 0.5% based on the weight of all the components of the composition. In some embodiments, the concentration of the colorant in the composition is between 0.001% and 5%, inclusive, by weight. In some embodiments, the concentration of the colorant in the composition is between 0.001% and 1%, inclusive, by weight. [00309] In certain embodiments, a provided composition further comprises a flavoring agent.
- the selection of a suitable flavoring agent to be added depends on the original taste sensation of the composition, including metallic, acidic, alkaline, salty, sweet, bitter and sour taste sensation.
- Certain flavoring agents, alone or in combination, mask specific taste sensations.
- metallic taste could be masked with, but not limited to, flavoring agents based on berry fruits, grape, and/or peppermint.
- acidic taste could be masked with, but not limited to, flavoring agents based on lemon, lime, grapefruit, orange, cherry, and/or strawberry.
- alkaline taste could be masked with, but not limited to, flavoring agents based on aniseed, caramel, passion fruit, peach and/or banana.
- salty taste could be masked with, but not limited to, flavoring agents based on butterscotch, caramel, hazelnut, spicy, maple, apricot, apple, peach, vanilla, and/or wintergreen mint.
- bitter taste could be masked with, but not limited to, flavoring agents based on licorice, passion fruit, coffee, chocolate, peppermint, grapefruit, cherry, peach, raspberry, wild cherry, walnut, mint, and/or anise.
- sweet taste could be masked with, but not limited to, flavoring agents based on grape, cream, caramel, banana, vanilla and/or fruit berry.
- sour taste could be masked with, but not limited to, flavoring agents based on citrus flavors, licorice, root, bear and/or raspberry.
- Flavoring agents can be used alone or in combination and its selection will be dependent also upon the target population and any other substance (e.g., a pharmaceutical or nutraceutical agent) incorporated in the composition.
- the perception of the flavoring agent changes from individual to individual and also with age: typically a geriatric population will prefer mint or
- a flavoring agent is a palatable flavor that has a long shelf life and which does not crystallize or precipitate out of the composition upon storage.
- flavoring agents are natural flavors, derived from various parts of the plants like leaves, fruits and flowers, or synthetic flavor oils or powders. Exemplary flavor oils for use in or as flavoring agents include, but are not limited to, peppermint oil, cinnamon oil, spearmint oil, and oil of nutmeg.
- Exemplary fruity flavors that for use in or as flavoring agents include, but are not limited to, vanilla, cocoa, coffee, chocolate and citrus.
- Exemplary fruit essence flavors for use in or as flavoring agents include, but are not limited to, apple, raspberry, cherry, and pineapple.
- the amount of flavoring agent added can vary with the flavor employed.
- the concentration of the flavoring agent in the composition is between about 0% and 5%, by weight.
- the concentration of the flavoring agent in the composition is between 0.001% and 5%, inclusive, by weight.
- the concentration of the flavoring agent in the composition is between 0.1% and 1%, inclusive, by weight.
- the concentration of the flavoring agent in the composition is between 0.5% and 1%, inclusive, by weight.
- a provided composition further comprises taste-masking.
- Taste-masking agents can be added to ameliorate the general organoleptic characteristics of the compositions.
- taste-masking agents are used to mask unpleasant taste of some components.
- the main taste sensations include metallic, acidic, alkaline, salty, sweet, bitter and sour.
- Exemplary of taste-masking agents include, but are not limited to, menthol, peppermint oil, L-menthol, cyclodextrins, glycerol, maltodextrins, ion-exchange resins, amino acids, gelatin, gelatinized starch, liposomes, lecithin, or lecithin-like substances and salts.
- a provided composition further comprises a cooling agent. Cooling agents may also be added in order to improve the after-taste of the composition. Exemplary cooling agents include, but are not limited to, neohesperidine dihydrochalcone, menthol
- the cooling agents in the composition is one or a combination of neohesperidine dihydrochalcone, menthol, and/or polyol sugar.
- the mucoadhesive composition further comprises cooling agents of about 0% to about 5% based on the weight of all the components of the composition.
- the mucoadhesive composition further comprises cooling agents as about 0.001% to about 2.5% based on the weight of all the components of the composition.
- a provided composition further comprises one or more preservatives.
- the preservative employed in the present disclosure can be any preservative, as long as does not negate other desirable properties of the composition.
- Example of a preservative is an antimicrobial preservative that is used to prevent or inhibit the growth of micro-organisms in the composition.
- preservative agents include, but are not limited to, C 3 -C 8 alcohols, phenylethyl alcohol, chlorbutanol, p-hydroxybenzoic, acid esters, benzathonium chloride and benzalkonium chloride, benzoic acid, propyl galate, methylparaben, propylparaben, sorbic acid, sodium benzoate and/or potassium sorbate.
- the amount of preservative agent added can vary with the preservative agent employed. In certain embodiments, a preservative agent represents about 0% to about 45% based on the weight of all the components of the composition.
- kits e.g., pharmaceutical packs.
- the kits provided may comprise a pharmaceutical composition or compound provided herein and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container).
- a container e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container.
- provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of a pharmaceutical composition or compound provided herein.
- the pharmaceutical composition or compound provided in the first container and the second container are combined to form one unit dosage form.
- a kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition.
- kits comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; or a composition provided herein; and instructions for using the compound, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, prodrug, or composition thereof.
- kits including a first container comprising a compound or pharmaceutical composition described herein.
- the kits are useful for treating a disease, disorder, or condition in a subject in need thereof.
- kits are useful for preventing a disease, disorder, or condition in a subject in need thereof. In certain embodiments, the kits are useful for reducing the risk of developing a disease in a subject in need thereof. In certain embodiments, the kits are useful for treating a neurological disease in a subject in need thereof. In certain embodiments, the kits are useful for preventing a neurological disease in a subject in need thereof. In certain embodiments, the kits are useful for reducing the risk of developing a neurological disease in a subject in need thereof. In certain embodiments, the kits are useful for treating Alzheimer’s disease in a subject in need thereof. In certain embodiments, the kits are useful for preventing Alzheimer’s disease in a subject in need thereof.
- kits are useful for reducing the risk of developing Alzheimer’s disease in a subject in need thereof.
- a kit described herein further includes instructions for using the kit.
- a kit described herein may also include information as required by a regulatory agency such as the U.S. Food and Drug Administration (FDA).
- the information included in the kits is prescribing information.
- the kits and instructions provide for treating a disease, disorder, or condition in a subject in need thereof.
- the kits and instructions provide for preventing a disease, disorder, or condition in a subject in need thereof.
- the kits and instructions provide for reducing the risk of developing a disease in a subject in need thereof.
- kits described herein may include one or more additional pharmaceutical agents described herein as a separate composition.
- Methods of Use Provided herein are methods and uses of the compounds provided herein, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers,
- a method of treating a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof.
- a method of preventing a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof.
- a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof.
- a method of treating a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof.
- a compound of Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof.
- a method of preventing a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof.
- the present disclosure provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, in the manufacture of a medicament for treating a disease, disorder, or condition in a subject.
- the present disclosure provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, in the manufacture of a medicament for preventing a disease, disorder, or condition in a subject.
- the present disclosure provides the use of a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, in the manufacture of a medicament for treating a disease, disorder, or condition in a subject.
- the present disclosure provides the use of a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, in the manufacture of a medicament for preventing a disease, disorder, or condition in a subject.
- the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in treating a disease, disorder, or condition in a subject.
- the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in preventing a disease, disorder, or condition in a subject.
- the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in treating a disease, disorder, or condition in a subject.
- the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in preventing a disease, disorder, or condition in a subject.
- the disease, disorder, or condition is a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition, a psychiatric disorder, an immune disorder, or a spleen disease.
- the disease is a neurological disease, ophthalmic disease, liver disease, metabolic disease, cardiovascular disease, cancer, pulmonary disease, or genetic disease.
- the disease is a neurological disease, ophthalmic disease, liver disease, metabolic disease, cardiovascular disease, or cancer.
- the disease, disorder, or condition is a liver disease, a neurological disease, an ophthalmic disease, metabolic disorder, pulmonary disease, or genetic disease. In certain embodiments, the disease, disorder, or condition is a liver disease, a neurological disease, an ophthalmic disease, or a metabolic disorder. In some embodiments, the disease, disorder, or condition is a neurological disease, an ophthalmic disease, a pulmonary disease, or a genetic disorder.
- the disease, disorder, or condition is a neurological disease or an ophthalmic disease. In certain embodiments, the disease, disorder, or condition is an ophthalmic disease. In some embodiments, the disease is a peroxisomal disorder. [00331] In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a congenital disorder. In some embodiments, the disease is a leukodystrophy. In some embodiments, the disease is Zellweger syndrome, neonatal adrenoleukodystrophy (NALD), or infantile Refsum disease. In some embodiments, the disease is Zellweger syndrome. In some embodiments, the disease is neonatal adrenoleukodystrophy (NALD).
- NALD neonatal adrenoleukodystrophy
- the disease is infantile Refsum disease.
- the disease, disorder, or condition is a pulmonary disease.
- the pulmonary disease is bronchiectasis, bronchitis, bronchopulmonary dysplasia, interstitial lung disease, occupational lung disease, emphysema, cystic fibrosis, acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, bronchopulmonary dysplasia, asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, interstitial lung disease, sarcoidosis, asbestosis, aspergilloma, aspergillosis, pneumonia, pulmonary fibrosis, pulmonary tuberculosis, r
- the pulmonary disease is acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, or bronchopulmonary dysplasia.
- the pulmonary disease is respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, or bronchopulmonary dysplasia.
- the pulmonary disease is acute respiratory distress syndrome (ARDS).
- the pulmonary disease is severe acute respiratory syndrome (SARS).
- the pulmonary disease is respiratory distress syndrome. In certain embodiments, the pulmonary disease is neonatal respiratory distress syndrome (NRDS). In certain embodiments, the pulmonary disease is infant respiratory distress syndrome (IRDS). In certain embodiments, the pulmonary disease is hyaline membrane disease. In certain embodiments, the pulmonary disease is surfactant deficiency. In certain embodiments, the pulmonary disease is surfactant
- the pulmonary disease is bronchopulmonary dysplasia.
- the disease, disorder, or condition is a neurological disease.
- the neurological disease is a neurodegenerative disease.
- the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV-related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supranuclear palsy, vascular dementia
- ALS
- the disease is a synuclienopathy.
- the disease is Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy.
- the disease is dementia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, a prion disease, amyotrophic lateral sclerosis, or multiple sclerosis.
- the disease is dementia, or Alzheimer’s disease.
- the disease is Alzheimer’s disease.
- the disease is an advanced neurological disease.
- the disease is an advanced neurodegenerative disease.
- the disease is advanced Alzheimer’s disease.
- the disease is a neurological disease in the early stages.
- the disease is a neurodegenerative disease in the early stages. In some embodiments, the disease is Alzheimer’s disease in the early stages. In certain embodiments, treating and/or preventing the early-stage disease leads to reversal. [00334] In certain embodiments, the disease is a neurological disease, and treating and/or preventing the disease improves cognitive function. In some embodiments, the disease is a neurological disease, and treating and/or preventing the disease delays disease progression. In certain embodiments, the disease is a neurological disease, and treating and/or preventing the
- the disease corrects issues with neurological function.
- the disease is a neurodegenerative disease, and treating and/or preventing the disease improves cognitive function.
- the disease is a neurodegenerative disease, and treating and/or preventing the disease delays disease progression.
- the disease is a neurodegenerative disease, and treating and/or preventing the disease corrects issues with neurological function.
- the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV- related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supranuclear pals
- ALS Amyotrophic Later
- the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV-related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supranuclear palsy, vascular dementia
- ALS
- the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV-related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio- skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior
- the neurodegenerative disease is dementia.
- the neurodegenerative disease is mild cognitive impairment, Creutzfeldt-Jakob disease, dementia with Lewy bodies, vascular dementia, mixed dementia, young-onset dementia, alcohol-related dementia, HIV-associated neurocognitive disorder, frontotemporal lobar dementia, or Alzheimer’s disease.
- the neurodegenerative disease is mild cognitive impairment.
- the neurodegenerative disease is Creutzfeldt-Jakob disease.
- the neurodegenerative disease is dementia with Lewy bodies.
- the neurodegenerative disease is vascular dementia.
- the neurodegenerative disease is mixed dementia.
- the neurodegenerative disease is young-onset dementia.
- the neurodegenerative disease is alcohol-related dementia. In some embodiments, the neurodegenerative disease is HIV-associated neurocognitive disorder. In some embodiments, the neurodegenerative disease is frontotemporal lobar dementia. In some embodiments, the neurodegenerative disease is neuronal ceroid lipofuscinosis. In some embodiments, the neurodegenerative disease is associated with cerebral ischemia reperfusion injury. In some embodiments, the disease is Alzheimer’s disease or Parkinson’s disease.
- the disease is Alzheimer’s disease. In certain embodiments, the disease is Alzheimer’s disease, and treating and/or preventing the disease improves cognitive function. In some embodiments, the disease is Alzheimer’s disease, and treating and/or preventing the disease delays disease progression. In certain embodiments, the disease is Alzheimer’s disease, and treating and/or preventing the disease corrects issues with neurological function. In certain embodiments, the Alzheimer’s disease is early stage. In some embodiments, the Alzheimer’s disease is late stage. In certain embodiments, the Alzheimer’s disease is familial Alzheimer’s disease. In certain embodiments, the Alzheimer’s disease is early-onset Alzheimer’s disease. In certain embodiments, the Alzheimer’s disease is inflammatory, non-inflammatory, or cortical Alzheimer’s disease.
- the Alzheimer’s disease is inflammatory Alzheimer’s disease. In certain embodiments, the Alzheimer’s disease is non-inflammatory Alzheimer’s disease. In some embodiments, the Alzheimer’s disease is cortical Alzheimer’s disease. In some embodiments, the Alzheimer’s disease is mild, moderate, or severe. In certain embodiments, the Alzheimer’s disease is mild. In some embodiments, the Alzheimer’s disease is moderate. In certain embodiments, the Alzheimer’s disease is severe. [00338] In some embodiments, the disease is Parkinson’s disease. In certain embodiments, the disease is Parkinson’s disease, and treating and/or preventing the disease improves cognitive function. In some embodiments, the disease is Parkinson’s disease, and treating and/or preventing the disease delays disease progression.
- the disease is Parkinson’s disease, and treating and/or preventing the disease corrects issues with neurological function.
- the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof is administered orally.
- the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof is administered once daily.
- the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof is administered orally once daily.
- brain barrier or blood-retinal barrier comprising administering to a subject the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a method of transporting a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, across the blood- brain barrier or blood-retinal barrier comprising administering to a subject the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof for transport across the blood-brain barrier or blood-retinal barrier comprising administering to a subject the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a compound of Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof for transport across the blood-brain barrier or blood-retinal barrier comprising administering to a subject the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- transport is across the blood-brain barrier.
- transport is across the blood-retinal barrier.
- the compound accumulates in the blood-brain barrier.
- the compound accumulates in the brain.
- the compound accumulates in the blood retinal barrier.
- the compound accumulates in the eye.
- transport across the blood-brain barrier or blood-retinal barrier occurs via the Mfsd2a protein.
- tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof via the Mfsd2a protein in a subject, biological sample, tissue, or cell comprising administering to the subject or contacting the biological sample, tissue, or cell with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the method comprises administering to a subject the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, and Mfsd2a transports the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
- the method comprises contacting a cell, tissue, or biological sample with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the method comprises contacting a cell or biological sample with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a method of transporting a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, via the Mfsd2a protein in a subject, biological sample, tissue, or cell comprising administering to the subject or contacting the biological sample, tissue, or cell with the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the method comprises administering to a subject the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, and Mfsd2a transports the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
- the method comprises contacting a cell, tissue, or biological sample with the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In some embodiments, the method comprises contacting a cell or biological sample with the compound of Formula (II), or a
- a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport via the Mfsd2a protein in a subject, biological sample, tissue, or cell.
- a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof for transport via the Mfsd2a protein comprising administering to a subject the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof for transport via the Mfsd2a protein comprising contacting a biological sample, tissue, or cell with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof for transport via the Mfsd2a protein comprising administering to a subject the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof for transport via the Mfsd2a protein comprising contacting a biological sample, tissue, or cell with the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a method of increasing plasmalogen levels in a subject, biological sample, tissue, or cell comprising administering to the subject or contacting the biological sample, tissue, or cell with a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a method of increasing plasmalogen levels in the brain or central nervous system of a subject comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a method of increasing plasmalogen levels in a subject, biological sample, tissue, or cell comprising administering to the subject or contacting the biological sample, tissue, or cell with a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a compound of Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- a method of increasing plasmalogen levels in the brain or central nervous system of a subject comprising administering to the subject a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
- the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in increasing plasmalogen levels in a subject, biological sample, tissue, or cell.
- the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in increasing plasmalogen levels in the brain or central nervous system of a subject.
- the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in increasing plasmalogen levels in a subject, biological sample, tissue, or cell.
- the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer,
- a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, for increasing plasmalogen levels in a subject, biological sample, tissue, or cell.
- a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof for increasing plasmalogen levels in the brain or central nervous system of a subject.
- plasmalogen levels are increased in a subject.
- the method comprises administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof to a subject.
- the method comprises administering a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof to a subject.
- plasmalogen levels are increased in a biological sample, tissue, or cell.
- the method comprises contacting a biological sample, tissue, or cell with a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof to a subject.
- the method comprises contacting a biological sample, tissue, or cell with a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer,
- the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or the composition is transported by the Mfsd2a protein.
- plasmalogen levels are increased in the blood, brain, central nervous system, heart, kidney, muscle, and/or liver. In some embodiments, plasmalogen levels increase in the blood, brain, central nervous system, muscle, and/or heart. In some embodiments, plasmalogen levels increase in the brain and/or central nervous system.
- plasmalogen levels in the brain increase.
- plasmalogen levels in the CNS increase.
- plasmalogen levels increase in the blood.
- plasmalogen levels increase in plasma.
- plasmalogen levels increase in serum.
- plasmalogen levels increase in the heart.
- plasmalogen levels increase in the kidney.
- plasmalogen levels increase in the muscle.
- plasmalogen levels increase in the liver.
- levels of one or more docosahexaenoic acid (DHA)-containing plasmalogens increase.
- plasmalogen levels increase by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%,90%, 100%, 125%, 150%, 200%, 300%, 400%, or 500%. In some embodiments, plasmalogen levels increase by at least 5%, 10%, 15%, or 20%. In some embodiments, plasmalogen levels increase by at least 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, plasmalogen levels increase by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. In some embodiments, plasmalogen levels increase by at least 100%, 125%, 150%, or 200%.
- plasmalogen levels increase by at least 200%, 300%, 400%, or 500%. In some embodiments, plasmalogen levels increase by about 5-25%, about 10-40%, about 25-50%, about 40-60%, about 50-75%, about 60-80%, about 75-100%, or greater than about 100%.
- transport via the Mfsd2a protein occurs across the blood- brain barrier or blood-retinal barrier. In certain embodiments, transport via the Mfsd2a protein occurs across the blood-brain barrier. In some embodiments, transport via the Mfsd2a protein occurs across the blood-retinal barrier. In some embodiments, the compound accumulates in the blood-brain barrier. In certain embodiments, the compound accumulates in the brain. In some embodiments, the compound accumulates in the blood retinal barrier. In certain embodiments, the compound accumulates in the eye.
- the method is in vivo.
- in vivo methods provided herein comprise administering to a subject an effective amount of a compound provided herein, or a composition thereof.
- the subject is a mammal.
- the subject is a human.
- the subject is mouse.
- the subject is a wild type mouse.
- the subject is a genetically modified mouse.
- the genetically modified mouse comprises in its genome a homozygous disruption of the Mfsd2a gene.
- the method is in vitro.
- in vitro methods provided herein can be carried out, e.g., in an assay, cell culture, or biological sample.
- the cell comprises a human wild type Mfsd2a cDNA or mutant human Mfsd2a cDNA.
- the cell comprises a human wild type Mfsd2a cDNA.
- the cell comprises a mutant human Mfsd2a cDNA.
- the cell is HEK 293.
- the mutant human Mfsd2a cDNA comprises a mutation at a position corresponding to D93 or D97 in the human Mfsd2a protein sequence.
- the present disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
- any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
- elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided herein are compounds (e.g., compounds of Formulae (I) and (II)), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein include plasmalogens and plasmalogen derivatives. The compounds provided herein may cross the blood-brain barrier and/or blood-retinal barrier or be transported by the Mfsd2a protein. Accordingly, such compounds are useful for the treatment and/or prevention of various diseases and conditions (e.g., liver diseases, neurological diseases, ophthalmic diseases, metabolic disorders, mitochondrial diseases, cardiovascular diseases, infectious diseases, pulmonary diseases, skin diseases, genetic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, hematological diseases, painful conditions, psychiatric disorders, immune disorders, and spleen diseases).
Description
PLASMALOGEN DERIVATIVES AND USES THEREOF RELATED APPLICATIONS [0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application, U.S.S.N.63/212,034, filed June 17, 2021, which is incorporated herein by reference in its entirety. BACKGROUND [0002] Plasmalogens are ether phospholipids that comprise a vinyl ether moiety at the sn1 or sn2 position. In mammals, the vinyl ether moiety is typically incorporated at the sn1 position, while the sn2 substituent usually comprises an unsaturated fatty acid residue. Plasmalogens are found throughout various human tissues, including the nervous, immune, and cardiovascular systems. Changes to lipid metabolism are associated with the onset and pathology of various diseases, including, but not limited to, neurological diseases, cardiovascular diseases, metabolic diseases, liver diseases, and cancer. There is a particular need for compounds that cross the blood-brain barrier so that the compounds can exert their activity in the central nervous system (CNS). Despite efforts towards understanding transport across the blood-brain barrier and blood-retinal barriers, efficient delivery directly into the CNS has remained a major challenge in developing potential therapeutics. SUMMARY OF THE INVENTION [0003] Impairment to the biosynthetic pathway of ether lipids may have deleterious downstream effects in subjects with various diseases (e.g., liver diseases, neurological diseases, ophthalmic diseases, metabolic disorders, mitochondrial diseases, cardiovascular diseases, infectious diseases, pulmonary diseases, skin diseases, genetic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, hematological diseases, painful conditions, psychiatric disorders, immune disorders, and spleen diseases). Ether lipids and, in particular, plasmalogen ether species are negatively associated with neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, some genetic diseases, such as Zellweger syndrome, and pulmonary diseases, such as neonatal respiratory distress syndrome. Plasmalogen deficiency is also linked to defects in peroxisome functions and associated disorders. Accordingly, plasmalogen replacement therapy may be used to increase plasmalogen levels in deficient patients. This therapeutic approach may correct various issues, including issues associated with neurological function. Without
1/200
wishing to be bound by a particular theory, the inventors posit that plasmalogen species disclosed herein may be effectively transported by Mfsd2a and achieve improved blood-brain barrier and/or blood-retinal barrier permeability. Additionally, compounds comprising a vinyl ether moiety do not require metabolic conversion and may therefore be effective at low doses. [0004] The present disclosure relates in part to new compounds that can be transported across the blood-brain barrier or blood-retinal barrier, such as by Mfsd2a, and compositions, kits, and methods of using and preparing such compounds. [0005] In one aspect, provided herein are compounds, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and pharmaceutical compositions thereof. In certain embodiments, the compounds provided herein are transported by Mfsd2a and can therefore be used for the treatment and/or prevention of diseases (e.g., liver diseases, neurological diseases, ophthalmic diseases, metabolic disorders, mitochondrial diseases, cardiovascular diseases, infectious diseases, pulmonary diseases, skin diseases, genetic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, hematological diseases, painful conditions, psychiatric disorders, immune disorders, and spleen diseases). [0006] The present disclosure also provides methods of using the compounds and compositions provided herein, e.g., for treating and/or preventing a disease, disorder, or condition (e.g., a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition, a psychiatric disorder, an immune disorder, or a spleen disease) in a subject. In some embodiments, the disease is a neurological disease. In some embodiments, the disease is a pulmonary disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is an ophthalmic disease. [0007] In another aspect, the present disclosure provides kits comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co- crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof.
2/200
[0008] In one aspect, the disclosure provides compounds of Formula (I):
and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, wherein R1, R2, L1, and X are as defined herein. [0009] In certain embodiments, the compound is of Formula (I-A):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1, R2, R3, R4, R5, L1 and L2 are as defined herein. [0010] In certain embodiments, the compound is of Formula (I-A-i):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and L2 are as defined herein. [0011] In certain embodiments, the compound is of Formula (I-A-ii):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1, R2, L1, and L2 are as defined herein.
3/200
[0012] In certain embodiments, the compound is of Formula (I-A-iii):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1, R2, L1, and L2 are as defined herein. [0013] In certain embodiments, the compound is of Formula (I-B):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1, R2, R3, R4, L1, and L2 are as defined herein. [0014] In certain embodiments, the compound is of Formula (I-C):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1, R2, R6, R7, R8, R9, R10, and X are as defined herein. [0015] In another aspect, the disclosure provides compounds of Formula (II):
and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrug thereof, wherein R1', R2', R3', R4', X, Y, Z, *, and n are as defined herein.
4/200
[0016] In certain embodiments, the compound is of Formula (II-A):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1', R2", R3', R4', X, Y, Z, *, and n are as defined herein. [0017] In certain embodiments the compound is of Formula (II-B):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1', R2', R3', R4', Y, Z, and n are as defined herein. [0018] In certain embodiments, the compound is of Formula (II-C):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1', R2', R3', R4', X, Z, and n are as defined herein.
5/200
[0019] In certain embodiments, the compound is of Formula (II-D):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein R1', R2', R3', R4', X, Y, and n are as defined herein. [0020] In another aspect, the present disclosure provides compositions comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; and a pharmaceutically acceptable carrier and/or excipient. In certain embodiments, the composition is a pharmaceutical composition. In some embodiments, the pharmaceutical composition further comprises an additional pharmaceutical agent. In certain embodiments, a pharmaceutical composition provided herein is formulated for oral administration. In some embodiments, the composition is a nutraceutical composition comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co- crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; and a nutraceutically acceptable carrier and/or excipient. In certain embodiments, a nutraceutical composition provided herein is formulated for oral administration. [0021] In another aspect, the present disclosure provides methods for treating and/or preventing a disease, disorder, or condition in a subject comprising administering to the subject an effective amount of a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a pharmaceutical composition thereof. In some embodiments, the disease is a neurological disease. In some embodiments, the disease is a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition, a psychiatric disorder, an immune disorder, or a spleen disease. In certain embodiments, the disease is a
6/200
neurodegenerative disease. In some embodiments, the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington’s disease, amyotrophic lateral sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV-related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supranuclear palsy, vascular dementia, progressive multifocal leukoencephalopathy, dementia with Lewy bodies, lacunar syndromes, hydrocephalus, Wernicke-Korsakoff's syndrome, post-encephalitic dementia, cancer and chemotherapy- associated cognitive impairment and dementia, or depression-induced dementia and pseudodementia. In certain embodiments, the disease is dementia, Alzheimer’s disease, other Parkinson’s disease, Huntington’s disease, a prion disease, amyotrophic lateral sclerosis, or multiple sclerosis. In some embodiments, the disease is dementia, or Alzheimer’s disease. In some embodiments, the disease is dementia. In certain embodiments, the disease is Alzheimer’s disease. In certain embodiments, the disease is Parkinson’s disease. [0022] In another aspect, provided herein is a method of transporting a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, across the blood-brain barrier or blood-retinal barrier. In some embodiments, the method comprises administering to a subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In certain embodiments, the method comprises contacting a cell, tissue, or biological sample with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In some embodiments, the method is an in vitro method. In some embodiments, the method is an in vivo method. [0023] In yet another aspect, provided herein is a method of transporting a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co- crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a
7/200
pharmaceutical composition thereof, via the Mfsd2a protein in a subject, biological sample, tissue, or cell. In some embodiments, the method comprises administering to a subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In certain embodiments, the method comprises contacting a cell, tissue, or biological sample with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In some embodiments, the method is an in vitro method. In some embodiments, the method is an in vivo method. In some embodiments, the method is an ex vivo method. [0024] In another aspect, provided herein is a method of increasing plasmalogen levels in a subject, biological sample, tissue, or cell, comprising administering to the subject or contacting the biological sample, tissue, or cell with compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [0025] In another aspect, provided herein is a method of increasing plasmalogen levels in the brain or central nervous system of a subject, comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [0026] In another aspect, the present disclosure provides a kit comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co- crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; or a composition provided herein; and instructions for using the compound, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, prodrug, or composition thereof. [0027] The details of certain embodiments of the present disclosure are set forth in the Detailed Description of Certain Embodiments, as described below. Other features, objects, and advantages of the present disclosure will be apparent from the Definitions, Examples, and Claims. It should be understood that the aspects described herein are not limited to specific embodiments, methods, or configurations, and as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting.
8/200
DEFINITIONS Chemical Definitions [0028] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999;Michael B. Smith, March’s Advanced Organic Chemistry, 7th Edition, John Wiley & Sons, Inc., New York, 2013; Richard C. Larock, Comprehensive Organic Transformations, John Wiley & Sons, Inc., New York, 2018; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987. [0029] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw–Hill, NY, 1962); and Wilen, S.H., Tables of Resolving Agents and Optical Resolutions p.268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present disclosure additionally encompasses compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers. [0030] Unless otherwise provided, formulae and structures depicted herein include compounds that do not include isotopically enriched atoms, and also include compounds that include isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, replacement of 19F with 18F, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of the disclosure. Such compounds are useful, for example, as analytical tools or probes in biological assays.
9/200
[0031] The term “isotopes” refers to variants of a particular chemical element such that, while all isotopes of a given element share the same number of protons in each atom of the element, those isotopes differ in the number of neutrons. [0032] When a range of values is listed, it is intended to encompass each value and sub-range within the range. A range is inclusive of the values at the two ends of the range unless otherwise provided. For example “C1-6 alkyl” encompasses, C1, C2, C3, C4, C5, C6, C1–6, C1–5, C1–4, C1–3, C1–2, C2–6, C2–5, C2–4, C2–3, C3–6, C3–5, C3–4, C4–6, C4–5, and C5–6 alkyl. [0033] The term “aliphatic” refers to alkyl, alkenyl, alkynyl, and carbocyclic groups. Likewise, the term “heteroaliphatic” refers to heteroalkyl, heteroalkenyl, heteroalkynyl, and heterocyclic groups. [0034] The term “alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1–20 alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C1–12 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C1–10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C1–9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C1–8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C1–7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C1–6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1–5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1–4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1–3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1–2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C1 alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”). Examples of C1–6 alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C4) (e.g., n-butyl, tert-butyl, sec-butyl, isobutyl), pentyl (C5) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tert-amyl), and hexyl (C6) (e.g., n-hexyl). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (C8), n-dodecyl (C12), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents (e.g., halogen, such as F). In certain embodiments, the alkyl group is an unsubstituted C1–12 alkyl (such as unsubstituted C1–6 alkyl, e.g., −CH3 (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g., unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (i-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n-butyl (n-Bu), unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted sec-butyl (sec-Bu or s-Bu), unsubstituted isobutyl (i-Bu)). In certain embodiments, the alkyl group is a substituted C1–12 alkyl (such as
10/200
substituted C1–6 alkyl, e.g., –CH2F, –CHF2, –CF3, –CH2CH2F, –CH2CHF2, –CH2CF3, or benzyl (Bn)). [0035] The term “haloalkyl” is a substituted alkyl group, wherein one or more of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. “Perhaloalkyl” is a subset of haloalkyl, and refers to an alkyl group wherein all of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. In some embodiments, the haloalkyl moiety has 1 to 20 carbon atoms (“C1–20 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 10 carbon atoms (“C1–10 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 9 carbon atoms (“C1–9 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 8 carbon atoms (“C1–8 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 7 carbon atoms (“C1–7 haloalkyl”).In some embodiments, the haloalkyl moiety has 1 to 6 carbon atoms (“C1–6 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 5 carbon atoms (“C1–5 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 4 carbon atoms (“C1–4 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 3 carbon atoms (“C1–3 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 2 carbon atoms (“C1–2 haloalkyl”). In some embodiments, all of the haloalkyl hydrogen atoms are independently replaced with fluoro to provide a “perfluoroalkyl” group. In some embodiments, all of the haloalkyl hydrogen atoms are independently replaced with chloro to provide a “perchloroalkyl” group. Examples of haloalkyl groups include –CHF2, −CH2F, −CF3, −CH2CF3, −CF2CF3, −CF2CF2CF3, −CCl3, −CFCl2, −CF2Cl, and the like. [0036] The term “alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 1 to 20 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 1 to 20 carbon atoms (“C1-20 alkenyl”). In some embodiments, an alkenyl group has 1 to 12 carbon atoms (“C1–12 alkenyl”). In some embodiments, an alkenyl group has 1 to 11 carbon atoms (“C1–11 alkenyl”). In some embodiments, an alkenyl group has 1 to 10 carbon atoms (“C1–10 alkenyl”). In some embodiments, an alkenyl group has 1 to 9 carbon atoms (“C1–9 alkenyl”). In some embodiments, an alkenyl group has 1 to 8 carbon atoms (“C1–8 alkenyl”). In some embodiments, an alkenyl group has 1 to 7 carbon atoms (“C1–7 alkenyl”). In some embodiments, an alkenyl group has 1 to 6 carbon atoms (“C1–6 alkenyl”). In some embodiments, an alkenyl group has 1 to 5 carbon atoms (“C1–5 alkenyl”). In some embodiments, an alkenyl group has 1 to 4 carbon atoms (“C1–4 alkenyl”). In some embodiments, an alkenyl group has 1 to 3 carbon atoms (“C1–3 alkenyl”). In some
11/200
embodiments, an alkenyl group has 1 to 2 carbon atoms (“C1–2 alkenyl”). In some embodiments, an alkenyl group has 1 carbon atom (“C1 alkenyl”). The one or more carbon- carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C1–4 alkenyl groups include methylidenyl (C1), ethenyl (C2), 1-propenyl (C3), 2- propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C1–6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C1-20 alkenyl. In certain embodiments, the alkenyl group is a substituted C1-20 alkenyl. In an alkenyl group, a C=C double bond for which the stereochemistry is not specified (e.g., −CH=CHCH3 or
) may be in the (E)- or (Z)- configuration. [0037] The term “alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 1 to 20 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) (“C1-20 alkynyl”). In some embodiments, an alkynyl group has 1 to 10 carbon atoms (“C1-10 alkynyl”). In some embodiments, an alkynyl group has 1 to 9 carbon atoms (“C1-9 alkynyl”). In some embodiments, an alkynyl group has 1 to 8 carbon atoms (“C1- 8 alkynyl”). In some embodiments, an alkynyl group has 1 to 7 carbon atoms (“C1-7 alkynyl”). In some embodiments, an alkynyl group has 1 to 6 carbon atoms (“C1-6 alkynyl”). In some embodiments, an alkynyl group has 1 to 5 carbon atoms (“C1-5 alkynyl”). In some embodiments, an alkynyl group has 1 to 4 carbon atoms (“C1-4 alkynyl”). In some embodiments, an alkynyl group has 1 to 3 carbon atoms (“C1-3 alkynyl”). In some embodiments, an alkynyl group has 1 to 2 carbon atoms (“C1-2 alkynyl”). In some embodiments, an alkynyl group has 1 carbon atom (“C1 alkynyl”). The one or more carbon- carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C1-4 alkynyl groups include, without limitation, methylidynyl (C1), ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C1-6 alkenyl groups include the aforementioned C2-4 alkynyl groups as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted
12/200
alkynyl”) with one or more substituents. In certain embodiments, the alkynyl group is an unsubstituted C1-20 alkynyl. In certain embodiments, the alkynyl group is a substituted C1-20 alkynyl. [0038] The term “carbocyclyl” or “carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 14 ring carbon atoms (“C3-14 carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 14 ring carbon atoms (“C3-14 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 13 ring carbon atoms (“C3-13 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 12 ring carbon atoms (“C3-12 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 11 ring carbon atoms (“C3-11 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 10 ring carbon atoms (“C3-10 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C3-8 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms (“C3-7 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms (“C4-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms (“C5-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5-10 carbocyclyl”). Exemplary C3-6 carbocyclyl groups include cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-8 carbocyclyl groups include the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C3-10 carbocyclyl groups include the aforementioned C3-8 carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like. Exemplary C3-8 carbocyclyl groups include the aforementioned C3-10 carbocyclyl groups as well as cycloundecyl (C11), spiro[5.5]undecanyl (C11), cyclododecyl (C12), cyclododecenyl (C12), cyclotridecane (C13), cyclotetradecane (C14), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds. “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one
13/200
or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group is an unsubstituted C3-14 carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C3-14 carbocyclyl. [0039] In some embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 14 ring carbon atoms (“C3-14 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 10 ring carbon atoms (“C3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 4 to 6 ring carbon atoms (“C4-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10 cycloalkyl”). Examples of C5-6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-6 cycloalkyl groups include the aforementioned C5-6 cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8 cycloalkyl groups include the aforementioned C3-6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is an unsubstituted C3-14 cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C3-14 cycloalkyl. In certain embodiments, the carbocyclyl includes 0, 1, or 2 C=C double bonds in the carbocyclic ring system, as valency permits. [0040] The term “heterocyclyl” or “heterocyclic” refers to a radical of a 3- to 14-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3–14 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon- carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more
14/200
heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is an unsubstituted 3–14 membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3–14 membered heterocyclyl. In certain embodiments, the heterocyclyl is substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, wherein 1, 2, or 3 atoms in the heterocyclic ring system are independently oxygen, nitrogen, or sulfur, as valency permits. [0041] In some embodiments, a heterocyclyl group is a 5–10 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5–8 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5–6 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heterocyclyl”). In some embodiments, the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. [0042] Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include azirdinyl, oxiranyl, and thiiranyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5- dione. Exemplary 5-membered heterocyclyl groups containing 2 heteroatoms include dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5-membered heterocyclyl groups
15/200
containing 3 heteroatoms include triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6- membered heterocyclyl groups containing 1 heteroatom include piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include triazinyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetra- hydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, 1H-benzo[e][1,4]diazepinyl, 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6- dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro-5H-furo[3,2-b]pyranyl, 5,7-dihydro-4H- thieno[2,3-c]pyranyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, 2,3-dihydrofuro[2,3- b]pyridinyl, 4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2- c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, 1,2,3,4-tetrahydro-1,6-naphthyridinyl, and the like. [0043] Affixing the suffix “-ene” to a group indicates the group is a divalent moiety, e.g., alkylene is the divalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl, alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of heteroalkyl, heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is the divalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl, heterocyclylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl, and heteroarylene is the divalent moiety of heteroaryl. [0044] A group is optionally substituted unless expressly provided otherwise. The term “optionally substituted” refers to being substituted or unsubstituted. In certain embodiments, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted. “Optionally substituted” refers to a group which is substituted or unsubstituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” heteroalkenyl, “substituted” or “unsubstituted” heteroalkynyl, “substituted” or “unsubstituted” carbocyclyl,
16/200
“substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group). In general, the term “substituted” means that at least one hydrogen present on a group is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds, and includes any of the substituents described herein that results in the formation of a stable compound. The present disclosure contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety. The present disclosure is not limited in any manner by the exemplary substituents described herein.
C1–20 alkenyl, C1–20 alkynyl, heteroC1–20 alkyl, heteroC1–20 alkenyl, heteroC1–20 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
17/200
or two geminal hydrogens on a carbon atom are replaced with the group
wherein: each instance of Raa is independently selected from C1–20 alkyl, C1–20 perhaloalkyl, C1–20 alkenyl, C1–20 alkynyl, heteroC1–20 alkyl, heteroC1–20alkenyl, heteroC1–20alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5- 14 membered heteroaryl, or two Raa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups; each instance of Rbb is independently selected from hydrogen, −OH, −ORaa,
alkyl, C1–20 perhaloalkyl, C1–20 alkenyl, C1–20 alkynyl, heteroC1–20alkyl, heteroC1– 20alkenyl, heteroC1–20alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two Rbb groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups; each instance of Rcc is independently selected from hydrogen, C1–20 alkyl, C1– 20 perhaloalkyl, C1–20 alkenyl, C1–20 alkynyl, heteroC1–20 alkyl, heteroC1–20 alkenyl, heteroC1–20 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5- 14 membered heteroaryl, or two Rcc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups;
−C(=O)SRee, −C(=S)SRee, −SC(=S)SRee, −P(=O)(ORee)2, −P(=O)(Ree)2, −OP(=O)(Ree)2, −OP(=O)(ORee)2, C1–10 alkyl, C1–10 perhaloalkyl, C1–10 alkenyl, C1–10 alkynyl, heteroC1–10alkyl, heteroC1–10alkenyl, heteroC1–10alkynyl, C3-10 carbocyclyl, 3- 10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups, or two geminal Rdd substituents are joined to form =O or =S; each instance of Ree is independently selected from C1–10 alkyl, C1–10 perhaloalkyl, C1–10 alkenyl, C1–10 alkynyl, heteroC1–10 alkyl, heteroC1–10 alkenyl, heteroC1–10 alkynyl, C3-10 carbocyclyl, C6-10 aryl, 3-10 membered heterocyclyl, and 3- 10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups; each instance of Rff is independently selected from hydrogen, C1–10 alkyl, C1–10 perhaloalkyl, C1–10 alkenyl, C1–10 alkynyl, heteroC1–10 alkyl, heteroC1–10 alkenyl, heteroC1–10 alkynyl, C3-10 carbocyclyl, 3-10 membered heterocyclyl, C6-10 aryl, and 5- 10 membered heteroaryl, or two Rff groups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgg groups; each instance of Rgg is independently halogen, −CN, −NO2, −N3, −SO2H, −SO3H, −OH, −OC1–6 alkyl, −ON(C1–6 alkyl)2, −N(C1–6 alkyl)2, −N(C1–6 alkyl)3+X−, −NH(C1–6 alkyl)2+X−, −NH2(C1–6 alkyl) +X−, −NH3+X−, −N(OC1–6 alkyl)(C1–6 alkyl), −N(OH)(C1–6 alkyl), −NH(OH), −SH, −SC1–6 alkyl, −SS(C1–6 alkyl), −C(=O)(C1–6 alkyl), −CO2H, −CO2(C1–6 alkyl), −OC(=O)(C1–6 alkyl), −OCO2(C1–6 alkyl), −C(=O)NH2, −C(=O)N(C1–6 alkyl)2, −OC(=O)NH(C1–6 alkyl), −NHC(=O)( C1–6 alkyl), −N(C1–6 alkyl)C(=O)( C1–6 alkyl), −NHCO2(C1–6 alkyl), −NHC(=O)N(C1–6 alkyl)2, −NHC(=O)NH(C1–6 alkyl), −NHC(=O)NH2, −C(=NH)O(C1–6 alkyl), −OC(=NH)(C1–6 alkyl), −OC(=NH)OC1–6 alkyl, −C(=NH)N(C1–6 alkyl)2, −C(=NH)NH(C1–6 alkyl), −C(=NH)NH2, −OC(=NH)N(C1–6 alkyl)2, −OC(NH)NH(C1– 6 alkyl), −OC(NH)NH2, −NHC(NH)N(C1–6 alkyl)2, −NHC(=NH)NH2, −NHSO2(C1–6 alkyl), −SO2N(C1–6 alkyl)2, −SO2NH(C1–6 alkyl), −SO2NH2, −SO2C1–6 alkyl, −SO2OC1–6 alkyl, −OSO2C1–6 alkyl, −SOC1–6 alkyl, −Si(C1–6 alkyl)3, −OSi(C1–6 alkyl)3 −C(=S)N(C1–6 alkyl)2, C(=S)NH(C1–6 alkyl), C(=S)NH2, −C(=O)S(C1–6 alkyl),
19/200
−C(=S)SC1–6 alkyl, −SC(=S)SC1–6 alkyl, −P(=O)(OC1–6 alkyl)2, −P(=O)(C1–6 alkyl)2, −OP(=O)(C1–6 alkyl)2, −OP(=O)(OC1–6 alkyl)2, C1–10 alkyl, C1–10 perhaloalkyl, C1–10 alkenyl, C1–10 alkynyl, heteroC1–10 alkyl, heteroC1–10 alkenyl, heteroC1–10 alkynyl, C3- 10 carbocyclyl, C6-10 aryl, 3-10 membered heterocyclyl, or 5-10 membered heteroaryl; or two geminal Rgg substituents are joined to form =O or =S; and each X− is a counterion. [0046] In certain embodiments, each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, −ORaa, −SRaa, −N(Rbb)2, –CN, –SCN, –NO2, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, −OC(=O)Raa, −OCO2Raa, −OC(=O)N(Rbb)2, −NRbbC(=O)Raa, −NRbbCO2Raa, or −NRbbC(=O)N(Rbb)2. In certain embodiments, each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1–10 alkyl, −ORaa, −SRaa, −N(Rbb)2,
−OC(=O)N(Rbb)2, −NRbbC(=O)Raa, −NRbbCO2Raa, or −NRbbC(=O)N(Rbb)2, wherein Raa is hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1–10 alkyl, an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl) when attached to an oxygen atom, or a sulfur protecting group (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine- sulfenyl, or triphenylmethyl) when attached to a sulfur atom; and each Rbb is independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1–10 alkyl, or a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts). In certain embodiments, each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, −ORaa, −SRaa, −N(Rbb)2, –CN, –SCN, or –NO2. In certain embodiments, each carbon atom substituent is independently halogen, substituted (e.g., substituted with one or more halogen moieties) or unsubstituted C1–10 alkyl, −ORaa, −SRaa, −N(Rbb)2, –CN, –SCN, or –NO2, wherein Raa is hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1–10 alkyl, an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl) when attached to an oxygen atom, or a sulfur protecting group (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine-sulfenyl, or triphenylmethyl) when attached to a sulfur atom; and each Rbb is independently hydrogen, substituted (e.g.,
20/200
substituted with one or more halogen) or unsubstituted C1–10 alkyl, or a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts). [0047] In certain embodiments, the molecular weight of a carbon atom substituent is lower than 250, lower than 200, lower than 150, lower than 100, or lower than 50 g/mol. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, nitrogen, and/or silicon atoms. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, and/or nitrogen atoms. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, and/or iodine atoms. In certain embodiments, a carbon atom substituent consists of carbon, hydrogen, fluorine, and/or chlorine atoms. [0048] The term “halo” or “halogen” refers to fluorine (fluoro, −F), chlorine (chloro, −Cl), bromine (bromo, −Br), or iodine (iodo, −I). [0049] The term “amino” refers to the group −NH2. The term “substituted amino,” by extension, refers to a monosubstituted amino, a disubstituted amino, or a trisubstituted amino. In certain embodiments, the “substituted amino” is a monosubstituted amino or a disubstituted amino group. [0050] The term “monosubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with one hydrogen and one group other than hydrogen, and includes groups selected from −NH(Rbb), −NHC(=O)Raa, −NHCO2Raa, −NHC(=O)N(Rbb)2, −NHC(=NRbb)N(Rbb)2, −NHSO2Raa, −NHP(=O)(ORcc)2, and −NHP(=O)(N(Rbb)2)2, wherein Raa, Rbb and Rcc are as defined herein, and wherein Rbb of the group −NH(Rbb) is not hydrogen. [0051] The term “disubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with two groups other than hydrogen, and includes groups selected from −N(Rbb)2, −NRbb C(=O)Raa, −NRbbCO2Raa, −NRbbC(=O)N(Rbb)2, −NRbbC(=NRbb)N(Rbb)2, −NRbbSO2Raa, −NRbbP(=O)(ORcc)2, and −NRbbP(=O)(N(Rbb)2)2, wherein Raa, Rbb, and Rcc are as defined herein, with the proviso that the nitrogen atom directly attached to the parent molecule is not substituted with hydrogen. [0052] The term “acyl” refers to a group having the general formula −C(=O)Raa, −C(=O)ORaa, −C(=O)−O−C(=O)Raa, −C(=O)SRaa, −C(=O)N(Rbb)2, −C(=S)Raa, −C(=S)N(Rbb)2, and −C(=S)S(Raa), −C(=NRbb)Raa, −C(=NRbb)ORaa, −C(=NRbb)SRaa, and −C(=NRbb)N(Rbb)2, wherein Raa and Rbb are as defined herein. Exemplary acyl groups include
21/200
aldehydes (−CHO), carboxylic acids (−CO2H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas. [0053] The term “carbonyl” refers to a group wherein the carbon directly attached to the parent molecule is sp2 hybridized, and is substituted with an oxygen, nitrogen or sulfur atom, e.g., a group selected from ketones (–C(=O)Raa), carboxylic acids (–CO2H), aldehydes (– CHO), esters (–CO2Raa, –C(=O)SRaa, –C(=S)SRaa), amides (–C(=O)N(Rbb)2, – C(=O)NRbbSO2Raa, −C(=S)N(Rbb)2), and imines (–C(=NRbb)Raa, –C(=NRbb)ORaa), – C(=NRbb)N(Rbb)2), wherein Raa and Rbb are as defined herein. [0054] Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include hydrogen, −OH, −ORaa, −N(Rcc)2, −CN, −C(=O)Raa, −C(=O)N(Rcc)2,
−SO2Rcc, −SO2ORcc, −SORaa, −C(=S)N(Rcc)2, −C(=O)SRcc, −C(=S)SRcc, −P(=O)(ORcc)2, −P(=O)(Raa)2, −P(=O)(N(Rcc)2)2, C1–20 alkyl, C1–20 perhaloalkyl, C1–20 alkenyl, C1–20 alkynyl, hetero C1–20 alkyl, hetero C1–20 alkenyl, hetero C1–20 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two Rcc groups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups, and wherein Raa, Rbb, Rcc and Rdd are as defined above. [0055] In certain embodiments, each nitrogen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, or a nitrogen protecting group. In certain embodiments, each nitrogen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10 alkyl, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, or a nitrogen protecting group, wherein Raa is hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10 alkyl, or an oxygen protecting group when attached to an oxygen atom; and each Rbb is independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10 alkyl, or a nitrogen protecting group. In certain embodiments, each nitrogen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl or a nitrogen protecting group. [0056] In certain embodiments, the substituent present on the nitrogen atom is a nitrogen protecting group (also referred to herein as an “amino protecting group”). Nitrogen protecting groups include −OH, −ORaa, −N(Rcc)2, −C(=O)Raa, −CO2Raa, −C(=O)N(Rcc)2,
22/200
−SO2Raa, −C(=NRcc)Raa, −C(=NRcc)ORaa, −C(=NRcc)N(Rcc)2, −SO2N(Rcc)2, −SO2Rcc, −SO2ORcc, −SORaa, −C(=S)N(Rcc)2, −C(=O)SRcc, −C(=S)SRcc, C1–10 alkyl (e.g., aralkyl, heteroaralkyl), C1–20 alkenyl, C1–20 alkynyl, hetero C1–20 alkyl, hetero C1–20 alkenyl, hetero C1–20 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups, and wherein Raa, Rbb, Rcc and Rdd are as defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference. In certain embodiments, the nitrogen protecting group does not form a urea with the nitrogen to which it is attached. In certain embodiments, the nitrogen protecting group is not −C(=O)N(Rcc)2. [0057] For example, in certain embodiments, at least one nitrogen protecting group is an amide group (e.g., a moiety that include the nitrogen atom to which the nitrogen protecting groups (e.g., −C(=O)Raa) is directly attached). In certain such embodiments, each nitrogen protecting group, together with the nitrogen atom to which the nitrogen protecting group is attached, is independently selected from the group consisting of formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3- phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o- nitrophenoxyacetamide, acetoacetamide, (N’-dithiobenzyloxyacylamino)acetamide, 3-(p- hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o- nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4- chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivatives, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide. [0058] In certain embodiments, at least one nitrogen protecting group is a carbamate group (e.g., a moiety that include the nitrogen atom to which the nitrogen protecting groups (e.g., −C(=O)ORaa) is directly attached). In certain such embodiments, each nitrogen protecting group, together with the nitrogen atom to which the nitrogen protecting group is attached, is independently selected from the group consisting of methyl carbamate, ethyl carbamate, 9- fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7- dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10- tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-
23/200
phenylethyl carbamate (hZ), 1–(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1- dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1- dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2′- and 4′-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4- nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p- nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4- dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1- dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p- (dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)- 6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o- nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N- dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2- pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p’-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1- cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl- 1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4- pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t- butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.
24/200
[0059] In certain embodiments, at least one nitrogen protecting group is a sulfonamide group (e.g., a moiety that include the nitrogen atom to which the nitrogen protecting groups (e.g., −S(=O)2Raa) is directly attached). In certain such embodiments, each nitrogen protecting group, together with the nitrogen atom to which the nitrogen protecting group is attached, is independently selected from the group consisting of p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6- trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4- methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9- anthracenesulfonamide, 4-(4′,8′-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide. [0060] In certain embodiments, each nitrogen protecting group, together with the nitrogen atom to which the nitrogen protecting group is attached, is independently selected from the group consisting of phenothiazinyl-(10)-acyl derivatives, N’-p-toluenesulfonylaminoacyl derivatives, N’-phenylaminothioacyl derivatives, N-benzoylphenylalanyl derivatives, N- acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N- dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4- tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5- triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1- substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2- (trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4- nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4- methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N- [(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7- dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N’- oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p- methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2- pyridyl)mesityl]methyleneamine, N-(N’,N’-dimethylaminomethylene)amine, N-p- nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2- hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1- cyclohexenyl)amine, N-borane derivatives, N-diphenylborinic acid derivatives, N-
25/200
[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N- nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys). In some embodiments, two instances of a nitrogen protecting group together with the nitrogen atoms to which the nitrogen protecting groups are attached are N,N’-isopropylidenediamine. [0061] In certain embodiments, at least one nitrogen protecting group is Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts. [0062] In certain embodiments, each oxygen atom substituent is hydrogen or independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10 alkyl, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, or an oxygen protecting group. In certain embodiments, each oxygen atom substituents is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, or an oxygen protecting group, wherein Raa is hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10 alkyl, or an oxygen protecting group when attached to an oxygen atom; and each Rbb is independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-10 alkyl, or a nitrogen protecting group. In certain embodiments, each oxygen atom substituent is independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl or an oxygen protecting group. [0063] In certain embodiments, the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as a “hydroxyl protecting group”). Oxygen protecting groups include −Raa, −N(Rbb)2, −C(=O)SRaa, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, −C(=NRbb)Raa, −C(=NRbb)ORaa, −C(=NRbb)N(Rbb)2, −S(=O)Raa, −SO2Raa, −Si(Raa)3, −P(Rcc)2, −P(Rcc)3+X−, −P(ORcc)2, −P(ORcc)3+X−, −P(=O)(Raa)2, −P(=O)(ORcc)2, and −P(=O)(N(Rbb) 2)2, wherein X−, Raa, Rbb, and Rcc are as defined herein. Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference. [0064] In certain embodiments, the oxygen protecting group, together with the oxygen atom to which the oxygen protecting group is attached, is selected from the group consisting of
26/200
methoxy, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p- methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2- methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2- (trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3- bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4- methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4- methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4- methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1- (2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1- benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t- butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p- methoxybenzyl (PMB), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p,p’-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α- naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p- methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4’- bromophenacyloxyphenyl)diphenylmethyl, 4,4′,4″-tris(4,5- dichlorophthalimidophenyl)methyl, 4,4′,4″-tris(levulinoyloxyphenyl)methyl, 4,4′,4″- tris(benzoyloxyphenyl)methyl, 4,4'-Dimethoxy-3"'-[N-(imidazolylmethyl) ]trityl Ether (IDTr- OR), 4,4'-Dimethoxy-3"'-[N-(imidazolylethyl)carbamoyl]trityl Ether (IETr-OR), 1,1-bis(4- methoxyphenyl)-1′-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10- oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t- butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4- oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6- trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), ethyl
27/200
carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), isobutyl carbonate, vinyl carbonate, allyl carbonate, t-butyl carbonate (BOC or Boc), p- nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, S-benzyl thiocarbonate, 4- ethoxy-1-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4- nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2- (methylthiomethoxy)ethyl carbonate (MTMEC-OR), 4-(methylthiomethoxy)butyrate, 2- (methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4- (1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o- (methoxyacyl)benzoate, α-naphthoate, nitrate, alkyl N,N,N’,N’- tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). In certain embodiments, at least one oxygen protecting group is silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl. [0065] In certain embodiments, the molecular weight of a substituent is lower than 250, lower than 200, lower than 150, lower than 100, or lower than 50 g/mol. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, nitrogen, and/or silicon atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, and/or nitrogen atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, and/or iodine atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, and/or chlorine atoms. In certain embodiments, a substituent comprises 0, 1, 2, or 3 hydrogen bond donors. In certain embodiments, a substituent comprises 0, 1, 2, or 3 hydrogen bond acceptors. [0066] Use of the phrase “at least one instance” refers to 1, 2, 3, 4, or more instances, but also encompasses a range, e.g., for example, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 4, from 2 to 3, or from 3 to 4 instances, inclusive. [0067] The disclosure is not intended to be limited in any manner by the above exemplary listing of substituents. Additional terms may be defined in other sections of this disclosure.
28/200
Other Definitions [0068] As used herein, the term “salt” refers to any and all salts, and encompasses pharmaceutically acceptable salts. Salts include ionic compounds that result from the neutralization reaction of an acid and a base. A salt is composed of one or more cations (positively charged ions) and one or more anions (negative ions) so that the salt is electrically neutral (without a net charge). Salts of the compounds of this disclosure include those derived from inorganic and organic acids and bases. Examples of acid addition salts are salts of an amino group formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange. Other salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2– naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3–phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, hippurate, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1–4 alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate. [0069] The term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic
29/200
acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N+(C1-4 alkyl)4 − salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate. In some embodiments, the pharmaceutically acceptable salt is an alkali metal salt. In some embodiments, the pharmaceutically acceptable salt is a nontoxic ammonium, quaternary ammonium, or amine cation. [0070] The term “solvate” refers to forms of the compound, or a salt thereof, that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds described herein may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, and methanolates. [0071] The term “stoichiometric solvate” refers to a solvate, which comprises a compound (e.g., a compound disclosed herein) and a solvent, wherein the solvent molecules are an integral part of the crystal lattice, in which they interact strongly with the compound and each other. The removal of the solvent molecules will cause instability of the crystal network,
30/200
which subsequently collapses into an amorphous phase or recrystallizes as a new crystalline form with reduced solvent content. [0072] The term “non-stoichiometric solvate” refers to a solvate, which comprises a compound (e.g., a compound disclosed herein) and a solvent, wherein the solvent content may vary without major changes in the crystal structure. The amount of solvent in the crystal lattice only depends on the partial pressure of solvent in the surrounding atmosphere. In the fully solvated state, non-stoichiometric solvates may, but not necessarily have to, show an integer molar ratio of solvent to the compound. During drying of a non-stoichiometric solvate, a portion of the solvent may be removed without significantly disturbing the crystal network, and the resulting solvate can subsequently be resolvated to give the initial crystalline form. Unlike stoichiometric solvates, the desolvation and resolvation of non- stoichiometric solvates is not accompanied by a phase transition, and all solvation states represent the same crystal form. [0073] The term “hydrate” refers to a compound that is associated with water. Typically, the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R⋅x H2O, wherein R is the compound, and x is a number greater than 0. A given compound may form more than one type of hydrate, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R⋅0.5 H2O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R⋅2 H2O) and hexahydrates (R⋅6 H2O)). [0074] The term “tautomers” or “tautomeric” refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base. Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(a different enamine) tautomerizations. [0075] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”.
31/200
[0076] Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (−)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”. [0077] The term “co-crystal” refers to a crystalline structure comprising at least two different components (e.g., a compound disclosed herein and an acid), wherein each of the components is independently an atom, ion, or molecule. In certain embodiments, none of the components is a solvent. In certain embodiments, at least one of the components is a solvent. A co-crystal of a compound disclosed herein and an acid is different from a salt formed from a compound disclosed herein and the acid. In the salt, a compound disclosed herein is complexed with the acid in a way that proton transfer (e.g., a complete proton transfer) from the acid to a compound disclosed herein easily occurs at room temperature. In the co-crystal, however, a compound disclosed herein is complexed with the acid in a way that proton transfer from the acid to a compound disclosed herein does not easily occur at room temperature. In certain embodiments, in the co-crystal, there is no proton transfer from the acid to a compound disclosed herein. In certain embodiments, in the co-crystal, there is partial proton transfer from the acid to a compound disclosed herein. Co-crystals may be useful to improve the properties (e.g., solubility, stability, and ease of formulation) of a compound disclosed herein. [0078] The term “polymorph” refers to a crystalline form of a compound (or a salt, hydrate, or solvate thereof). All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Various polymorphs of a compound can be prepared by crystallization under different conditions. [0079] The term “prodrugs” refers to compounds that have cleavable groups and become by solvolysis or under physiological conditions the compounds described herein, which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like. Other derivatives of the
32/200
compounds described herein have activity in both their acid and acid derivative forms, but in the acid sensitive form often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp.7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds described herein are particular prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C7-C12 substituted aryl, and C7-C12 arylalkyl esters of the compounds described herein may be preferred. [0080] Glycerol is prochiral with respect to reactions of the two primary alcohols. In substituted derivatives, such as plasmalogens, stereospecific numbering (sn) is used. Conventionally, the hydroxyl group of the second carbon of glycerol (sn2) is on the left on a Fischer projection, the sn1 carbon at the top, and the sn3 carbon at the bottom. The spatial configuration (D or L) of the glycero-molecule is identified by the residues on the positions sn1 and sn3. [0081] The term “plasmalogen” refers to vinyl ether phospholipids comprising a vinyl ether moiety at the 1-position, an ester moiety at the 2-position, and a head group (e.g., a phosphate head group) at the 3-position of a glycerol backbone. Plasmalogens include plasmenylcholines and plasmenylethalomines. The term “plasmalogen species” refers to both plasmalogens and plasmalogen derivatives. In some embodiments, the vinyl ether moiety is a saturated or unsaturated aliphatic group (e.g., C16:0, C18:0, or C18:1). In some embodiments, the acyl group is a saturated or unsaturated fatty acid (e.g., docosahexaenoic acid or arachidonic acid). In some embodiments, the vinyl ether moiety is at the sn1 position. In some embodiments, the phosphate head group is at the sn3 position. [0082] The terms “composition” and “formulation” are used interchangeably herein. [0083] A “subject” to which administration is contemplated refers to a human (i.e., male or female of any age group, e.g., pediatric subject (e.g., infant, child, or adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) or non-human animal. In certain embodiments, the non-human animal is a mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog), or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or
33/200
turkey)). In certain embodiments, the non-human animal is a fish, reptile, or amphibian. The non-human animal may be a male or female at any stage of development. The non-human animal may be a transgenic animal or genetically engineered animal. The term “patient” refers to a human subject in need of treatment of a disease. [0084] The term “biological sample” refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise). Other examples of biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (e.g., obtained by a surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample. [0085] The term “tissue” refers to any biological tissue of a subject (including a group of cells, a body part, or an organ) or a part thereof, including blood and/or lymph vessels. In some embodiments, the tissue is a biological tissue which is the object to which a compound, particle, and/or composition of the invention is delivered. A tissue may be an abnormal or unhealthy tissue, which may need to be treated. A tissue may also be a normal or healthy tissue that is under a higher than normal risk of becoming abnormal or unhealthy, which may need to be prevented. [0086] The term “administer,” “administering,” or “administration” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a composition thereof, in or on a subject. [0087] The terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease. For example, treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of exposure to a pathogen). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence. [0088] The terms “condition,” “disease,” and “disorder” are used interchangeably.
34/200
[0089] An “effective amount” of a compound described herein refers to an amount sufficient to elicit the desired biological response. An effective amount of a compound described herein may vary depending on such factors as the desired biological endpoint, severity of side effects, disease, or disorder, the identity, pharmacokinetics, and pharmacodynamics of the particular compound, the condition being treated, the mode, route, and desired or required frequency of administration, the species, age and health or general condition of the subject. In certain embodiments, an effective amount is a therapeutically effective amount. In certain embodiments, an effective amount is a prophylactic treatment. In certain embodiments, an effective amount is the amount of a compound described herein in a single dose. In certain embodiments, an effective amount is the combined amounts of a compound described herein in multiple doses. In certain embodiments, the desired dosage is delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage is delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). [0090] In certain embodiments, an effective amount of a compound for administration one or more times a day to a 70 kg adult human comprises about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosage form. [0091] In certain embodiments, the compounds of the present disclosure may be administered orally or parenterally at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and more preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect. [0092] It will be appreciated that dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
35/200
[0093] A “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and/or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient for transport via Mfsd2a in a subject. In certain embodiments, a therapeutically effective amount is an amount sufficient for treating a disease, disorder, or condition in a subject. In certain embodiments, a therapeutically effective amount is an amount sufficient for treating a neurological disease in a subject. In certain embodiments, a therapeutically effective amount is an amount sufficient for transport via Mfsd2a and treating a disease, disorder, or condition in a subject. In certain embodiments, a therapeutically effective amount is an amount sufficient for transport via Mfsd2a and treating a neurological disease in a subject. [0094] A “prophylactically effective amount” of a compound described herein is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent. In certain embodiments, a prophylactically effective amount is an amount sufficient for transport via Mfsd2a in a subject. In certain embodiments, a prophylactically effective amount is an amount sufficient for preventing a disease, disorder, or condition in a subject. In certain embodiments, a prophylactically effective amount is an amount sufficient for preventing a neurological disease in a subject. In certain embodiments, a prophylactically effective amount is an amount sufficient for transport via Mfsd2a and preventing a disease, disorder, or condition in a subject. In certain embodiments, a prophylactically effective amount is an amount sufficient for transport via Mfsd2a and preventing a neurological disease in a subject. [0095] The term “prevent,” “preventing,” or “prevention” refers to a prophylactic treatment of a subject who is not and was not with a disease but is at risk of developing the disease or who was with a disease, is not with the disease, but is at risk of regression of the disease. In
36/200
certain embodiments, the subject is at a higher risk of developing the disease or at a higher risk of regression of the disease than an average healthy member of a population. [0096] The term “neurological disease” refers to any disease of the nervous system, including diseases that involve the central nervous system (brain, brainstem and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both central and peripheral nervous system). Neurodegenerative diseases refer to a type of neurological disease marked by the loss of nerve cells, including, but not limited to, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, tauopathies (including frontotemporal dementia), and Huntington’s disease. Examples of neurological diseases include, but are not limited to, headache, stupor and coma, dementia, seizure, sleep disorders, trauma, infections, neoplasms, neuro-ophthalmology, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of peripheral nerves, muscle and neuromuscular junctions. Neurological disorders also include synuclienopathies. Synuclienopathies include, but are not limited to Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Addiction and mental illness, include, but are not limited to, bipolar disorder and schizophrenia, are also included in the definition of neurological diseases. Further examples of neurological diseases include acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers’ disease; alternating hemiplegia; Alzheimer’s disease; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Arnold-Chiari malformation; arteriovenous malformation; Asperger syndrome; ataxia telangiectasia; attention deficit hyperactivity disorder; autism; autonomic dysfunction; back pain; Batten disease; Behcet’s disease; Bell’s palsy; benign essential blepharospasm; benign focal; amyotrophy; benign intracranial hypertension; Binswanger’s disease; blepharospasm; Bloch Sulzberger syndrome; brachial plexus injury; brain abscess; bbrain injury; brain tumors (including glioblastoma multiforme); spinal tumor; Brown-Sequard syndrome; Canavan disease; carpal tunnel syndrome (CTS); causalgia; central pain syndrome; central pontine myelinolysis; cephalic disorder; cerebral aneurysm; cerebral arteriosclerosis; cerebral atrophy; cerebral gigantism; cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy- induced neuropathy and neuropathic pain; Chiari malformation; chorea; chronic inflammatory demyelinating polyneuropathy (CIDP); chronic pain; chronic regional pain syndrome; Coffin Lowry syndrome; coma, including persistent vegetative state; congenital facial diplegia; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt-
37/200
Jakob disease; cumulative trauma disorders; Cushing’s syndrome; cytomegalic inclusion body disease (CIBD); cytomegalovirus infection; dancing eyes-dancing feet syndrome; Dandy-Walker syndrome; Dawson disease; De Morsier’s syndrome; Dejerine-Klumpke palsy; dementia; dermatomyositis; diabetic neuropathy; diffuse sclerosis; dysautonomia; dysgraphia; dyslexia; dystonias; early infantile epileptic encephalopathy; empty sella syndrome; encephalitis; encephaloceles; encephalotrigeminal angiomatosis; epilepsy; Erb’s palsy; essential tremor; Fabry’s disease; Fahr’s syndrome; fainting; familial spastic paralysis; febrile seizures; Fisher syndrome; Friedreich’s ataxia; frontotemporal dementia and other “tauopathies”; Gaucher’s disease; Gerstmann’s syndrome; giant cell arteritis; giant cell inclusion disease; globoid cell leukodystrophy; Guillain-Barre syndrome; HTLV-1 associated myelopathy; Hallervorden-Spatz disease; head injury; headache; hemifacial spasm; hereditary spastic paraplegia; heredopathia atactica polyneuritiformis; herpes zoster oticus; herpes zoster; Hirayama syndrome; HIV-associated dementia and neuropathy (see also neurological manifestations of AIDS); holoprosencephaly; Huntington’s disease and other polyglutamine repeat diseases; hydranencephaly; hydrocephalus; hypercortisolism; hypoxia; immune- mediated encephalomyelitis; inclusion body myositis; incontinentia pigmenti; infantile; phytanic acid storage disease; Infantile Refsum disease; infantile spasms; inflammatory myopathy; intracranial cyst; intracranial hypertension; Joubert syndrome; Kearns-Sayre syndrome; Kennedy disease; Kinsbourne syndrome; Klippel Feil syndrome; Krabbe disease; Kugelberg-Welander disease; kuru; Lafora disease; Lambert-Eaton myasthenic syndrome; Landau-Kleffner syndrome; lateral medullary (Wallenberg) syndrome; learning disabilities; Leigh’s disease; Lennox-Gastaut syndrome; Lesch-Nyhan syndrome; leukodystrophy; Lewy body dementia; lissencephaly; locked-in syndrome; Lou Gehrig’s disease (aka motor neuron disease or amyotrophic lateral sclerosis); lumbar disc disease; lyme disease-neurological sequelae; Machado-Joseph disease; macrencephaly; megalencephaly; Melkersson-Rosenthal syndrome; Menieres disease; meningitis; Menkes disease; metachromatic leukodystrophy; microcephaly; migraine; Miller Fisher syndrome; mini-strokes; mitochondrial myopathies; Mobius syndrome; monomelic amyotrophy; motor neurone disease; moyamoya disease; mucopolysaccharidoses; multi-infarct dementia; multifocal motor neuropathy; multiple sclerosis and other demyelinating disorders; multiple system atrophy with postural hypotension; muscular dystrophy; myasthenia gravis; myelinoclastic diffuse sclerosis; myoclonic encephalopathy of infants; myoclonus; myopathy; myotonia congenital; narcolepsy; neurofibromatosis; neuroleptic malignant syndrome; neurological manifestations of AIDS; neurological sequelae of lupus; neuromyotonia; neuronal ceroid lipofuscinosis;
38/200
neuronal migration disorders; Niemann-Pick disease; O’Sullivan-McLeod syndrome; occipital neuralgia; occult spinal dysraphism sequence; Ohtahara syndrome; olivopontocerebellar atrophy; opsoclonus myoclonus; optic neuritis; orthostatic hypotension; overuse syndrome; paresthesia; Parkinson’s disease; paramyotonia congenita; paraneoplastic diseases; paroxysmal attacks; Parry Romberg syndrome; Pelizaeus-Merzbacher disease; periodic paralyses; peripheral neuropathy; painful neuropathy and neuropathic pain; persistent vegetative state; pervasive developmental disorders; photic sneeze reflex; phytanic acid storage disease; Pick’s disease; pinched nerve; pituitary tumors; polymyositis; porencephaly; Post-Polio syndrome; postherpetic neuralgia (PHN); postinfectious encephalomyelitis; postural hypotension; Prader-Willi syndrome; primary lateral sclerosis; prion diseases; progressive; hemifacial atrophy; progressive multifocal leukoencephalopathy; progressive sclerosing poliodystrophy; progressive supranuclear palsy; pseudotumor cerebri; Ramsay-Hunt syndrome (Type I and Type II); Rasmussen’s Encephalitis; reflex sympathetic dystrophy syndrome; Refsum disease; repetitive motion disorders; repetitive stress injuries; restless legs syndrome; retrovirus-associated myelopathy; Rett syndrome; Reye’s syndrome; Saint Vitus Dance; Sandhoff disease; Schilder’s disease; schizencephaly; septo-optic dysplasia; shaken baby syndrome; shingles; Shy-Drager syndrome; Sjogren’s syndrome; sleep apnea; Soto’s syndrome; spasticity; spina bifida; spinal cord injury; spinal cord tumors; spinal muscular atrophy; stiff-person syndrome; stroke; Sturge-Weber syndrome; subacute sclerosing panencephalitis; subarachnoid hemorrhage; subcortical arteriosclerotic encephalopathy; sydenham chorea; syncope; syringomyelia; tardive dyskinesia; Tay-Sachs disease; temporal arteritis; tethered spinal cord syndrome; Thomsen disease; thoracic outlet syndrome; tic douloureux; Todd’s paralysis; Tourette syndrome; transient ischemic attack; transmissible spongiform encephalopathies; transverse myelitis; traumatic brain injury; tremor; trigeminal neuralgia; tropical spastic paraparesis; tuberous sclerosis; vascular dementia (multi-infarct dementia); vasculitis including temporal arteritis; Von Hippel-Lindau Disease (VHL); Wallenberg’s syndrome; Werdnig-Hoffman disease; West syndrome; whiplash; Williams syndrome; Wilson’s disease; neonatal adrenoleukodystrophy (NALD), and Zellweger syndrome. [0097] The term “dementia” is used herein to indicate both cognitive impairment per se, as well as pathologies causing cognitive impairment. In some embodiments, dementia is caused by one or more neurological disorders. Dementia includes, but is not limited to, dementia associated with Alzheimer’s disease, dementia with Lewy bodies, frontotemporal lobe dementia, vascular induced dementia (e.g., multi-infarct dementia), anoxic event induced
39/200
dementia (e.g., cardiac arrest), trauma to the brain induced dementia (e.g., dementia pugilistica), dementia resulting from exposure to an infectious agent (e.g., Creutzfeldt-Jakob Disease) or toxic agent (e.g., alcohol-induced dementia), autism, multiple sclerosis, Parkinson's disease, bipolar disorder, ischemia, Huntington's chorea, major depressive disorder, closed head injury, hydrocephalus, amnesia, anxiety disorder, traumatic brain injury, obsessive compulsive disorder, schizophrenia, mental retardation, and/or epilepsy. [0098] The term “metabolic disorder” refers to any disorder that involves an alteration in the normal metabolism of carbohydrates, lipids, proteins, nucleic acids, or a combination thereof. A metabolic disorder is associated with either a deficiency or excess in a metabolic pathway resulting in an imbalance in metabolism of nucleic acids, proteins, lipids, and/or carbohydrates. Factors affecting metabolism include, and are not limited to, the endocrine (hormonal) control system (e.g., the insulin pathway, the enteroendocrine hormones including GLP-1, PYY or the like), the neural control system (e.g., GLP-1 in the brain), or the like. Examples of metabolic disorders include, but are not limited to, diabetes (e.g., Type I diabetes, Type II diabetes, gestational diabetes), hyperglycemia, hyperinsulinemia, insulin resistance, and obesity. [0099] The terms “cardiovascular disease” or “cardiac diseases and disorders” refers to conditions affecting the heart of blood vessels. In some embodiments, cardiovascular disease is associated with build-up of fatty deposits inside the arteries. In some embodiments, cardiovascular disease is associated with damage to arteries (e.g., in the brain, heart, kidneys, ad eyes). Cardiovascular diseases include, but are not limited to, angina, arrhythmia, congenital heart disease, coronary artery disease, heart attack, heart failure, dilated cardiomyopathy, hypertrophic cardiomyopathy, mitral regurgitation, mitral valve prolapse, pulmonary stenosis, aortic stenosis, atrial fibrillation, rheumatic heart disease, radiation heart disease, peripheral artery disease, aneurysm, renal artery disease, Raynaud’s disease, peripheral venous disease, ischemic stroke, transient ischemic attack, venous blood clots, blood clotting disorders, or Buerger’s disease, cerebrovascular disease, deep vein thrombosis, pulmonary embolism, hypertension, circulatory shock, myocardial reperfusion injury, and atherosclerosis. [00100] A “proliferative disease” refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990). In some embodiments, a proliferative disease is associated with one or more of: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g.,
40/200
metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (i.e., “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases. [00101] The term “angiogenesis” refers to the physiological process through which new blood vessels form from pre-existing vessels. Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development. Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. In some embodiments, angiogenesis is chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF). “Pathological angiogenesis” refers to abnormal (e.g., excessive or insufficient) angiogenesis that amounts to and/or is associated with a disease. [00102] The terms “neoplasm” and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue. In certain embodiments, a neoplasm or tumor is “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. A “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin. In addition, a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias. In some cases, certain “benign” tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor’s neoplastic cells, and these tumors are referred to as “pre-malignant neoplasms.” An exemplary pre-malignant neoplasm is a teratoma. In contrast, a “malignant neoplasm” is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites. The term “metastasis,” “metastatic,”
41/200
or “metastasize” refers to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue and is typically identifiable by the presence of a “secondary tumor” or “secondary cell mass” of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located. For example, a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue. [00103] The term “cancer” refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See, e.g., Stedman’s Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990. Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett’s adenocarcinoma); Ewing’s sarcoma; ocular cancer (e.g., intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); hematopoietic cancers (e.g., leukemia such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B- cell CLL, T-cell CLL)); lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma
42/200
(MCL), marginal zone B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenström’s macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T-lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); a mixture of one or more leukemia/lymphoma as described above; and multiple myeloma (MM)), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease); hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic amyloidosis; kidney cancer (e.g., nephroblastoma a.k.a. Wilms’ tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor); osteosarcoma (e.g.,bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget’s disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma);
43/200
sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget’s disease of the vulva). [00104] The term “liver disease” or “hepatic disease” refers to damage to or a disease of the liver. Non-limiting examples of liver disease include intrahepatic cholestasis (e.g., alagille syndrome, biliary liver cirrhosis), fatty liver (e.g., alcoholic fatty liver, Reye’s syndrome), hepatic vein thrombosis, hepatolenticular degeneration (i.e., Wilson's disease), hepatomegaly, liver abscess (e.g., amebic liver abscess), liver cirrhosis (e.g., alcoholic, biliary, and experimental liver cirrhosis), alcoholic liver diseases (e.g., fatty liver, hepatitis, cirrhosis), parasitic liver disease (e.g., hepatic echinococcosis, fascioliasis, amebic liver abscess), jaundice (e.g., hemolytic, hepatocellular, cholestatic jaundice), cholestasis, portal hypertension, liver enlargement, ascites, hepatitis (e.g., alcoholic hepatitis, animal hepatitis, chronic hepatitis (e.g., autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced chronic hepatitis), toxic hepatitis, viral human hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E), granulomatous hepatitis, secondary biliary cirrhosis, hepatic encephalopathy, varices, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangiomas, bile stones, liver failure (e.g., hepatic encephalopathy, acute liver failure), angiomyolipoma, calcified liver metastases, cystic liver metastases, fibrolamellar hepatocarcinoma, hepatic adenoma, hepatoma, hepatic cysts (e.g., Simple cysts, Polycystic liver disease, hepatobiliary cystadenoma, choledochal cyst), mesenchymal tumors (mesenchymal hamartoma, infantile hemangioendothelioma, hemangioma, peliosis hepatis, lipomas, inflammatory pseudotumor), epithelial tumors (e.g., bile duct hamartoma, bile duct adenoma), focal nodular hyperplasia, nodular regenerative hyperplasia, hepatoblastoma, hepatocellular carcinoma, cholangiocarcinoma, cystadenocarcinoma, tumors of blood vessels, angiosarcoma, Karposi's sarcoma, hemangioendothelioma, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary lymphoma, peliosis hepatis, erythrohepatic porphyria, hepatic porphyria (e.g., acute intermittent porphyria, porphyria cutanea tarda), and Zellweger syndrome. [00105] The term “ophthalmic disease” includes diseases of the eye and ocular appendages. In some embodiments, an ophthalmic disease may affect the eyelids, tear organ, cornea, iris, pupil, lens, retina, or sclera. In certain embodiments, the ophthalmic disease or disorder is
44/200
selected from dry eye, retinal disease, glaucoma, retinal degeneration, macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal vein occlusion, retinal vascular occlusion, traumatic optic neuropathy, neurotrophic keratopathy, Leber congenital amaurosis, diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), and optic nerve degeneration. [00106] The term “lung disease” or “pulmonary disease” refers to a disease of the lung. Examples of lung diseases include, but are not limited to, bronchiectasis, bronchitis, bronchopulmonary dysplasia, interstitial lung disease, occupational lung disease, emphysema, cystic fibrosis, acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, bronchopulmonary dysplasia, asthma (e.g., intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma), chronic bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, interstitial lung disease, sarcoidosis, asbestosis, aspergilloma, aspergillosis, pneumonia (e.g., lobar pneumonia, multilobar pneumonia, bronchial pneumonia, interstitial pneumonia), pulmonary fibrosis, pulmonary tuberculosis, rheumatoid lung disease, pulmonary embolism, and lung cancer (e.g., non-small-cell lung carcinoma (e.g., adenocarcinoma, squamous-cell lung carcinoma, large-cell lung carcinoma), small-cell lung carcinoma). [00107] The term “genetic disease” refers to a disease caused by one or more abnormalities in the genome of a subject, such as a disease that is present from birth of the subject. In some embodiments, a genetic disease is heritable and is passed down from the parents’ genes. In other embodiments, a genetic disease is caused by mutations or changes of the DNAs and/or RNAs of the subject. In such cases, the genetic disease will be heritable if it occurs in the germline. Exemplary genetic diseases include, but are not limited to, Aarskog-Scott syndrome, Aase syndrome, achondroplasia, acrodysostosis, addiction, adreno- leukodystrophy, albinism, ablepharon-macrostomia syndrome, alagille syndrome, alkaptonuria, alpha-1 antitrypsin deficiency, Alport’s syndrome, Alzheimer’s disease, asthma, autoimmune polyglandular syndrome, androgen insensitivity syndrome, Angelman syndrome, ataxia, ataxia telangiectasia, atherosclerosis, attention deficit hyperactivity disorder (ADHD), autism, baldness, Batten disease, Beckwith-Wiedemann syndrome, Best disease, bipolar disorder, brachydactyl), breast cancer, Burkitt lymphoma, chronic myeloid leukemia, Charcot-Marie-Tooth disease, Crohn’s disease, cleft lip, Cockayne syndrome, Coffin Lowry syndrome, colon cancer, congenital adrenal hyperplasia, Cornelia de Lange
45/200
syndrome, Costello syndrome, Cowden syndrome, craniofrontonasal dysplasia, Crigler- Najjar syndrome, Creutzfeldt-Jakob disease, cystic fibrosis, deafness, depression, diabetes, diastrophic dysplasia, DiGeorge syndrome, Down’s syndrome, dyslexia, Duchenne muscular dystrophy, Dubowitz syndrome, ectodermal dysplasia Ellis-van Creveld syndrome, Ehlers- Danlos, epidermolysis bullosa, epilepsy, essential tremor, familial hypercholesterolemia, familial Mediterranean fever, fragile X syndrome, Friedreich’s ataxia, Gaucher disease, glaucoma, glucose galactose malabsorption, glutaricaciduria, gyrate atrophy, Goldberg Shprintzen syndrome (velocardiofacial syndrome), Gorlin syndrome, Hailey-Hailey disease, hemihypertrophy, hemochromatosis, hemophilia, hereditary motor and sensory neuropathy (HMSN), hereditary non polyposis colorectal cancer (HNPCC), Huntington’s disease, immunodeficiency with hyper-IgM, juvenile onset diabetes, Klinefelter’s syndrome, Kabuki syndrome, Leigh’s disease, long QT syndrome, lung cancer, malignant melanoma, manic depression, Marfan syndrome, Menkes syndrome, miscarriage, mucopolysaccharide disease, multiple endocrine neoplasia, multiple sclerosis, muscular dystrophy, myotrophic lateral sclerosis, myotonic dystrophy, neurofibromatosis, Niemann-Pick disease, Noonan syndrome, obesity, ovarian cancer, pancreatic cancer, Parkinson’s disease, paroxysmal nocturnal hemoglobinuria, Pendred syndrome, peroneal muscular atrophy, phenylketonuria (PKU), polycystic kidney disease, Prader-Willi syndrome, primary biliary cirrhosis, prostate cancer, REAR syndrome, Refsum disease, retinitis pigmentosa, retinoblastoma, Rett syndrome, Sanfilippo syndrome, schizophrenia, severe combined immunodeficiency, sickle cell anemia, spina bifida, spinal muscular atrophy, spinocerebellar atrophy, sudden adult death syndrome, Tangier disease, Tay-Sachs disease, thrombocytopenia absent radius syndrome, Townes- Brocks syndrome, tuberous sclerosis, Turner syndrome, Usher syndrome, von Hippel-Lindau syndrome, Waardenburg syndrome, Weaver syndrome, Werner syndrome, Williams syndrome, Wilson’s disease, xeroderma piginentosum, and Zellweger syndrome. [00108] The terms “inflammatory disease” and “inflammatory condition” are used interchangeably herein, and refer to a disease or condition caused by, resulting from, or resulting in inflammation. Inflammatory diseases and conditions include those diseases, disorders or conditions that are characterized by signs of pain (dolor, from the generation of noxious substances and the stimulation of nerves), heat (calor, from vasodilatation), redness (rubor, from vasodilatation and increased blood flow), swelling (tumor, from excessive inflow or restricted outflow of fluid), and/or loss of function (functio laesa, which can be partial or complete, temporary or permanent. Inflammation takes on many forms and includes, but is not limited to, acute, adhesive, atrophic, catarrhal, chronic, cirrhotic, diffuse,
46/200
disseminated, exudative, fibrinous, fibrosing, focal, granulomatous, hyperplastic, hypertrophic, interstitial, metastatic, necrotic, obliterative, parenchymatous, plastic, productive, proliferous, pseudomembranous, purulent, sclerosing, seroplastic, serous, simple, specific, subacute, suppurative, toxic, traumatic, and/or ulcerative inflammation. The term “inflammatory disease” may also refer to a dysregulated inflammatory reaction that causes an exaggerated response by macrophages, granulocytes, and/or T-lymphocytes leading to abnormal tissue damage and/or cell death. An inflammatory disease can be either an acute or chronic inflammatory condition and can result from infections or non-infectious causes. Inflammatory diseases include, without limitation, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthrosteitis, rheumatoid arthritis, inflammatory arthritis, Sjogren’s syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g., Type I), myasthenia gravis, Hashimoto’s thyroiditis, Graves’ disease, Goodpasture’s disease, mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, pernicious anemia, inflammatory dermatoses, usual interstitial pneumonitis (UIP), asbestosis, silicosis, bronchiectasis, berylliosis, talcosis, pneumoconiosis, sarcoidosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, extrinsic allergic alveolitis, Wegener’s granulomatosis and related forms of angiitis (temporal arteritis and polyarteritis nodosa), inflammatory dermatoses, hepatitis, delayed-type hypersensitivity reactions (e.g., poison ivy dermatitis), pneumonia, respiratory tract inflammation, Adult Respiratory Distress Syndrome (ARDS), encephalitis, immediate hypersensitivity reactions, asthma, hayfever, allergies, acute anaphylaxis, rheumatic fever, glomerulonephritis, pyelonephritis, cellulitis, cystitis, chronic cholecystitis, ischemia (ischemic injury), reperfusion injury, allograft rejection, host- versus-graft rejection, appendicitis, arteritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, chorioamnionitis, conjunctivitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, testitis, tonsillitis, urethritis, urocystitis, uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, angitis, chronic bronchitis, osteomyelitis, optic neuritis, temporal arteritis, transverse
47/200
myelitis, necrotizing fasciitis, and necrotizing enterocolitis. An ocular inflammatory disease includes, but is not limited to, post-surgical inflammation. [00109] Additional exemplary inflammatory conditions include, but are not limited to, inflammation associated with acne, anemia (e.g., aplastic anemia, haemolytic autoimmune anaemia), asthma, arteritis (e.g., polyarteritis, temporal arteritis, periarteritis nodosa, Takayasu's arteritis), arthritis (e.g., crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis and Reiter's arthritis), ankylosing spondylitis, amylosis, amyotrophic lateral sclerosis, autoimmune diseases, allergies or allergic reactions, atherosclerosis, bronchitis, bursitis, chronic prostatitis, conjunctivitis, Chagas disease, chronic obstructive pulmonary disease, cermatomyositis, diverticulitis, diabetes (e.g., type I diabetes mellitus, Type II diabetes mellitus), a skin condition (e.g., psoriasis, eczema, burns, dermatitis, pruritus (itch)), endometriosis, Guillain-Barre syndrome, infection, ischaemic heart disease, Kawasaki disease, glomerulonephritis, gingivitis, hypersensitivity, headaches (e.g., migraine headaches, tension headaches), ileus (e.g., postoperative ileus and ileus during sepsis), idiopathic thrombocytopenic purpura, interstitial cystitis (painful bladder syndrome), gastrointestinal disorder (e.g., selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet's syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS)), lupus, multiple sclerosis, morphea, myeasthenia gravis, myocardial ischemia, nephrotic syndrome, pemphigus vulgaris, pernicious aneaemia, peptic ulcers, polymyositis, primary biliary cirrhosis, neuroinflammation associated with brain disorders (e.g., Parkinson's disease, Huntington's disease, and Alzheimer's disease), prostatitis, chronic inflammation associated with cranial radiation injury, pelvic inflammatory disease, reperfusion injury, regional enteritis, rheumatic fever, systemic lupus erythematosus, schleroderma, scierodoma, sarcoidosis, spondyloarthopathies, Sjogren's syndrome, thyroiditis, transplantation rejection, tendonitis, trauma or injury (e.g., frostbite, chemical irritants, toxins, scarring, burns, physical injury), vasculitis, vitiligo and Wegener's granulomatosis. In certain embodiments, the inflammatory disorder is selected from arthritis (e.g., rheumatoid arthritis), inflammatory bowel disease, inflammatory bowel syndrome, asthma, psoriasis, endometriosis, interstitial cystitis and prostatistis. In certain embodiments, the inflammatory condition is an acute inflammatory condition (e.g., for example,
48/200
inflammation resulting from infection). In certain embodiments, the inflammatory condition is a chronic inflammatory condition (e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease). The compounds may also be useful in treating inflammation associated with trauma and non-inflammatory myalgia. The compounds disclosed herein may also be useful in treating inflammation associated with cancer. [00110] An “autoimmune disease” refers to a disease arising from an inappropriate immune response of the body of a subject against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells. In certain embodiments, this is restricted to certain organs (e.g., in autoimmune thyroiditis) or involve a particular tissue in different places (e.g., Goodpasture’s disease which may affect the basement membrane in both the lung and kidney). The treatment of autoimmune diseases is typically with immunosuppression, e.g., medications which decrease the immune response. Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture’s syndrome, necrotizing vasculitis, lymphadenitis, peri- arteritis nodosa, systemic lupus erythematosis, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosis, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis/polymyositis, anti-phospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener’s granulomatosis, microscopic polyangiitis), uveitis, Sjogren’s syndrome, Crohn’s disease, Reiter’s syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barré syndrome, Hashimoto’s thyroiditis, and cardiomyopathy. [00111] A “hematological disease” includes a disease which affects a hematopoietic cell or tissue. Hematological diseases include diseases associated with aberrant hematological content and/or function. Examples of hematological diseases include diseases resulting from bone marrow irradiation or chemotherapy treatments for cancer, diseases such as pernicious anemia, hemorrhagic anemia, hemolytic anemia, aplastic anemia, sickle cell anemia, sideroblastic anemia, anemia associated with chronic infections such as malaria, trypanosomiasis, HTV, hepatitis virus or other viruses, myelophthisic anemias caused by marrow deficiencies, renal failure resulting from anemia, anemia, polycythemia, infectious mononucleosis (EVI), acute non-lymphocytic leukemia (ANLL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute myelomonocytic leukemia (AMMoL), polycythemia vera, lymphoma, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia, Wilm’s tumor, Ewing’s sarcoma, retinoblastoma, hemophilia, disorders associated with an increased risk of thrombosis, herpes, thalassemia, antibody-mediated disorders such
49/200
as transfusion reactions and erythroblastosis, mechanical trauma to red blood cells such as micro-angiopathic hemolytic anemias, thrombotic thrombocytopenic purpura and disseminated intravascular coagulation, infections by parasites such as Plasmodium, chemical injuries from, e.g., lead poisoning, and hypersplenism. [00112] A “painful condition” includes, but is not limited to, neuropathic pain (e.g., peripheral neuropathic pain), central pain, deafferentiation pain, chronic pain (e.g., chronic nociceptive pain, and other forms of chronic pain such as post–operative pain, e.g., pain arising after hip, knee, or other replacement surgery), pre–operative pain, stimulus of nociceptive receptors (nociceptive pain), acute pain (e.g., phantom and transient acute pain), noninflammatory pain, inflammatory pain, pain associated with cancer, wound pain, burn pain, postoperative pain, pain associated with medical procedures, pain resulting from pruritus, painful bladder syndrome, pain associated with premenstrual dysphoric disorder and/or premenstrual syndrome, pain associated with chronic fatigue syndrome, pain associated with pre–term labor, pain associated with withdrawl symptoms from drug addiction, joint pain, arthritic pain (e.g., pain associated with crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis or Reiter’s arthritis), lumbosacral pain, musculo–skeletal pain, headache, migraine, muscle ache, lower back pain, neck pain, toothache, dental/maxillofacial pain, visceral pain and the like. One or more of the painful conditions contemplated herein can comprise mixtures of various types of pain provided above and herein (e.g., nociceptive pain, inflammatory pain, neuropathic pain, etc.). In some embodiments, a particular pain can dominate. In other embodiments, the painful condition comprises two or more types of pains without one dominating. A skilled clinician can determine the dosage to achieve a therapeutically effective amount for a particular subject based on the painful condition. [00113] The term “psychiatric disorder” refers to a disease of the mind and includes diseases and disorders listed in the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV), published by the American Psychiatric Association, Washington D. C. (1994). Psychiatric disorders include, but are not limited to, anxiety disorders (e.g., acute stress disorder agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, and specific phobia), childhood disorders, (e.g., attention-deficit/hyperactivity disorder, conduct disorder, and oppositional defiant disorder), eating disorders (e.g., anorexia nervosa and bulimia nervosa), mood disorders (e.g., depression, bipolar disorder, cyclothymic disorder, dysthymic disorder, and major depressive disorder), personality disorders (e.g., antisocial
50/200
personality disorder, avoidant personality disorder, borderline personality disorder, dependent personality disorder, histrionic personality disorder, narcissistic personality disorder, obsessive-compulsive personality disorder, paranoid personality disorder, schizoid personality disorder, and schizotypal personality disorder), psychotic disorders (e.g., brief psychotic disorder, delusional disorder, schizoaffective disorder, schizophreniform disorder, schizophrenia, and shared psychotic disorder), substance-related disorders (e.g., alcohol dependence, amphetamine dependence, cannabis dependence, cocaine dependence, hallucinogen dependence, inhalant dependence, nicotine dependence, opioid dependence, phencyclidine dependence, and sedative dependence), adjustment disorder, autism, delirium, dementia, multi-infarct dementia, learning and memory disorders (e.g., amnesia and age- related memory loss), and Tourette’s disorder. [00114] Immune disorders, such as auto-immune disorders, include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren’s syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet’s disease, haemolytic autoimmune anaemias, multiple sclerosis, amyotrophic lateral sclerosis, amylosis, acute painful shoulder, psoriatic, and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin condition (e.g., psoriasis, eczema, burns, dermatitis, pruritus (itch)), enuresis, eosinophilic disease, gastrointestinal disorder (e.g., selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet’s syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS)), and disorders ameliorated by a gastroprokinetic agent (e.g., ileus, postoperative ileus and ileus during sepsis; gastroesophageal reflux disease (GORD, or its synonym GERD); eosinophilic esophagitis, gastroparesis such as diabetic gastroparesis; food intolerances and food allergies and other functional bowel disorders, such as non-ulcerative dyspepsia (NUD) and non- cardiac chest pain (NCCP, including costo-chondritis)). [00115] An “infection” or “infectious disease” refers to an infection with a microorganism, such as a protozoa, fungus, bacteria, or virus. Various infections include, but are not limited to, skin infections, GI infections, urinary tract infections, genito-urinary infections, sepsis, blood infections, and systemic infections.
51/200
[00116] As used herein, “mitochondrial disorders” related to disorders that are due to abnormal mitochondria, such as, for example, a mitochondrial genetic mutation, enzyme pathways, etc. Examples of disorders include, but are not limited to: loss of motor control, muscle weakness and pain, gastro-intestinal disorders and swallowing difficulties, poor growth, cardiac disease, liver disease, diabetes, respiratory complications, seizures, visual/hearing problems, lactic acidosis, developmental delays, and susceptibility to infection. [00117] The term “skin condition” or “skin disease” refers to a condition related to the skin. Exemplary skin conditions or skin diseases include, but are not limited to, but are not limited to, acanthoma fissuratum, acanthosis nigricans, accessory tragus, acne, acne excoriée, acne keloidalis nuchae, acquired digital fibrokeratoma, acrochordons, acrodermatitis enteropathica, acropustulosis of infancy, actinic cheilitis, actinic keratosis, actinic purpura, dolorosa (Dercum’s disease), albinism, alkaptonuria, allergic contact dermatitis, alopecia areata, alopecia mucinosa, androgenetic alopecia, anetoderma, angioedema, angiofibroma, angiokeratoma, angiomas, angular cheilitis, aphthous ulcer, aplasia cutis congenita, ashy dermatosis, asteatotic eczema, atopic dermatitis, atrophie blanche, atrophoderma of pasini and pierini, atypical moles, balanitis, basal cell carcinoma, basal cell nevus syndrome, Becker’s nevus, bee and wasp stings, black hairy tongue, Blaschko’s lines, blue nevus, boils, Bowen’s disease, Bowenoid papulosis, brachioradial pruritus, bullous pemphigoid, Buruli ulcer, calcipotriene, canker sore, capsaicin, carbuncle, cellulitis, central centrifugal cicatricial alopecia, chancroid, cherry angioma, chicken pox, chondrodermatitis nodularis helicis, condyloma acuminata, confluent and reticulated papillomatosis, congenital adrenal hyperplasia, contact dermatitis, Cowden syndrome, cutaneous T cell lymphoma, cutis marmorata, cysts, dandruff, Darier disease, dermal fillers, dermatitis herpetiformis, dermatofibroma, dermatofibrosarcoma protuberans, dermatographism, dermatomyositis, dermatosis papulosa nigra, diaper dermatitis, digital mucous cyst, discoid lupus erythematosus, disseminated superficial actinic porokeratosis, DRESS syndrome, dry skin, dyshidrotic dermatitis, dysplastic moles, eczema, Ehlers-Danlos syndrome, elastosis perforans serpiginosa, epidermal cyst, epidermal nevus, epidermolysis bullosa, epidermolysis bullosa acquisita, erosive pustular dermatosis, erysipelas, erythema ab igne, erythema annulare centrifugum, erythema dyschromicum perstans, erythema infectiosum, erythema multiforme, erythema nodosum, erythema toxicum neonatorum, erythrasma, erythromelalgia, etanercept, exanthem subitum, Fabry disease, Favre-Racouchot syndrome, female pattern hair loss, fifth disease (also referred to as erythema infectiosum), fire ant bites, fish tank granuloma, flea bites, focal dermal hypoplasia, folliculitis, Fordyce spots, Fox-Fordyce
52/200
disease, frostbite, fungal infections, furuncle, geographic tongue, Gianotti-Crosti syndrome, glomus tumor, Gorlin syndrome, granuloma annulare, granuloma inguinale, green nail syndrome, Grover’s disease, habit tic nail deformity, Hailey-Hailey disease, hair loss, hair removal, hair transplantation, halo moles, hand rashes, hand foot and mouth disease, head lice, hemangiomas, Henoch-Schonlein purpura, hereditary hemorrhagic telangiectasia, herpes, herpes zoster, hidradenitis suppurativa, hidrocystoma, hirsutism, hives, hot tub folliculitis, hyperhidrosis, hyperpigmentation, hypersensitivity vasculitis, hypomelanosis of ito, ichthyosis, idiopathic guttate hypomelanosis, impetigo, incontinentia pigmenti, ingenol mebutate, intertrigo, itching, Jessner lymphocytic infiltrate, jiggers, juvenile plantar dermatosis, juvenile xanthogranuloma, Kaposi’s sarcoma, Kawasaki’s disease, keloids and hypertrophic scars, keratoacanthoma, keratosis follicularis spinulosa decalvans, keratosis pilaris, Kyrle’s disease, leiomyoma, leishmaniasis, lentigines, lentigo maligna, leprosy, leukocytoclastic vasculitis, leukoplakia, lice, lichen amyloidosis, lichen nitidus, lichen planus, lichen sclerosus, lichen simplex chronicus, lichen spinulosus, lichen striatus, linear IgA bullous dermatosis, lipodermatosclerosis, lipoma, loose anagen syndrome, Lyme disease, lymphangioma circumscriptum, lymphogranuloma venereum, majocchi granuloma, mastocytoma, mastocytosis, measles, melanoma, acral lentiginous, melanoma in situ, melanonychia, melasma, Melkersson-Rosenthal syndrome, meralgia paresthetica, Merkel cell carcinoma, metastatic skin cancer, methotrexate, milia, miliaria, moles, molluscum contagiosum, Mongolian spot, monilethrix, morphea, mucocele, muir-torre syndrome, mycophenolate mofetil, mycosis fungoides, myiasis, nail fungus, necrobiosis lipoidica diabeticorum, neurofibromatosis, nevoid basal cell carcinoma syndrome, nevus achromicus, nevus anemicus, nevus flammeus, nevus sebaceus, nevus spilus, nevus of ota and ito, notalgia paresthetica, nummular eczema, ochronosis, onycholysis, onychomycosis, onychophagia, orange palpebral spots, paederus dermatitis, Paget’s disease, palmoplantar pustulosis, panniculitis, parapsoriasis, paronychia nail infection, pediculosis, pellagra, pemphigus, pemphigoid gestationis, perioral dermatitis, perleche, Peutz-Jeghers syndrome, phytophotodermatitis, pilar cyst, pilomatricoma, pimecrolimus, pitted keratolysis, pityriasis alba, pityriasis lichenoides, pityriasis rosea, pityriasis rubra pilaris, pityrosporum folliculitis, poikiloderma of civatte, poison ivy dermatitis, polymorphous light eruption, porokeratosis of mibelli, porphyria cutanea tarda, postherpetic neuralgia, pressure ulcers, progressive pigmentary purpura, prurigo nodularis, prurigo pigmentosa, pruritic urticarial papules and plaques of pregnancy, pseudofolliculitis barbae, pseudoxanthoma elasticum, psoriasis, punctate palmoplantar keratoderma, pyoderma gangrenosum, pyogenic granuloma, red
53/200
scrotum syndrome, rheumatoid nodules, rocky mountain spotted fever, rosacea, roseola infantum, sarcoidosis, scabies, scarlet fever, Schamberg’s disease, scleroderma, sebaceous cyst, sebaceous hyperplasia, seborrheic dermatitis, seborrheic keratoses, shingles, skin tags, spider angioma, spider bites, spitz nevus, sporotrichosis, squamous cell carcinoma, staphylococcal scalded skin syndrome, stasis dermatitis, steatocystoma multiplex, Stevens Johnson syndrome, stretch marks, striae, Sturge-Weber syndrome, subacute cutaneous lupus erythematosus, subungual hematoma, sweet’s syndrome, swimmer’s itch, syphilis, syringoma, systemic lupus erythematosus, systemic sclerosis, elangiectasia macularis eruptiva perstans, telogen effluvium hair loss, tinea, tinea incognito, tinea versicolor, toxic epidermal necrolysis, transient neonatal pustular melanosis, tretinoin, trichilemmal cyst, trichotillomania, tuberous sclerosis, twenty nail dystrophy, urticaria, urticaria pigmentosum, varicella, vitiligo, warts, washboard nail, xanthelasma, xeroderma pigmentosum, xerosis, or xerotic eczema. [00118] The term “spleen disease” refers to a disease of the spleen. Example of spleen diseases include, but are not limited to, splenomegaly, spleen cancer, asplenia, spleen trauma, idiopathic purpura, Felty’s syndrome, Hodgkin’s disease, and immune-mediated destruction of the spleen. [00119] Other than in the examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” “About” and “approximately” mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, or more typically, within 5%, 4%, 3%, 2%, or 1% of a given value or range of values. [00120] Unless otherwise required by context, singular terms shall include pluralities, and plural terms shall include the singular. DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS [00121] Provided herein are compounds, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and pharmaceutical compositions and kits thereof. The compounds provided herein may cross the blood-brain barrier and/or blood-retinal barrier and can therefore be used to treat and/or prevent diseases and conditions in a subject, such as diseases or conditions associated with plasmalogen deficiency of one or more plasmalogens, including, but not limited to, neurodegenerative diseases, genetic diseases, and pulmonary
54/200
diseases. Without wishing to be bound by any particular theory, the plasmalogen deficiency may be caused by reduced synthesis (e.g., due to peroxisomal dysfunction) or transport, or by increased degradation (e.g., due to cytochrome C activity, oxidative stress, inflammation, or homeostatic conversion). [00122] Also provided herein are methods of treating and/or preventing a disease, disorder, or condition in a subject comprising administering an effective amount of a compound or composition provided herein to the subject. The compound or composition may be administered as a monotherapy or in combination with another therapy, as described herein. Other uses of the compounds and pharmaceutical compositions provided herein include methods of transporting a compound or composition provided herein via Mfsd2a, including but not limited to transport via Mfsd2a across the blood-brain barrier or blood-retinal barrier, and methods of increasing plasmalogen levels in the brain or central nervous system of a subject. Compounds Compounds of Formula (I) [00123] In one aspect, provided herein are compounds of Formula (I):
and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted
, optionally substituted carbocyclylene, or optionally substituted heterocyclylene; X is selected from
R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl, or R5 is absent when
55/200
L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00124] In certain embodiments, the compound of Formula (I) is not:
, or a pharmaceutically acceptable salt thereof. [00125] In another aspect, the present disclosure provides a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
;
56/200
L1 is optionally substituted
, optionally substituted carbocyclylene, or optionally substituted heterocyclylene; X is selected from
R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl, or R5 is absent when
L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00126] In certain embodiments, the compound is of Formula (I-A):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00127] In certain embodiments, the compound is of Formula (I-A):
or a pharmaceutically acceptable salt thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
;
57/200
L1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00128] In certain embodiments, the compound is of Formula (I-A-i):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl; R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or C1-6 alkyl, or R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene; provided that at least one of R6, R7, R8, R9, and R10 is not hydrogen. [00129] In certain embodiments, the compound is of Formula (I-A-i):
or a pharmaceutically acceptable salt thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl;
58/200
R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or C1-6 alkyl, or R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene; provided that at least one of R6, R7, R8, R9, and R10 is not hydrogen. [00130] In certain embodiments, the compound is of Formula (I-A-ii):
-ii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
L1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00131] In certain embodiments, the compound is of Formula (I-A-ii):
-ii), or a pharmaceutically acceptable salt thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted
, optionally substituted carbocyclylene, or optionally substituted heterocyclylene; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene.
59/200
[00132] In certain embodiments, the compound is of Formula (I-A-iii):
-iii), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00133] In certain embodiments, the compound is of Formula (I-A-iii):
-iii), or a pharmaceutically acceptable salt thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted
, optionally substituted carbocyclylene, or optionally substituted heterocyclylene; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00134] In certain embodiments, the compound is of Formula (I-B):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
60/200
L1 is optionally substituted
, optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R3 and R4 are each independently hydrogen or optionally substituted C1-6 alkyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00135] In certain embodiments, the compound is of Formula (I-B):
or a pharmaceutically acceptable salt thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R3 and R4 are each independently hydrogen or optionally substituted C1-6 alkyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. [00136] In certain embodiments, the compound is of Formula (I-C):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; X is selected from
R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl, or R5 is absent when
61/200
L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene; and R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or C1-6 alkyl, or R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. [00137] In some embodiments, R1 is optionally substituted C7-25 alkyl. In certain embodiments, R1 is unsubstituted C7-25 alkyl. In some embodiments, R1 is C7-25 haloalkyl. In certain embodiments, R1 is C7-25 fluoroalkyl. In some embodiments, R1 is C7-25 alkyl substituted with at least one deuterium. In certain embodiments, R1 is C7-25 alkyl substituted with at least two deuterium atoms. In some embodiments, R1 is optionally substituted C12-20 alkyl. In certain embodiments, R1 is unsubstituted C12-20 alkyl. In some embodiments, R1 is C12-20 haloalkyl. In certain embodiments, R1 is C12-20 fluoroalkyl. In some embodiments, R1 is C12-20 alkyl substituted with at least one deuterium. In certain embodiments, R1 is C12-20 alkyl substituted with at least two deuterium atoms. In some embodiments, R1 is optionally substituted C14-18 alkyl. In certain embodiments, R1 is unsubstituted C14-18 alkyl. In some embodiments, R1 is C14-18 haloalkyl. In certain embodiments, R1 is C14-18 fluoroalkyl. In some embodiments, R1 is C14-18 alkyl substituted with at least one deuterium. In certain embodiments, R1 is C14-18 alkyl substituted with at least two deuterium atoms. In some embodiments, R1 is optionally substituted C14 alkyl. In certain embodiments, R1 is unsubstituted C14 alkyl. In some embodiments, R1 is C14 haloalkyl. In certain embodiments, R1 is C14 fluoroalkyl. In some embodiments, R1 is C14 alkyl substituted with at least one deuterium. In certain embodiments, R1 is C14 alkyl substituted with at least two deuterium atoms. In some embodiments, R1 is optionally substituted C16 alkyl. In certain embodiments, R1 is unsubstituted C16 alkyl. In some embodiments, R1 is C16 haloalkyl. In certain embodiments, R1 is C16 fluoroalkyl. In some embodiments, R1 is C16 alkyl substituted with at least one deuterium. In certain embodiments, R1 is C16 alkyl substituted with at least two deuterium atoms. [00138] In certain embodiments, R1 is selected from the group consisting of
,
62/200
. embodiments, R1 is selected from
. [00139] In certain embodiments, R1 is selected from the group consisting of:
. [00140] In some embodiments, R1 is selected from the group consisting of:
some embodiments, R1 is selected from the group consisting of:
. [00141] In certain embodiments, R1 is selected from the group consisting of:
,
63/200
. certain embodiments, R1 is selected from
. [00142] In certain embodiments, R1 is selected from the group consisting of:
. In certain embodiments, R1 is selected from the group
. [00143] In some embodiments, R2 is optionally substituted
. certain embodiments, R2 is unsubstituted
. some embodiments, R2 is
substituted with a non-aliphatic substituent. In some embodiments, R2 is not substituted with an aliphatic substituent. In some embodiments, R2 is not substituted with an alkyl, alkenyl, alkynyl group.
64/200
In some embodiments, R2 is not substituted with an alkyl, alkenyl, alkynyl group at the terminal position. In some embodiments, R2 is substituted at a vinylic or allylic position. [00144] In some embodiments, R2 is
substituted with deuterium, halogen,
−OC(=O)Raa, −OCO2Raa, −OC(=O)N(Rbb)2, −NRbbC(=O)Raa, −NRbbCO2Raa, or −NRbbC(=O)N(Rbb)2. In some embodiments, R2 is
substituted C1-10 alkyl, deuterium, halogen, −ORaa, −SRaa, −N(Rbb)2, –CN, –SCN, –NO2, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, −OC(=O)Raa, −OCO2Raa, −OC(=O)N(Rbb)2, −NRbbC(=O)Raa, −NRbbCO2Raa, or −NRbbC(=O)N(Rbb)2, provided that the optionally substituted C1-10 alkyl is not at the terminal position. [00145] In some embodiments, R2 is
some embodiments, R2 is
substituted with at least one fluorine. In certain embodiments, R2 is
substituted with at least one deuterium. [00146] In certain embodiments, R2 is selected from the group consisting of
. [00147] In certain embodiments, R1 is unsubstituted C7-25 alkyl, and R2 is unsubstituted
. some embodiments, R1 is C7-25 haloalkyl, and R2 is unsubstituted
. In certain embodiments, R1 is C7-25 fluoroalkyl, and R2 is unsubstituted
. some embodiments, R1 is unsubstituted C12-20 alkyl, and R2 is unsubstituted
. certain embodiments, R1 is C12- 20 haloalkyl, and R2 is unsubstituted
65/200
. some embodiments, R1 is C12- 20 fluoroalkyl, and R2 is unsubstituted
. [00148] In certain embodiments, R1 is unsubstituted C7-25 alkyl, and R2 is
substituted with at least one fluorine. In some embodiments, R1 is C7-25 haloalkyl, and R2 is
substituted with at least one fluorine. In certain embodiments, R1 is C7-25 fluoroalkyl, and R2 is
substituted with at least one fluorine. In some embodiments, R1 is unsubstituted C12-20 alkyl, and R2 is
substituted with at least one fluorine. In certain embodiments, R1 is C12-20 haloalkyl, and R2 is
substituted with at least one fluorine. In some embodiments, R1 is C12-20 fluoroalkyl, and R2 is
substituted with at least one fluorine. [00149] In certain embodiments, R1 is unsubstituted C7-25 alkyl, and R2 is
substituted with at least one deuterium. In some embodiments, R1 is C7-25 haloalkyl, and R2 is
substituted with at least one deuterium. In certain embodiments, R1 is C7-25 fluoroalkyl, and R2 is
substituted with at least one deuterium. In some embodiments, R1 is unsubstituted C12-20 alkyl, and R2 is
substituted with at least one deuterium. In certain embodiments, R1 is C12-20 haloalkyl, and R2 is
substituted with at least one deuterium. In some embodiments, R1 is C12-20 fluoroalkyl, and R2 is
substituted with at least one deuterium.
66/200
[00150] In some embodiments, X is selected from
. [00151] In some embodiments, R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl. In certain embodiments, R3, R4, and R5 are each independently hydrogen or optionally substituted C1-4 alkyl. In some embodiments, R3, R4, and R5 are each independently hydrogen or optionally substituted C1-2 alkyl. In certain embodiments, R3, R4, and R5 are each independently hydrogen or unsubstituted C1-6 alkyl. In certain embodiments, R3, R4, and R5 are each independently hydrogen or unsubstituted C1-4 alkyl. In some embodiments, R3, R4, and R5 are each independently hydrogen or unsubstituted C1-2 alkyl. [00152] In certain embodiments, at least one of R3, R4, and R5 is hydrogen. In some embodiments, at least two of R3, R4, and R5 are hydrogen. In certain embodiments, R3, R4, and R5 are each hydrogen. In some embodiments, R3 and R4 are each hydrogen. In certain embodiments, R3 and R5 are each hydrogen. In some embodiments, R4 and R5 are each hydrogen. [00153] In certain embodiments, at least one of R3, R4, and R5 is unsubstituted C1-6 alkyl. In some embodiments, at least one of R3 and R4 is optionally substituted C1-6 alkyl. In certain embodiments, at least one of R3 and R5 is optionally substituted C1-6 alkyl. In some embodiments, at least one of R4 and R5 is optionally substituted C1-6 alkyl. In certain embodiments, R3 and R4 are each independently optionally substituted C1-6 alkyl. In some embodiments, R3 and R5 are each independently optionally substituted C1-6 alkyl. In certain embodiments, R4 and R5 are each independently optionally substituted C1-6 alkyl. In some embodiments, R3 and R4 are each methyl. In some embodiments, R3 and R5 are each methyl. In some embodiments, R4 and R5 are each methyl. In certain embodiments, R5 is optionally substituted C1-6 alkyl. In some embodiments, R5 is methyl. [00154] In certain embodiments, R3 and R4 are hydrogen, and R5 is unsubstituted C1-6 alkyl. In some embodiments, at least two of R3, R4, and R5 are unsubstituted C1-6 alkyl. In some embodiments, R3 is hydrogen, and at least one of R4 and R5 is unsubstituted C1-6 alkyl. In
67/200
certain embodiments, R3, R4, and R5 are each unsubstituted C1-6 alkyl. In some embodiments, are each independently methyl, ethyl, propyl, or butyl. In certain embodiments, R3, R4, and R5 are each methyl. In some embodiments, R3, R4, and R5 are each ethyl. In certain embodiments, R3, R4, and R5 are each propyl. In some embodiments, R3, R4, and R5 are each butyl. [00155] In certain embodiments, at least one of R3, R4, and R5 is optionally substituted C1-6 alkyl. In certain embodiments, R3 and R4 are hydrogen, and R5 is optionally substituted C1-6 alkyl. In some embodiments, at least two of R3, R4, and R5 are optionally substituted C1-6 alkyl. In some embodiments, R3 is hydrogen, and at least one of R4 and R5 is optionally substituted C1-6 alkyl. In certain embodiments, R3 is hydrogen, and R4 is optionally substituted C1-6 alkyl. In some embodiments, R3 is hydrogen, and R5 is optionally substituted C1-6 alkyl. In certain embodiments, R3, R4, and R5 are each optionally substituted C1-6 alkyl. [00156] In certain embodiments, at least one of R3, R4, and R5 is C1-6 fluoroalkyl. In some embodiments, at least one of R3 and R4 is C1-6 fluoroalkyl. In certain embodiments, at least one of R3 and R5 is C1-6 fluoroalkyl. In some embodiments, at least one of R4 and R5 is C1-6 fluoroalkyl. In certain embodiments, R5 is C1-6 fluoroalkyl. In some embodiments, R5 is - CH2F, -CHF2, or -CF3. [00157] In certain embodiments, R3 and R4 are hydrogen, and R5 is C1-6 fluoroalkyl. In some embodiments, at least two of R3, R4, and R5 are C1-6 fluoroalkyl. In some embodiments, R3 is hydrogen, and at least one of R4 and R5 is C1-6 fluoroalkyl. In certain embodiments, R3, R4, and R5 are each C1-6 fluoroalkyl. In some embodiments, at least one of R3, R4, and R5 is - CH2F, -CHF2, or -CF3. In certain embodiments, at least one of R3 and R4 is -CH2F, -CHF2, or -CF3. In some embodiments, at least one of R3 and R5 is -CH2F, -CHF2, or -CF3. In certain embodiments, at least one of R4 and R5 is -CH2F, -CHF2, or -CF3. In certain embodiments, at least one of R3, R4, and R5 is -CH2F. In some embodiments, at least one of R3, R4, and R5 is - CHF2. In certain embodiments, at least one of R3, R4, and R5 is -CF3. [00158] In certain embodiments, R3 and R4 are joined together with the intervening atoms to form optionally substituted heterocyclyl. In certain embodiments, R3 and R4 are joined together with the intervening atoms to form substituted heterocyclyl. In certain embodiments, R3 and R4 are joined together with the intervening atoms to form unsubstituted heterocyclyl. In certain embodiments, R3 and R4 are joined together with the intervening atoms to form 3- to 7-membered optionally substituted heterocyclyl. In certain embodiments, R3 and R4 are
68/200
joined together with the intervening atoms to form 5- to 6-membered optionally substituted heterocyclyl. In certain embodiments, R3 and R4 are joined together with the intervening atoms to form optionally substituted an aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl ring. In certain embodiments, R3 and R4 are joined together with the intervening atoms to form an unsubstituted aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl ring. In certain embodiments, R3 and R4 are joined together with the intervening atoms to form optionally substituted pyrrolidinyl or piperidinyl. In certain embodiments, R3 and R4 are joined together with the intervening atoms to form unsubstituted pyrrolidinyl or piperidinyl.
[00160] In certain embodiments, R1 is unsubstituted C7-25 alkyl, and at least one of R3, R4, and R5 is hydrogen. In some embodiments, R1 is C7-25 haloalkyl, and at least one of R3, R4, and R5 is hydrogen. In certain embodiments, R1 is C7-25 fluoroalkyl, and at least one of R3, R4, and R5 is hydrogen. In some embodiments, R1 is unsubstituted C12-20 alkyl, and at least one of R3, R4, and R5 is hydrogen. In certain embodiments, R1 is C12-20 haloalkyl, and at least one of R3, R4, and R5 is hydrogen. In some embodiments, R1 is C12-20 fluoroalkyl, and at least one of R3, R4, and R5 is hydrogen. [00161] In certain embodiments, R1 is unsubstituted C7-25 alkyl, and at least one of R3, R4, and R5 is optionally substituted C1-6 alkyl. In some embodiments, R1 is C7-25 haloalkyl, and at
69/200
least one of R3, R4, and R5 is optionally substituted C1-6 alkyl. In certain embodiments, R1 is C7-25 fluoroalkyl, and at least one of R3, R4, and R5 is optionally substituted C1-6 alkyl. In some embodiments, R1 is unsubstituted C12-20 alkyl, and at least one of R3, R4, and R5 is optionally substituted C1-6 alkyl. In certain embodiments, R1 is C12-20 haloalkyl, and at least one of R3, R4, and R5 is optionally substituted C1-6 alkyl. In some embodiments, R1 is C12-20 fluoroalkyl, and at least one of R3, R4, and R5 is optionally substituted C1-6 alkyl. [00162] In certain embodiments, R1 is unsubstituted C7-25 alkyl, and at least one of R3, R4, and R5 is C1-6 fluoroalkyl. In some embodiments, R1 is C7-25 haloalkyl, and at least one of R3, R4, and R5 is C1-6 fluoroalkyl. In certain embodiments, R1 is C7-25 fluoroalkyl, and at least one of R3, R4, and R5 is C1-6 fluoroalkyl. In some embodiments, R1 is unsubstituted C12-20 alkyl, and at least one of R3, R4, and R5 is C1-6 fluoroalkyl. In certain embodiments, R1 is C12-20 haloalkyl, and at least one of R3, R4, and R5 is C1-6 fluoroalkyl. In some embodiments, R1 is C12-20 fluoroalkyl, and at least one of R3, R4, and R5 is C1-6 fluoroalkyl. [00163] In some embodiments, L1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene. In certain embodiments, L1 is optionally substituted or optionally substituted carbocyclylene. In some embodiments, L1 is optionally substituted
or optionally substituted heterocyclylene. In certain embodiments, L1 is optionally substituted carbocyclylene, or optionally substituted heterocyclylene. [00164] In some embodiments, L1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene, wherein ** designates the point of attachment to -OC(O)R2. In certain embodiments, L1 is optionally substituted
or optionally substituted carbocyclylene, wherein ** designates the point of attachment to -OC(O)R2. In some embodiments, L1 is optionally substituted or optionally substituted heterocyclylene, wherein ** designates the point of attachment to -
70/200
OC(O)R2. In certain embodiments, L1 is optionally substituted carbocyclylene, or optionally substituted heterocyclylene, wherein ** designates the point of attachment to -OC(O)R2. [00165] In some embodiments, L1 is optionally substituted . In certain embodiments, L1 is optionally substituted . In some embodiments, L1 is unsubstituted
. In certain embodiments, L1 is substituted
. In some embodiments, L1 is substituted with one or more fluorine atoms. In certain embodiments, L1 is
substituted with one or more deuterium atoms. In some embodiments, L1 is
substituted with one or more instances of optionally substituted C1-6 alkyl. In certain embodiments, L1 is
substituted with one or more instances of unsubstituted C1-6 alkyl. In some embodiments, L1 is substituted with one or more instances of substituted C1-6 alkyl. In some embodiments, L1 is
substituted with optionally substituted carbocyclyl. In certain embodiments, L1 is substituted with unsubstituted carbocyclyl. In some embodiments, L1 is substituted with substituted carbocyclyl. In some embodiments, L1 is
substituted with optionally substituted C3-6 carbocyclyl. In certain embodiments, L1 is substituted with unsubstituted C3-6 carbocyclyl. In some embodiments, L1 is
substituted with substituted C3-6 carbocyclyl. In some embodiments, L1 is
substituted with optionally substituted C3-4 carbocyclyl. In certain embodiments, L1 is
substituted with unsubstituted C3-4 carbocyclyl. In some embodiments, L1 is
substituted with substituted C3-4 carbocyclyl.
71/200
1
[00166] In some embodiments, L is optionally substituted , wherein ** designates the point of attachment to -OC(O)R2. In certain embodiments, L1 is optionally
substituted , wherein ** designates the point of attachment to -OC(O)R2. In 1
some embodiments, L is unsubstituted , wherein ** designates the point of 2 1
attachment to -OC(O)R . In certain embodiments, L is substituted , wherein **
designates the point of attachment to -OC(O)R2. In some embodiments, L1 is substituted with one or more fluorine atoms, wherein ** designates the point of attachment to 2 1
-OC(O)R . In certain embodiments, L is substituted with one or more deuterium atoms, wherein ** designates the point of attachment to -OC(O)R2. In some 1
embodiments, L is substituted with one or more instances of optionally substituted C1-6 alkyl, wherein ** designates the point of attachment to -OC(O)R2. In certain 1
embodiments, L is substituted with one or more instances of unsubstituted C1- 6 alkyl, wherein ** designates the point of attachment to -OC(O)R2. In some embodiments, 1
L is substituted with one or more instances of substituted C1-6 alkyl, wherein ** designates the point of attachment to -OC(O)R2. In some embodiments, L1 is
substituted with optionally substituted carbocyclyl, wherein ** designates the
72/200
2 1
point of attachment to -OC(O)R . In certain embodiments, L is substituted with unsubstituted carbocyclyl, wherein ** designates the point of attachment to -OC(O)R2. 1
In some embodiments, L is substituted with substituted carbocyclyl, wherein ** designates the point of attachment to -OC(O)R2. In some embodiments, L1 is
substituted with optionally substituted C3-6 carbocyclyl, wherein ** designates 2 1
the point of attachment to -OC(O)R . In certain embodiments, L is substituted with unsubstituted C3-6 carbocyclyl, wherein ** designates the point of attachment to - 2 1
OC(O)R . In some embodiments, L is substituted with substituted C3-6 carbocyclyl, wherein ** designates the point of attachment to -OC(O)R2. In some
embodiments, L1 is substituted with optionally substituted C3-4 carbocyclyl, wherein ** designates the point of attachment to -OC(O)R2. In certain embodiments, L1 is
substituted with unsubstituted C3-4 carbocyclyl, wherein ** designates the 2 1
point of attachment to -OC(O)R . In some embodiments, L is substituted with substituted C3-4 carbocyclyl, wherein ** designates the point of attachment to -OC(O)R2. [00167] In certain embodiments, L1 is optionally substituted carbocyclylene. In some embodiments, L1 is unsubstituted carbocyclylene. In certain embodiments, L1 is substituted carbocyclylene. In certain embodiments, L1 is optionally substituted C3-14 carbocyclylene. In certain embodiments, L1 is optionally substituted C3-8 carbocyclylene. In certain embodiments, L1 is C3-6 carbocyclylene. In certain embodiments, L1 is optionally substituted monocyclic carbocyclylene. In some embodiments, L1 is unsubstituted monocyclic carbocyclylene. In certain embodiments, L1 is substituted monocyclic carbocyclylene. In
73/200
certain embodiments, L1 is optionally substituted C3-14 monocyclic carbocyclylene. In certain embodiments, L1 is optionally substituted C3-8 monocyclic carbocyclylene. In certain embodiments, L1 is C3-6 monocyclic carbocyclylene. In certain embodiments, L1 is optionally substituted cyclopropylene, optionally substituted cyclobutylene, optionally substituted cyclopentylene, or optionally substituted cyclohexylene. In some embodiments, L1 is optionally substituted bicyclic carbocyclylene. In certain embodiments, L1 is unsubstituted bicyclic carbocyclylene. In some embodiments, L1 is substituted bicyclic carbocyclylene. In certain embodiments, L1 is optionally substituted C3-14 bicyclic carbocyclylene. In certain embodiments, L1 is optionally substituted C5-14 bicyclic carbocyclylene. In certain embodiments, L1 is optionally substituted C5-10 bicyclic carbocyclylene. [00168] In some embodiments, L1 is optionally substituted heterocyclylene. In certain embodiments, L1 is unsubstituted heterocyclylene. In some embodiments, L1 is substituted heterocyclylene. In certain embodiments, L1 is optionally substituted 3-14 membered heterocyclylene. In certain embodiments, L1 is optionally substituted 3-8 membered heterocyclylene. In certain embodiments, L1 is optionally substituted monocyclic heterocyclylene. In some embodiments, L1 is unsubstituted monocyclic heterocyclylene. In certain embodiments, L1 is substituted monocyclic heterocyclylene. In certain embodiments, L1 is optionally substituted 3-14 membered monocyclic heterocyclylene. In certain embodiments, L1 is optionally substituted 3-8 membered monocyclic heterocyclylene. In some embodiments, L1 is optionally substituted bicyclic heterocyclylene. In certain embodiments, L1 is unsubstituted bicyclic heterocyclylene. In some embodiments, L1 is substituted bicyclic heterocyclylene. In certain embodiments, L1 is optionally substituted 5-14 membered bicyclic heterocyclylene. In certain embodiments, L1 is optionally substituted 5-10 membered bicyclic heterocyclylene. In certain embodiments, L1 is heterocyclylene comprising at least one oxygen atom. In some embodiments, L1 is heterocyclylene comprising at least one sulfur atom. In certain embodiments, L1 is heterocyclylene comprising at least one optionally substituted nitrogen atom. In some embodiments, L1 is heterocyclylene comprising at least one nitrogen atom substituted with hydrogen, optionally substituted C1-6 alkyl, or a nitrogen protecting group. In certain embodiments, L1 is heterocyclylene comprising at least one nitrogen atom substituted with hydrogen, unsubstituted C1-6 alkyl, or a nitrogen protecting group. In certain embodiments, L1 is optionally substituted piperidinylene, optionally substituted tetrahydro-2H-pyranylene, or optionally substituted tetrahydro-2H-thiopyranylene.
74/200
[00169] In certain embodiments, L1 is selected from the group consisting of: ,
embodiments, L1 is selected from the group consisting of: , and
certain embodiments, L1 is selected from the group consisting of:
75/200
[00170] In certain embodiments, L1 is selected from the group consisting of: ,
wherein ** designates the point of attachment to -OC(O)R2. In certain embodiments, L1 is selected from the group consisting of: ,
76/200
, wherein ** designates the point of attachment to -OC(O)R2. In certain embodiments, L1 is selected from the group consisting of:
, , , , , ,
, wherein ** designates the point of attachment to -OC(O)R2. In some embodiments, L1 is selected from the group consisting of:
, wherein ** designates the point of attachment to -OC(O)R2. In certain embodiments, L1 is selected from the group consisting of:
wherein ** designates the point of attachment to -OC(O)R2. In certain embodiments, L1 is selected from the group consisting of:
, wherein ** designates the point of attachment to -OC(O)R2. [00171] In some embodiments, L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. In certain embodiments, L2 is optionally substituted C1-6 alkylene or optionally substituted carbocyclylene. In some embodiments, L2 is optionally substituted
77/200
C1-4 alkylene or optionally substituted carbocyclylene. In some embodiments, L2 is substituted with fluorine. In some embodiments, L2 is optionally substituted C1-10 alkylene or optionally substituted C3-14 carbocyclylene. In certain embodiments, L2 is optionally substituted C1-6 alkylene or optionally substituted C3-8 carbocyclylene. In some embodiments, L2 is optionally substituted C1-4 alkylene or optionally substituted C3-8 carbocyclylene. In some embodiments, L2 is substituted with fluorine. [00172] In some embodiments, L2 is –(optionally substituted C1-10 alkylene)-(optionally substituted carbocyclylene)-. In some embodiments, L2 is –(optionally substituted C1-10 alkylene)-(optionally substituted C3-14 carbocyclylene)-. In some embodiments, L2 is – (optionally substituted C1-6 alkylene)-(optionally substituted C3-8 carbocyclylene)-. In some embodiments, L2 is -(optionally substituted C1-4 alkylene)-(optionally substituted C3-14 carbocyclylene). In some embodiments, L2 is –(optionally substituted C1-4 alkylene)- (optionally substituted C3-8 carbocyclylene)-. In some embodiments, L2 is -(optionally substituted C1 alkylene)-(optionally substituted C3-8 carbocyclylene)-. In some embodiments, L2 is -(optionally substituted C2 alkylene)-(optionally substituted C3-8 carbocyclylene)-. In some embodiments, L2 is -(optionally substituted C1-6 alkylene)-(optionally substituted C3-8 carbocyclylene)-(optionally substituted C0-4 alkylene)-. In some embodiments, L2 is - (optionally substituted C1-4 alkylene)-(optionally substituted C3-8 carbocyclylene)-(optionally substituted C0-4 alkylene)-. [00173] In certain embodiments, L2 is optionally substituted C1-10 alkylene. In some embodiments, L2 is unsubstituted C1-10 alkylene. In certain embodiments, L2 is substituted C1- 10 alkylene. In certain embodiments, L2 is optionally substituted C1-6 alkylene. In some embodiments, L2 is unsubstituted C1-6 alkylene. In certain embodiments, L2 is substituted C1-6 alkylene. In certain embodiments, L2 is optionally substituted C1-4 alkylene. In some embodiments, L2 is unsubstituted C1-4 alkylene. In certain embodiments, L2 is substituted C1-4 alkylene. In some embodiments, L2 is optionally substituted ethylene, propylene, or butylene. In certain embodiments, L2 is optionally substituted ethylene or propylene. In some embodiments, L2 is optionally substituted ethylene. In some embodiments L2 is optionally substituted propylene. In some embodiments, L2 is C1-10 alkylene substituted with fluorine. In some embodiments, L2 is C1-6 alkylene substituted with fluorine. In some embodiments, L2 is C1-4 alkylene substituted with fluorine. [00174] In certain embodiments, L2 is optionally substituted carbocyclylene. In some embodiments, L2 is unsubstituted carbocyclylene. In certain embodiments, L2 is substituted carbocyclylene. In certain embodiments, L2 is carbocyclylene substituted with fluorine. In
78/200
some embodiments, L2 is optionally substituted C3-14 carbocyclylene. In some embodiments, L2 is optionally substituted C3-8 carbocyclylene. In certain embodiments, L2 is C3-6 carbocyclylene. In certain embodiments, L2 is optionally substituted monocyclic carbocyclylene. In some embodiments, L2 is unsubstituted monocyclic carbocyclylene. In certain embodiments, L2 is substituted monocyclic carbocyclylene. In certain embodiments, L2 is optionally substituted C3-14 monocyclic carbocyclylene. In certain embodiments, L2 is optionally substituted C3-8 monocyclic carbocyclylene. In certain embodiments, L2 is C3-6 monocyclic carbocyclylene. In certain embodiments, L2 is optionally substituted cyclopropylene, optionally substituted cyclobutylene, optionally substituted cyclopentylene, or optionally substituted cyclohexylene. In some embodiments, L2 is optionally substituted bicyclic carbocyclylene. In certain embodiments, L2 is unsubstituted bicyclic carbocyclylene. In some embodiments, L2 is substituted bicyclic carbocyclylene. In certain embodiments, L2 is optionally substituted C3-14 bicyclic carbocyclylene. In certain embodiments, L2 is optionally substituted C5-14 bicyclic carbocyclylene. In certain embodiments, L2 is optionally substituted C5-10 bicyclic carbocyclylene. In some embodiments, L2 is optionally substituted tricyclic carbocyclylene. In certain embodiments, L2 is unsubstituted tricyclic carbocyclylene. In some embodiments, L2 is substituted tricyclic carbocyclylene. In certain embodiments, L2 is optionally substituted C3-14 tricyclic carbocyclylene. In certain embodiments, L2 is optionally substituted C5-14 tricyclic carbocyclylene. In certain embodiments, L2 is optionally substituted C5-10 tricyclic carbocyclylene.
,
certain embodiments, L2 is selected from the group consisting of:
,
some embodiments, L2 is selected from the group consisting of:
79/200
group consisting of:
. In certain embodiments, L2 is selected from the group consisting of:
[00176] In some embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or optionally substituted C1-6 alkyl, or R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl, or R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. In some embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or C1-6 alkyl, or R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl, or R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. In some embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or optionally substituted C1-6 alkyl, or R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl, or R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; provided that at least one of R6, R7, R8, R9, and R10 is not hydrogen. In some embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or C1-6 alkyl, or R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl, or R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; provided that at least one of R6, R7, R8, R9, and R10 is not hydrogen.
80/200
[00177] In some embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or optionally substituted C1-6 alkyl. In certain embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen, fluorine, or optionally substituted C1-6 alkyl. In some embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or unsubstituted C1-6 alkyl. In certain embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or substituted C1-6 alkyl. In some embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen or halogen. In certain embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen or fluorine. In some embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen or optionally substituted C1-6 alkyl. In certain embodiments, R6, R7, R8, R9, and R10 are each independently hydrogen or unsubstituted C1-6 alkyl. In some embodiments, R6, R7, R8, R9, and R10 are each independently halogen or optionally substituted C1-6 alkyl. In certain embodiments, R6, R7, R8, R9, and R10 are each independently halogen or optionally substituted C1-6 alkyl. In some embodiments, R6, R7, R8, R9, and R10 are each independently fluorine or optionally substituted C1-6 alkyl. In some embodiments, R6, R7, R8, R9, and R10 are each independently fluorine or unsubstituted C1-6 alkyl. In some embodiments, R6 and R7 are each methyl. In some embodiments, R9 and R10 are each methyl. [00178] In certain embodiments, at least two of R6, R7, R8, R9, and R10 are not hydrogen. In some embodiments, R8, R9, and R10 are each hydrogen. In certain embodiments, R6, R7, and R8 are each hydrogen. In some embodiments, R6, R7, R8, R9, and R10 are hydrogen. [00179] In certain embodiments, at least one of R6, R7, R8, R9, and R10 is halogen. In some embodiments, one of R6, R7, R8, R9, and R10 is fluorine; and the others are hydrogen. In certain embodiments, R6 is fluorine, and R7, R8, R9, and R10 are hydrogen. In some embodiments, R8 is fluorine, and R6, R7, R9, and R10 are hydrogen. In certain embodiments, R10 is fluorine, and R6, R7, R8, and R9 are hydrogen. [00180] In some embodiments, R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. In certain embodiments, R6 and R7 are joined together with the intervening carbon atom to form an unsubstituted carbocyclyl. In some embodiments, R6 and R7 are joined together with the intervening carbon atom to form a substituted carbocyclyl. In certain embodiments, R6 and R7 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl, an unsubstituted cyclopentyl, an unsubstituted cyclobutyl, or an unsubstituted cyclopropyl. In some embodiments, R6 and R7 are joined together with the intervening carbon atom to form an unsubstituted cyclobutyl or an unsubstituted cyclopropyl. In certain embodiments, R6 and R7 are joined together with
81/200
the intervening carbon atom to form an unsubstituted cyclobutyl. In some embodiments, R6 and R7 are joined together with the intervening carbon atom to form an unsubstituted cyclopropyl. [00181] In certain embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl. In some embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl. In certain embodiments, R6 and R9 are joined together with the intervening carbon atom to form an unsubstituted carbocyclyl. In some embodiments, R6 and R9 are joined together with the intervening carbon atom to form a substituted carbocyclyl. In certain embodiments, R6 and R9 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl, unsubstituted cyclopentyl, unsubstituted cyclobutyl, or unsubstituted cyclopropyl. In some embodiments, R6 and R9 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl or unsubstituted cyclopentyl. In certain embodiments, R6 and R9 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl. In some embodiments, R6 and R9 are joined together with the intervening carbon atom to form an unsubstituted cyclopentyl. In certain embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl. In some embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an unsubstituted heterocyclyl. In certain embodiments, R6 and R9 are joined together with the intervening carbon atoms to form a substituted heterocyclyl. In some embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl comprising at least one oxygen atom. In certain embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl comprising at least one sulfur atom. In some embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl comprising at least one optionally substituted nitrogen atom. In certain embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl comprising at least one nitrogen atom substituted with hydrogen, optionally substituted C1-6 alkyl, or a nitrogen protecting group. In certain embodiments, R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted heterocyclyl, comprising at least one nitrogen atom substituted with hydrogen, unsubstituted C1-6 alkyl, or a nitrogen protecting group. [00182] In some embodiments, R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. In certain embodiments, R9 and R10 are
82/200
joined together with the intervening carbon atom to form an unsubstituted carbocyclyl. In some embodiments, R9 and R10 are joined together with the intervening carbon atom to form a substituted carbocyclyl. In certain embodiments, R9 and R10 are joined together with the intervening carbon atom to form an unsubstituted cyclohexyl, unsubstituted cyclopentyl, unsubstituted cyclobutyl, or unsubstituted cyclopropyl. In some embodiments, R9 and R10 are joined together with the intervening carbon atom to form an unsubstituted cyclobutyl or unsubstituted cyclopropyl. In certain embodiments, R9 and R10 are joined together with the intervening carbon atom to form an unsubstituted cyclobutyl. In some embodiments, R9 and R10 are joined together with the intervening carbon atom to form an unsubstituted cyclopropyl. [00183] In certain embodiments, the compound is: , , ,
,
83/200
84/200
85/200
86/200
87/200
, ,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. [00184] In certain embodiments, the compound is: , , ,
,
88/200
89/200
90/200
91/200
92/200
, ,
, or a pharmaceutically acceptable salt thereof. [00185] In certain embodiments, the compound is: , , ,
,
93/200
94/200
95/200
, , , , ,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. [00186] In certain embodiments, the compound is: ,
,
96/200
97/200
98/200
99/200
[00187] In certain embodiments, the compound is: ,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. [00188] In certain embodiments, the compound is: ,
, or a pharmaceutically acceptable salt thereof. [00189] In certain embodiments, the compound is:
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. [00190] In certain embodiments, the compound is:
,
100/200
, or a pharmaceutically acceptable salt thereof. Compounds of Formula (II) [00191] In another aspect, provided herein are compounds of Formula (II):
and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2’ is optionally substituted C7-25 alkenyl; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen, halogen, or C1-6 alkyl. [00192] In another aspect, the compound is of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2’ is optionally substituted C7-25 alkenyl; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl;
101/200
n is 0, 1, 2, or 3; * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen, halogen, or C1-6 alkyl. [00193] In certain embodiments, the compound is of Formula (II-A):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2” is optionally substituted
; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; * designates a point of attachment at one of positions X, Y, or Z; and the other two of positions X, Y, or Z are each independently hydrogen, halogen, or C1- 6 alkyl. [00194] In some embodiments, the compound is of Formula (II-A):
or a pharmaceutically acceptable salt thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2” is optionally substituted
R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3;
102/200
* designates a point of attachment at one of positions X, Y, or Z; and the other two of positions X, Y, or Z are each independently hydrogen, halogen, or C1- 6 alkyl. [00195] In certain embodiments, the compound is of Formula (II-B):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2’ is optionally substituted C7-25 alkenyl; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; and Y and Z are each independently hydrogen, halogen, or C1-6 alkyl. [00196] In some embodiments, the compound is of Formula (II-B):
or a pharmaceutically acceptable salt thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2’ is optionally substituted C7-25 alkenyl; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; and Y and Z are each independently hydrogen, halogen, or C1-6 alkyl.
103/200
[00197] In certain embodiments, the compound is of Formula (II-C):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2’ is optionally substituted C7-25 alkenyl; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; and X and Z are each independently hydrogen, halogen, or C1-6 alkyl. [00198] In some embodiments, the compound is of Formula (II-C):
or a pharmaceutically acceptable salt thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2’ is optionally substituted C7-25 alkenyl; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; and X and Z are each independently hydrogen, halogen, or C1-6 alkyl.
104/200
[00199] In certain embodiments, the compound is of Formula (II-D):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2’ is optionally substituted C7-25 alkenyl; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; and X and Y are each independently hydrogen, halogen, or C1-6 alkyl. [00200] In some embodiments, the compound is of Formula (II-D):
or a pharmaceutically acceptable salt thereof, wherein: R1’ is optionally substituted C7-25 alkyl; R2’ is optionally substituted C7-25 alkenyl; R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl; n is 0, 1, 2, or 3; and X and Y are each independently hydrogen, halogen, or C1-6 alkyl. [00201] In some embodiments, R1’ is optionally substituted C7-25 alkyl. In certain embodiments, R1’ is unsubstituted C7-25 alkyl. In some embodiments, R1’ is C7-25 haloalkyl. In certain embodiments, R1’ is C7-25 fluoroalkyl. In some embodiments, R1’ is C7-25 alkyl substituted with at least one deuterium. In certain embodiments, R1’ is C7-25 alkyl substituted with at least two deuterium atoms. In some embodiments, R1’ is optionally substituted C12-20 alkyl. In certain embodiments, R1’ is unsubstituted C12-20 alkyl. In some embodiments, R1’ is
105/200
C12-20 haloalkyl. In certain embodiments, R1’ is C12-20 fluoroalkyl. In some embodiments, R1’ is C12-20 alkyl substituted with at least one deuterium. In certain embodiments, R1’ is C12-20 alkyl substituted with at least two deuterium atoms. In some embodiments, R1’ is optionally substituted C14-18 alkyl. In certain embodiments, R1’ is unsubstituted C14-18 alkyl. In some embodiments, R1’ is C14-18 haloalkyl. In certain embodiments, R1’ is C14-18 fluoroalkyl. In some embodiments, R1’ is C14-18 alkyl substituted with at least one deuterium. In certain embodiments, R1’ is C14-18 alkyl substituted with at least two deuterium atoms. In some embodiments, R1’ is optionally substituted C14 alkyl. In certain embodiments, R1’ is unsubstituted C14 alkyl. In some embodiments, R1’ is C14 haloalkyl. In certain embodiments, R1’ is C14 fluoroalkyl. In some embodiments, R1’ is C14 alkyl substituted with at least one deuterium. In certain embodiments, R1’ is C14 alkyl substituted with at least two deuterium atoms. In some embodiments, R1’ is optionally substituted C16 alkyl. In certain embodiments, R1’ is unsubstituted C16 alkyl. In some embodiments, R1’ is C16 haloalkyl. In certain embodiments, R1’ is C16 fluoroalkyl. In some embodiments, R1’ is C16 alkyl substituted with at least one deuterium. In certain embodiments, R1’ is C16 alkyl substituted with at least two deuterium atoms. [00202] In some embodiments, R1’ is selected from the group consisting of:
. some embodiments, R1’ is selected from
,
106/200
. [00203] In certain embodiments, R1’ is selected from the group consisting of:
. [00204] In some embodiments, R1’ is selected from the group consisting of:
some embodiments, R1’ is selected from the group consisting of:
. [00205] In certain embodiments, R1’ is selected from the group consisting of:
. [00206] In some embodiments, R1’ is selected from the group consisting of:
107/200
. In some embodiments, R1’ is selected from the group
. [00207] In some embodiments, R2’ is optionally substituted C7-25 alkenyl. In certain embodiments, R2’ is unsubstituted C7-25 alkenyl. In some embodiments, R2’ is C7-25 haloalkenyl. In certain embodiments, R2’ is C7-25 fluoroalkenyl. In some embodiments, R2’ is C7-25 alkenyl substituted with at least one deuterium. In certain embodiments, R2’ is C7-25 alkenyl substituted with at least two deuterium atoms. In some embodiments, R2’ is optionally substituted C12-20 alkenyl. In certain embodiments, R2’ is unsubstituted C12-20 alkenyl. In some embodiments, R2’ is C12-20 haloalkenyl. In certain embodiments, R2’ is C12-20 fluoroalkenyl. In some embodiments, R2’ is C12-20 alkenyl substituted with at least one deuterium. In certain embodiments, R2’ is C12-20 alkenyl substituted with at least two deuterium atoms. In some embodiments, R2’ is optionally substituted C14-18 alkenyl. In certain embodiments, R2’ is unsubstituted C14-18 alkenyl. In some embodiments, R2’ is C14-18 haloalkenyl. In certain embodiments, R2’ is C14-18 fluoroalkenyl. In some embodiments, R2’ is C14-18 alkenyl substituted with at least one deuterium. In certain embodiments, R2’ is C14-18 alkenyl substituted with at least two deuterium atoms. In some embodiments, R2’ is optionally substituted C14 alkenyl. In certain embodiments, R2’ is unsubstituted C14 alkenyl. In some embodiments, R2’ is C14 haloalkenyl. In certain embodiments, R2’ is C14 fluoroalkenyl. In some embodiments, R2’ is C14 alkenyl substituted with at least one deuterium. In certain embodiments, R2’ is C14 alkenyl substituted with at least two deuterium atoms. In some embodiments, R2’ is optionally substituted C16 alkenyl. In certain embodiments, R2’ is unsubstituted C16 alkenyl. In some embodiments, R2’ is C16 haloalkenyl. In certain embodiments, R2’ is C16 fluoroalkenyl. In some embodiments, R2’ is C16 alkenyl substituted with at least one deuterium. In certain embodiments, R2’ is C16 alkenyl substituted with at least two deuterium atoms.
108/200
[00208] In some embodiments, R2’ is linear optionally substituted C7-25 alkenyl. In certain embodiments, R2’ is linear unsubstituted C7-25 alkenyl. In some embodiments, R2’ is linear optionally substituted C12-20 alkenyl. In certain embodiments, R2’ is linear unsubstituted C12-20 alkenyl. In some embodiments, R2’ is linear optionally substituted C14-18 alkenyl. In certain embodiments, R2’ is linear unsubstituted C14-18 alkenyl. [00209] In some embodiments, R2’ comprises cis and trans double bonds. In certain embodiments, R2’ comprises only cis double bonds. In some embodiments, R2’ comprises only trans double bonds. [00210] In some embodiments, R2’ comprises at least two double bonds. In certain embodiments, R2’ comprises at least three double bonds. In some embodiments, R2’ comprises at least four double bonds. In certain embodiments, R2’ comprises at least five double bonds. In some embodiments, R2’ comprises at least six double bonds. In certain embodiments, R2’ comprises 1-8 double bonds. In some embodiments, R2’ comprises 1-6 double bonds. In certain embodiments, R2’ comprises 2-8 double bonds. In some embodiments, R2’ comprises 2-6 double bonds. In certain embodiments, R2’ comprises 1, 2, 3, 4, 5, or 6 double bonds. In some embodiments, R2’ comprises 2, 3, 4, 5, or 6 double bonds. In some embodiments, R2’ comprises 3, 4, 5, or 6 double bonds. In certain embodiments, R2’ comprises 3, 4, or 5 double bonds. [00211] In certain embodiments, R2’ comprises unconjugated double bonds. In some embodiments, R2’ comprises conjugated double bonds. In certain embodiments, R2’ comprises both conjugated and unconjugated double bonds. [00212] In some embodiments, R2’ is optionally substituted n embodiments, R2’ is u
nsubstituted . In certain embodiments, R2’ is substituted
. In some embodiments,
substituted with a non-aliphatic substituent. In some embodiments, R2’ is not substituted with an aliphatic substituent. In some embodiments, R2’ is not substituted with an alkyl, alkenyl, alkynyl group. In some embodiments, R2’ is not substituted with an alkyl, alkenyl, alkynyl group at the terminal position. In some embodiments, R2’ is substituted at a vinylic or allylic position. [00213] In some embodiments, R2’ is
substituted with deuterium,
109/200
halogen, −ORaa, −SRaa, −N(Rbb)2, –CN, –SCN, –NO2, −C(=O)Raa, −CO2Raa, −C(=O)N(Rbb)2, −OC(=O)Raa, −OCO2Raa, −OC(=O)N(Rbb)2, −NRbbC(=O)Raa, −NRbbCO2Raa, or −NRbbC(=O)N(Rbb)2. In some embodiments, R2’ is
substituted with optionally substituted C1-10 alkyl, deuterium, halogen, −ORaa, −SRaa, −N(Rbb)2, –CN, –SCN, –NO2,
−NRbbC(=O)Raa, −NRbbCO2Raa, or −NRbbC(=O)N(Rbb)2, provided that C1-10 alkyl is not at the terminal position. [00214] In some embodiments, R2’ is
substituted with halogen or deuterium. In some embodiments, R2’ is
substituted with halogen. In some embodiments, R2’ is
substituted with at least one fluorine. In certain embodiments, R2’ is
substituted with at least one deuterium. [00215] In certain embodiments, R2’ is selected from the group consisting of
. [00216] In certain embodiments, R2’ is
. [00217] In some embodiments, R2” is optionally substituted n embodiments, R2” is u
nsubstituted . In certain embodiments, R2” is substituted
. In some embodiments,
substituted with at least one fluorine. In certain embodiments, R2” is
110/200
substituted with at least one deuterium. [00218] In certain embodiments, R2” is selected from the group consisting of
. [00219] In certain embodiments, R2” is
. [00220] In certain embodiments, R1’ is unsubstituted C7-25 alkyl, and R2’ is unsubstituted C7-25 alkenyl. In some embodiments, R1’ is C7-25 haloalkyl, and R2’ is unsubstituted C7-25 alkenyl. In certain embodiments, R1’ is C7-25 fluoroalkyl, and R2’ is unsubstituted C7-25 alkenyl. In some embodiments, R1’ is unsubstituted C12-20 alkyl, and R2’ is unsubstituted C12-20 alkenyl. In certain embodiments, R1’ is C12-20 haloalkyl, and R2’ is unsubstituted C12-20 alkenyl. In some embodiments, R1’ is C12-20 fluoroalkyl, and R2’ is unsubstituted C12-20 alkenyl. [00221] In certain embodiments, R1’ is unsubstituted C7-25 alkyl, and R2’ is C7-25 haloalkenyl. In some embodiments, R1’ is C7-25 haloalkyl, and R2’ is C7-25 haloalkenyl. In certain embodiments, R1’ is C7-25 fluoroalkyl, and R2’ is C7-25 haloalkenyl. In some embodiments, R1’ is unsubstituted C12-20 alkyl, and R2’ is C12-20 haloalkenyl. In certain embodiments, R1’ is C12- 20 haloalkyl, and R2’ is C12-20 haloalkenyl. In some embodiments, R1’ is C12-20 fluoroalkyl, and R2’ is C12-20 haloalkenyl. [00222] In certain embodiments, R1’ is unsubstituted C7-25 alkyl, and R2’ is C7-25 fluoroalkenyl. In some embodiments, R1’ is C7-25 haloalkyl, and R2’ is C7-25 fluoroalkenyl. In certain embodiments, R1’ is C7-25 fluoroalkyl, and R2’ is C7-25 fluoroalkenyl. In some embodiments, R1’ is unsubstituted C12-20 alkyl, and R2’ is C12-20 fluoroalkenyl. In certain embodiments, R1’ is C12-20 haloalkyl, and R2’ is C12-20 fluoroalkenyl. In some embodiments, R1’ is C12-20 fluoroalkyl, and R2’ is C12-20 fluoroalkenyl. [00223] In certain embodiments, R1’ is unsubstituted C7-25 alkyl, and R2’ is C7-25 alkenyl substituted with at least one deuterium. In some embodiments, R1’ is C7-25 haloalkyl, and R2’ is C7-25 alkenyl substituted with at least one deuterium. In certain embodiments, R1’ is C7-25 fluoroalkyl, and R2’ is C7-25 alkenyl substituted with at least one deuterium. In some
111/200
embodiments, R1’ is unsubstituted C12-20 alkyl, and R2’ is C7-25 alkenyl substituted with at least one deuterium. In certain embodiments, R1’ is C12-20 haloalkyl, and R2’ is C7-25 alkenyl substituted with at least one deuterium. In some embodiments, R1’ is C12-20 fluoroalkyl, and R2’ is C7-25 alkenyl substituted with at least one deuterium. [00224] In some embodiments, R3’ and R4’ are each independently hydrogen or optionally substituted C1-6 alkyl. [00225] In certain embodiments, R3’ and R4’ are each independently hydrogen or optionally substituted C1-4 alkyl. In some embodiments, R3’ and R4’ are each independently hydrogen or optionally substituted C1-2 alkyl. In certain embodiments, R3’ and R4’ are each independently hydrogen or unsubstituted C1-6 alkyl. In certain embodiments, R3’ and R4’ are each independently hydrogen or unsubstituted C1-4 alkyl. In some embodiments, R3’ and R4’ are each independently hydrogen or unsubstituted C1-2 alkyl. [00226] In some embodiments, one of R3’ and R4’ is hydrogen. In certain embodiments, at least one of R3’ and R4’ is hydrogen. In some embodiments, R3’ and R4’ are each hydrogen. In certain embodiments, R3’ is hydrogen, and R4’ is unsubstituted C1-6 alkyl. In some embodiments, R3’ is hydrogen, and R4’ is methyl, ethyl, propyl, butyl, pentyl, or hexyl. In some embodiments, R3’ is hydrogen, and R4’ is methyl, ethyl, propyl, or butyl. In some embodiments, R3’ is hydrogen, and R4’ is methyl. In some embodiments, R3’ is hydrogen, and R4’ is ethyl. [00227] In some embodiments, one of R3’ and R4’ is unsubstituted C1-6 alkyl. In certain embodiments, at least one of R3’ and R4’ is unsubstituted C1-6 alkyl. In some embodiments, R3’ and R4’ are each unsubstituted C1-6 alkyl. In some embodiments, R3’ and R4’ are each independently methyl, ethyl, propyl, butyl, pentyl, or hexyl. In some embodiments, R3’ and R4’ are each independently methyl, ethyl, propyl, or butyl. In some embodiments, R3’ is methyl, and R4’ is methyl, ethyl, propyl, butyl, pentyl, or hexyl. In certain embodiments, R3’ is methyl, and R4’ is methyl, ethyl, propyl, or butyl. In certain embodiments, R3’ and R4’ are each methyl. In some embodiments, R3’ and R4’ are each ethyl. In certain embodiments, R3’ and R4’ are each propyl. In some embodiments, R3’ and R4’ are each butyl. [00228] In some embodiments, one of R3’ and R4’ is optionally substituted C1-6 alkyl. In certain embodiments, at least one of R3’ and R4’ is optionally substituted C1-6 alkyl. In some embodiments, R3’ and R4’ are each independently optionally substituted C1-6 alkyl. [00229] In certain embodiments, one of R3’ and R4’ is C1-6 fluoroalkyl. In certain embodiments, at least one of R3’ and R4’ is C1-6 fluoroalkyl. In some embodiments, R3’ and R4’ are each C1-6 fluoroalkyl. In some embodiments, at least one of R3’ and R4’ is -CH2F, -
112/200
CHF2, or -CF3. In certain embodiments, at least one of R3’ and R4’ is -CH2F. In some embodiments, at least one of R3’ and R4’ is -CHF2. In certain embodiments, at least one of R3’ and R4’ is -CF3. [00230] In some embodiments, R3’ is hydrogen, and R4’ is C1-6 fluoroalkyl. In certain embodiments, R3’ is hydrogen, and R4’ is -CH2F, CHF2, or -CF3. In some embodiments, R3’ is hydrogen, and R4’ is -CH2F. In certain embodiments, R3’ is hydrogen, and R4’ is -CHF2. In some embodiments, R3’ is hydrogen, and R4’ is -CF3. [00231] In some embodiments, R3’ is unsubstituted C1-6 alkyl, and R4’ is C1-6 fluoroalkyl. In certain embodiments, R3’ is unsubstituted C1-6 alkyl, and R4’ is -CH2F, CHF2, or -CF3. In some embodiments, R3’ is unsubstituted C1-6 alkyl, and R4’ is -CH2F. In certain embodiments, R3’ is unsubstituted C1-6 alkyl, and R4’ is -CHF2. In some embodiments, R3’ is unsubstituted C1-6 alkyl, and R4’ is -CF3. In some embodiments, R3’ is methyl, and R4’ is C1-6 fluoroalkyl. In certain embodiments, R3’ is methyl, and R4’ is -CH2F, CHF2, or -CF3. In some embodiments, R3’ is methyl, and R4’ is -CH2F. In certain embodiments, R3’ is methyl, and R4’ is -CHF2. In some embodiments, R3’ is methyl, and R4’ is -CF3. [00232] In some embodiments, n is 0, 1, 2, or 3. In certain embodiments, n is 0, 1, or 2. In some embodiments, n is 0 or 1. In certain embodiments, n is 1 or 2. In some embodiments, n is 2 or 3. In certain embodiments, n is 0. In some embodiments, n is 1. In certain embodiments, n is 2. In some embodiments, n is 3. [00233] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen, halogen, or C1-6 alkyl. [00234] In certain embodiments, * designates a point of attachment at position X. In some embodiments, * designates a point of attachment at position Y. In certain embodiments, * designates a point of attachment at position Z. [00235] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen or halogen. In certain embodiments, * designates a point of attachment at position X; and Y and Z are each independently hydrogen or halogen. In some embodiments, * designates a point of attachment at position Y; and X and Z are each independently hydrogen or halogen. In certain embodiments, * designates a point of attachment at position Z; and X and Y are each independently hydrogen or halogen. [00236] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen or
113/200
fluorine. In certain embodiments, * designates a point of attachment at position X; and Y and Z are each independently hydrogen or fluorine. In some embodiments, * designates a point of attachment at position Y; and X and Z are each independently hydrogen or fluorine. In certain embodiments, * designates a point of attachment at position Z; and X and Y are each independently hydrogen or fluorine. [00237] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen or C1-6 alkyl. In certain embodiments, * designates a point of attachment at position X; and Y and Z are each independently hydrogen or C1-6 alkyl. In some embodiments, * designates a point of attachment at position Y; and X and Z are each independently hydrogen or C1-6 alkyl. In certain embodiments, * designates a point of attachment at position Z; and X and Y are each independently hydrogen or C1-6 alkyl. [00238] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each hydrogen. In certain embodiments, * designates a point of attachment at position X; and Y and Z are each hydrogen. In some embodiments, * designates a point of attachment at position Y; and X and Z are each hydrogen. In certain embodiments, * designates a point of attachment at position Z; and X and Y are each hydrogen. [00239] In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently halogen. In some embodiments, * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently C1-6 alkyl. [00240] In certain embodiments, the compound is:
,
114/200
, , , ,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.
115/200
116/200
, or a pharmaceutically acceptable salt thereof. [00242] In certain embodiments, the compound is: , , ,
,
117/200
,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof. [00243] In certain embodiments, the compound is: , ,
,
118/200
, ,
, or a pharmaceutically acceptable salt thereof. [00244] In some instances, compounds and generic formulae provided herein are drawn in zwitterionic form. Any compound or generic formula drawn as a zwitterion herein is understood to also encompass the corresponding non-zwitterionic form. [00245] For example, compounds of Formula (I) wherein R3, R4, and R5 (if present) are hydrogen (drawn in zwitterionic form herein) also encompass compounds wherein X is selected from
(non-zwitterionic form). [00246] Similarly, for example, compounds of Formula (I-A), wherein R3, R4, and R5 are hydrogen (drawn in zwitterionic form herein), also encompass compounds of the following formula (non-zwitterionic form):
.
119/200
[00247] Similarly, for example, compounds of Formula (I-A-i), wherein R3, R4, and R5 are hydrogen (drawn in zwitterionic form herein), also encompass compounds of the following formula (non-zwitterionic form):
[00248] Similarly, for example, compounds of Formula (I-A-iii) (drawn in zwitterionic form herein) also encompass compounds of the following formula (non-zwitterionic form):
-iii). [00249] Similarly, for example, compounds of Formula (I-B), wherein R3 and R4 are hydrogen (drawn in zwitterionic form herein), also encompasses compounds of the following formula (non-zwitterionic form):
. [00250] Additionally, compounds of Formula (II) wherein R3’ and R4’ are hydrogen (drawn in zwitterionic form herein) also encompass compounds of the following formula (non- zwitterionic form):
.
120/200
[00251] Similarly, for example, compounds of Formula (II-A) wherein R3’ and R4’ are hydrogen (drawn in zwitterionic form herein) also encompass compounds of the following formula (non-zwitterionic form):
. [00252] Similarly, for example, compounds of Formula (II-B) wherein R3’ and R4’ are hydrogen (drawn in zwitterionic form herein) also encompass compounds of the following formula (non-zwitterionic form):
. [00253] Similarly, for example, compounds of Formula (II-C) wherein R3’ and R4’ are hydrogen (drawn in zwitterionic form herein) also encompass compounds of the following formula (non-zwitterionic form):
.
121/200
[00254] Similarly, for example, compounds of Formula (II-D) wherein R3’ and R4’ are hydrogen (drawn in zwitterionic form herein) also encompass compounds of the following formula (non-zwitterionic form):
. [00255] Compounds excluded by proviso in their zwitterionic form are also understood to be excluded in their non-zwitterionic form. Similarly, compounds excluded by proviso in their non-zwitterionic form are also understood to be excluded in their zwitterionic form. Compositions, Kits, and Administration [00256] The present disclosure provides compositions comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, and optionally a carrier and/or excipient. In some embodiments, the composition is a pharmaceutical composition. In certain embodiments, the pharmaceutical composition described herein comprises a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, and a pharmaceutically acceptable carrier and/or excipient. In some embodiments, the composition is a nutraceutical composition. In certain embodiments, the nutraceutical composition described herein comprises a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, and a carrier and/or excipient. [00257] In certain embodiments, the compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, is provided in an effective amount in the composition. In certain embodiments, the effective amount is a therapeutically or prophylactically effective amount. [00258] In certain embodiments, the effective amount is an amount effective for treating a disease, disorder, or condition in a subject in need thereof. In some embodiments, the
122/200
effective amount is an amount effective for treating a liver disease, neurological disease, ophthalmic disease, metabolic disorder, mitochondrial disease, cardiovascular disease, infectious disease, pulmonary disease, skin disease, genetic disease, proliferative disease, inflammatory disease, autoimmune disease, hematological disease, painful condition, psychiatric disorder, immune disorder, or spleen disease. In some embodiments, the effective amount is an amount effective for treating a neurological disease in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for treating Alzheimer’s disease in a subject in need thereof. In some embodiments, the effective amount is an amount effective for treating a genetic disease. In some embodiments, the effective amount is an amount effective for treating Zellweger syndrome. In some embodiments, the effective amount is an amount effective for treating a pulmonary disease. In some embodiments, the effective amount is an amount effective for treating NRDS. [00259] In some embodiments, the effective amount is an amount effective for preventing a disease, disorder, or condition in a subject in need thereof. In some embodiments, the effective amount is an amount effective for preventing a liver disease, neurological disease, ophthalmic disease, metabolic disorder, mitochondrial disease, cardiovascular disease, infectious disease, pulmonary disease, skin disease, genetic disease, proliferative disease, inflammatory disease, autoimmune disease, hematological disease, painful condition, psychiatric disorder, immune disorder, or spleen disease. In certain embodiments, the effective amount is an amount effective for preventing a neurological disease in a subject in need thereof. In some embodiments, the effective amount is an amount effective for preventing Alzheimer’s disease in a subject in need thereof. In some embodiments, the effective amount is an amount effective for preventing a genetic disease. In some embodiments, the effective amount is an amount effective for preventing Zellweger syndrome. In some embodiments, the effective amount is an amount effective for preventing a pulmonary disease. In some embodiments, the effective amount is an amount effective for preventing NRDS. [00260] Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include bringing the compound described herein (i.e., the “active ingredient”) into association with a carrier or excipient, and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping, and/or packaging the product into a desired single- or multi-dose unit. [00261] Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. A “unit dose” is a discrete amount
123/200
of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage. [00262] Relative amounts of the compound of the disclosure, pharmaceutically acceptable excipient, agent, and/or any additional ingredients in a composition described herein will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. The composition may comprise between 0.1% and 100% (w/w) agent. [00263] Pharmaceutically acceptable excipients used in manufacture of provided pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Excipients and accessory ingredients, such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents, may also be present in the composition. [00264] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof. [00265] Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross- linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof. [00266] Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and
124/200
propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g., carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate (Tween® 20), polyoxyethylene sorbitan (Tween® 60), polyoxyethylene sorbitan monooleate (Tween® 80), sorbitan monopalmitate (Span® 40), sorbitan monostearate (Span® 60), sorbitan tristearate (Span® 65), glyceryl monooleate, sorbitan monooleate (Span® 80), polyoxyethylene esters (e.g., polyoxyethylene monostearate (Myrj® 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., Cremophor®), polyoxyethylene ethers, (e.g., polyoxyethylene lauryl ether (Brij® 30)), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic® F-68, poloxamer P-188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and/or mixtures thereof. [00267] Exemplary binding agents include starch (e.g., cornstarch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and/or mixtures thereof. [00268] Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent. [00269] Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite. [00270] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium
125/200
disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal. [00271] Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid. [00272] Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol. [00273] Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta- carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid. [00274] Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant® Plus, Phenonip®, methylparaben, Germall® 115, Germaben® II, Neolone®, Kathon®, and Euxyl®. [00275] Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen- free water, isotonic saline, Ringer’s solution, ethyl alcohol, and mixtures thereof. [00276] Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol,
126/200
sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof. [00277] Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof. [00278] Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredients, the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. In certain embodiments for parenteral administration, the compounds described herein are mixed with solubilizing agents such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof. [00279] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer’s solution, U.S.P., and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or
127/200
suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. [00280] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. [00281] In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form may be accomplished by dissolving or suspending the drug in an oil vehicle. [00282] Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the compounds described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient. [00283] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may include a buffering agent. [00284] Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular
128/200
weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the art of pharmacology. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of encapsulating compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type can be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like. [00285] The active ingredient can be in a micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of encapsulating agents which can be used include polymeric substances and waxes. [00286] Dosage forms for topical and/or transdermal administration of a compound described herein may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and/or patches. Generally, the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier or excipient and/or any needed preservatives and/or buffers as can be required. Additionally, the present disclosure contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body. Such dosage forms can be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium. Alternatively or additionally, the rate can be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel. [00287] Formulations suitable for topical administration include, but are not limited to, liquid and/or semi-liquid preparations such as liniments, lotions, oil-in-water and/or water-in-oil
129/200
emulsions such as creams, ointments, and/or pastes, and/or solutions and/or suspensions. Topically administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient can be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein. [00288] Suitable devices for use in delivering injectable pharmaceutical compositions described herein include short needle devices. Injectable compositions can be administered by devices which limit the effective penetration length of a needle into the skin. Alternatively or additionally, conventional syringes can be used in the classical mantoux method of administration. Jet injection devices which deliver liquid formulations via a liquid jet injector and/or via a needle. Ballistic powder/particle delivery devices which use compressed gas to accelerate the compound in powder form are suitable. [00289] A pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, or from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder and/or using a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form. [00290] Low boiling propellants generally include liquid propellants having a boiling point of below 65 °F at atmospheric pressure. Generally, the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
130/200
[00291] Pharmaceutical compositions described herein formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension. Such formulations can be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative, such as methylhydroxybenzoate. The droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers. [00292] Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition described herein. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered by rapid inhalation through the nasal passage from a container of the powder held close to the nares. [00293] Formulations for nasal administration may, for example, comprise from about as little as 0.1% (w/w) to as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein. A pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein. [00294] A pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1-1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid carrier or excipient. Such drops may further comprise buffering agents, salts, and/or one or more other of the additional
131/200
ingredients described herein. Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are also contemplated as being within the scope of this disclosure. [00295] Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation. [00296] Compounds provided herein are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions described herein will be decided by a physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex, and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts. [00297] The compounds and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intraarticular, intra- arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. Specifically, contemplated routes are intraarticular administration, oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and/or lymph supply, and/or direct administration to an affected site. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its
132/200
stability in the environment of the gastrointestinal tract), and/or the condition of the subject (e.g., whether the subject is able to tolerate oral administration). [00298] In certain embodiments, the compound or pharmaceutical composition described herein is suitable for intraarticular administration. In some embodiments the compound or pharmaceutical composition described herein is suitable for intraarticular injection. In certain embodiments, the intraarticular injection comprises direct injection into the closed cavity of a joint. In some embodiments, the joint is a knee joint, wrist joint, ankle joint, hip joint, shoulder joint, elbow joint, neck joint, spine joint, vertebral disc joints, finger joints, and toe joints. [00299] The exact amount of a compound of the disclosure required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound of the disclosure, mode of administration, and the like. An effective amount may be included in a single dose (e.g., single oral dose) or multiple doses (e.g., multiple oral doses). In certain embodiments, when multiple doses are administered to a subject or applied to a biological sample, tissue, or cell, any two doses of the multiple doses include different or substantially the same amounts of an agent described herein. [00300] In certain embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, the frequency of administering the multiple doses to the subject or applying the multiple doses to the tissue or cell may be, in non-limiting examples, three doses a day, two doses a day, one dose a day, one dose every other day, one dose every third day, one dose every week, one dose every two weeks, one dose every three weeks, or one dose every four weeks, or even slow dose controlled delivery over a selected period of time using a drug delivery device. In certain embodiments, when multiple doses are administered to a subject or applied to a biological sample, tissue, or cell, the duration between the first dose and last dose of the multiple doses is one day, two days, four days, one week, two weeks, three weeks, one month, two months, three months, four months, six months, nine months, one year, two years, three years, four years, five years, seven years, ten years, fifteen years, twenty years, or the lifetime of the subject, tissue, or cell. In certain embodiments, the duration between the first dose and last dose of the multiple doses is three months, six months, or one year. In certain embodiments, the duration between the first dose and last dose of the multiple doses is the lifetime of the subject, tissue, or cell. In certain embodiments, a dose (e.g., a single dose, or any dose of multiple doses) described herein includes independently between 0.1 µg and 1 µg, between 0.001 mg and 0.01 mg, between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg,
133/200
between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, or between 1 g and 10 g, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 1 mg and 3 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 3 mg and 10 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 10 mg and 30 mg, inclusive, of a compound described herein. In certain embodiments, a dose described herein includes independently between 30 mg and 100 mg, inclusive, of a compound described herein. [00301] Dose ranges as described herein provide guidance for the administration of provided compounds or compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult. In certain embodiments, a dose described herein is a dose to an adult human whose body weight is 70 kg. [00302] A compound or composition, as described herein, can be administered in combination with one or more additional pharmaceutical agents (e.g., therapeutically and/or prophylactically active agents). The compounds or compositions can be administered in combination with additional pharmaceutical agents that improve their activity (e.g., potency and/or efficacy), improve bioavailability, improve safety, reduce drug resistance, reduce and/or modify metabolism, inhibit excretion, and/or modify distribution in a subject or cell. It will also be appreciated that the therapy employed may achieve a desired effect for the same disorder, and/or it may achieve different effects. In certain embodiments, a pharmaceutical composition described herein including a compound described herein and an additional pharmaceutical agent shows a synergistic effect that is absent in a pharmaceutical composition including one of the compound and the additional pharmaceutical agent, but not both. In some embodiments, the additional pharmaceutical agent achieves a desired effect for the same disorder. In some embodiments, the additional pharmaceutical agent achieves different effects. [00303] The compound or composition can be administered concurrently with, prior to, or subsequent to one or more additional pharmaceutical agents, which may be useful as, e.g., combination therapies. Pharmaceutical agents include therapeutically active agents. Pharmaceutical agents also include prophylactically active agents. Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved for
134/200
human or veterinary use by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells. In certain embodiments, the additional pharmaceutical agent is a pharmaceutical agent useful for treating and/or preventing a disease, disorder, or condition . [00304] Each additional pharmaceutical agent may be administered at a dose and/or on a time schedule determined for that pharmaceutical agent. The additional pharmaceutical agents may also be administered together with each other and/or with the compound or composition described herein in a single dose or composition or administered separately in different doses or compositions. The particular combination to employ in a regimen will take into account compatibility of the compound described herein with the additional pharmaceutical agent(s) and/or the desired therapeutic and/or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agent(s) in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually. [00305] The additional pharmaceutical agents include, but are not limited to, anti- proliferative agents, anti-cancer agents, anti-angiogenesis agents, steroidal or non-steroidal anti-inflammatory agents, immunosuppressants, anti-bacterial agents, anti-viral agents, cardiovascular agents, cholesterol-lowering agents, anti-diabetic agents, anti-allergic agents, contraceptive agents, pain-relieving agents, anesthetics, anti–coagulants, inhibitors of an enzyme, steroidal agents, steroidal or antihistamine, antigens, vaccines, antibodies, decongestant, sedatives, opioids, analgesics, anti-pyretics, hormones, and prostaglandins. [00306] In certain embodiments, the composition is a food product. In certain embodiments, the food product is any item that is to be processed, partially processed, or unprocessed for consumption by an animal. In some embodiments, the food product is for consumption by a mammal. In some embodiments, the food product is for consumption by a human. In some embodiments, the food product is a food supplement, medical food, or infant formula. In certain embodiments, the food product is a food supplement. In some embodiments, the food product is a medical food. In certain embodiments, the food product is infant formula. In another aspect, the food product is a food additive. In another aspect, the food product is a dietary supplement.
135/200
[00307] In certain embodiments, the composition further comprises a sweetener. Sweeteners can be used to improve palatability and are usually classified as natural or artificial. In some embodiments, a sweetener is a natural sweetener or artificial sweetener. Exemplary natural sweeteners include, but are not limited to, dextrose, fructose, glucose, liquid glucose, maltose, rebiana, glycyrrhizin, thaumatin, sorbitol, mannitol, isomalt, glycerol, maltitol, xylitol, and erythritol. Exemplary artificial sweeteners include, but are not limited to, saccharin, cyclamate, aspartame, acesulfame-K, sucralose, alitame, and neotame. In certain embodiments, sucralose is used as a sweetener. In certain embodiments, one or combination of neohespiridin dihydrochalcone, glycerol, and/or sucralose are used as sweeteners. In some embodiments, the concentration of the sweetener in the composition is between 0.01% and 5%, inclusive, by weight. In some embodiments, the concentration of the sweetener in the composition is between 0.01% and 1%, inclusive, by weight. In some embodiments, the concentration of the sweetener in the composition is between 0.5% and 1%, inclusive, by weight. In certain embodiments, the composition further comprises sucralose. In certain embodiments, the composition further comprises sucralose as about 0.01-0.25% based on the dry weight of all the components of the composition. [00308] In certain embodiments, a composition further comprises a colorant. A colorant can be added to enhance the aesthetic appeal of the composition, especially when formulation ingredients or drugs are presented in a non-solution form. Generally, any colorant could be added, such as for example FD&C pigments (for example, blue nº1, blue nº2, red nº3, red nº40, yellow nº5, or yellow nº 6). Exemplary colorants include, but are not limited to annatto extract, dehydrated beets (beet powder), canthaxanthin, caramel, β-apo-8'-carotenal, β- carotene, cochineal extract, carmine, sodium copper chlorophyllin, toasted partially defatted cooked cottonseed flour, ferrous gluconate, ferrous lactate, grape color extract, grape skin extract (enocianina), synthetic iron oxide, fruit juice, vegetable juice, carrot oil, paprika, paprika oleoresin, mica-based pearlescent pigments, riboflavin, saffron, spirulina extract, titanium dioxide, tomato lycopene extract; tomato lycopene concentrate, turmeric, turmeric oleoresin, alumina (dried aluminum hydroxide), calcium carbonate, potassium sodium copper chlorophyllin (chlorophyllin-copper complex), dihydroxyacetone, bismuth oxychloride, synthetic iron oxide, ferric ammonium ferrocyanide, ferric ferrocyanide, chromium hydroxide green, chromium oxide greens, guanine, pyrophyllite, mica, talc, aluminum powder, bronze powder, copper powder, zinc oxide, bismuth citrate, disodium EDTA-copper, guaiazulene, henna, lead acetate, pyrophyllite, silver, ultramarines, manganese violet, luminescent zinc sulfide, FD&C Blue No.1, FD&C Blue No.2, FD&C Green No.3, Orange B, Citrus Red
136/200
No.2, FD&C Red No.3, FD&C Red No.40, FD&C Yellow No.5, FD&C Yellow No.6, D&C Blue No.4, D&C Green No.5, D&C Green No.6, D&C Green No.8, D&C Orange No.4, D&C Orange No.5, D&C Orange No.10, D&C Orange No.11, FD&C Red No.4, D&C Red No.6, D&C Red No.7, D&C Red No.17, D&C Red No.21, D&C Red No.22, D&C Red No.27, D&C Red No.28, D&C Red No.30, D&C Red No.31, D&C Red No.33, D&C Red No.34, D&C Red No.36, D&C Red No.39, D&C Violet No.2, D&C Yellow No. 7, Ext. D&C Yellow No.7, D&C Yellow No.8, D&C Yellow No.10, D&C Yellow No.11, D&C Black No.2, D&C Black No.3, D&C Brown No.1, and Ext. D&C Violet No.2. In certain embodiments, a colorant represents 0.001% to about 0.5% based on the weight of all the components of the composition. In some embodiments, the concentration of the colorant in the composition is between 0.001% and 5%, inclusive, by weight. In some embodiments, the concentration of the colorant in the composition is between 0.001% and 1%, inclusive, by weight. [00309] In certain embodiments, a provided composition further comprises a flavoring agent. In certain embodiments, the selection of a suitable flavoring agent to be added depends on the original taste sensation of the composition, including metallic, acidic, alkaline, salty, sweet, bitter and sour taste sensation. Certain flavoring agents, alone or in combination, mask specific taste sensations. For example, metallic taste could be masked with, but not limited to, flavoring agents based on berry fruits, grape, and/or peppermint. For example, acidic taste could be masked with, but not limited to, flavoring agents based on lemon, lime, grapefruit, orange, cherry, and/or strawberry. For example, alkaline taste could be masked with, but not limited to, flavoring agents based on aniseed, caramel, passion fruit, peach and/or banana. For example, salty taste could be masked with, but not limited to, flavoring agents based on butterscotch, caramel, hazelnut, spicy, maple, apricot, apple, peach, vanilla, and/or wintergreen mint. For example, bitter taste could be masked with, but not limited to, flavoring agents based on licorice, passion fruit, coffee, chocolate, peppermint, grapefruit, cherry, peach, raspberry, wild cherry, walnut, mint, and/or anise. For example, sweet taste could be masked with, but not limited to, flavoring agents based on grape, cream, caramel, banana, vanilla and/or fruit berry. For example, sour taste could be masked with, but not limited to, flavoring agents based on citrus flavors, licorice, root, bear and/or raspberry. Flavoring agents can be used alone or in combination and its selection will be dependent also upon the target population and any other substance (e.g., a pharmaceutical or nutraceutical agent) incorporated in the composition. The perception of the flavoring agent changes from individual to individual and also with age: typically a geriatric population will prefer mint or
137/200
orange flavors whereas younger populations tend to prefer flavors like fruit punch, raspberry, etc. Generally, the amount of flavoring agent needed to mask an unpleasant taste or improve taste overall will depend not only on the composition of the formulation but also on the flavor type and its strength. [00310] In certain embodiments, a flavoring agent is a palatable flavor that has a long shelf life and which does not crystallize or precipitate out of the composition upon storage. In certain embodiments, flavoring agents are natural flavors, derived from various parts of the plants like leaves, fruits and flowers, or synthetic flavor oils or powders. Exemplary flavor oils for use in or as flavoring agents include, but are not limited to, peppermint oil, cinnamon oil, spearmint oil, and oil of nutmeg. Exemplary fruity flavors that for use in or as flavoring agents include, but are not limited to, vanilla, cocoa, coffee, chocolate and citrus. Exemplary fruit essence flavors for use in or as flavoring agents include, but are not limited to, apple, raspberry, cherry, and pineapple. The amount of flavoring agent added can vary with the flavor employed. In some embodiments, the concentration of the flavoring agent in the composition is between about 0% and 5%, by weight. In some embodiments, the concentration of the flavoring agent in the composition is between 0.001% and 5%, inclusive, by weight. In some embodiments, the concentration of the flavoring agent in the composition is between 0.1% and 1%, inclusive, by weight. In some embodiments, the concentration of the flavoring agent in the composition is between 0.5% and 1%, inclusive, by weight. [00311] In certain embodiments, a provided composition further comprises taste-masking. Taste-masking agents can be added to ameliorate the general organoleptic characteristics of the compositions. In certain embodiments, taste-masking agents are used to mask unpleasant taste of some components. The main taste sensations include metallic, acidic, alkaline, salty, sweet, bitter and sour. Exemplary of taste-masking agents include, but are not limited to, menthol, peppermint oil, L-menthol, cyclodextrins, glycerol, maltodextrins, ion-exchange resins, amino acids, gelatin, gelatinized starch, liposomes, lecithin, or lecithin-like substances and salts. The amount of taste-masking added can vary with the taste-masking employed. In certain embodiments, the taste-masking agent comprises about 0% to about 50% based on the dry weight of all the components of the composition. In certain embodiments, the taste- masking agent represents 0% to about 5% based on the dry weight of all the components of the composition. [00312] In another aspect, a provided composition further comprises a cooling agent. Cooling agents may also be added in order to improve the after-taste of the composition. Exemplary cooling agents include, but are not limited to, neohesperidine dihydrochalcone, menthol
138/200
flavor, L-Menthol and some polyol sugars which are widely used for this purpose. Other components can also be added that should compete with sensory stimuli, such as Cremophor (which is used to coat the surface protein receptors), or saline solutions (e.g., sodium chloride, which competes within channel receptors with the bitter stimuli to reduce the overall perception of bitterness). In certain embodiments, the cooling agents in the composition is one or a combination of neohesperidine dihydrochalcone, menthol, and/or polyol sugar. In certain embodiments, the mucoadhesive composition further comprises cooling agents of about 0% to about 5% based on the weight of all the components of the composition. In certain embodiments, the mucoadhesive composition further comprises cooling agents as about 0.001% to about 2.5% based on the weight of all the components of the composition. [00313] In certain embodiments, a provided composition further comprises one or more preservatives. The preservative employed in the present disclosure can be any preservative, as long as does not negate other desirable properties of the composition. Example of a preservative is an antimicrobial preservative that is used to prevent or inhibit the growth of micro-organisms in the composition. Exemplary preservative agents include, but are not limited to, C3-C8 alcohols, phenylethyl alcohol, chlorbutanol, p-hydroxybenzoic, acid esters, benzathonium chloride and benzalkonium chloride, benzoic acid, propyl galate, methylparaben, propylparaben, sorbic acid, sodium benzoate and/or potassium sorbate. The amount of preservative agent added can vary with the preservative agent employed. In certain embodiments, a preservative agent represents about 0% to about 45% based on the weight of all the components of the composition. In certain embodiments, a preservative agent represents about 0% to about 1% (e.g., 0.025% to 0.2%) based on the weight of all the components of the composition. [00314] Also encompassed by the disclosure are kits (e.g., pharmaceutical packs). The kits provided may comprise a pharmaceutical composition or compound provided herein and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container). In some embodiments, provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of a pharmaceutical composition or compound provided herein. In some embodiments, the pharmaceutical composition or compound provided in the first container and the second container are combined to form one unit dosage form. A kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition.
139/200
[00315] In one aspect, the present disclosure provides a kit comprising a compound provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; or a composition provided herein; and instructions for using the compound, pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, prodrug, or composition thereof. In some embodiments, provided are kits including a first container comprising a compound or pharmaceutical composition described herein. In certain embodiments, the kits are useful for treating a disease, disorder, or condition in a subject in need thereof. In certain embodiments, the kits are useful for preventing a disease, disorder, or condition in a subject in need thereof. In certain embodiments, the kits are useful for reducing the risk of developing a disease in a subject in need thereof. In certain embodiments, the kits are useful for treating a neurological disease in a subject in need thereof. In certain embodiments, the kits are useful for preventing a neurological disease in a subject in need thereof. In certain embodiments, the kits are useful for reducing the risk of developing a neurological disease in a subject in need thereof. In certain embodiments, the kits are useful for treating Alzheimer’s disease in a subject in need thereof. In certain embodiments, the kits are useful for preventing Alzheimer’s disease in a subject in need thereof. In certain embodiments, the kits are useful for reducing the risk of developing Alzheimer’s disease in a subject in need thereof. [00316] In certain embodiments, a kit described herein further includes instructions for using the kit. A kit described herein may also include information as required by a regulatory agency such as the U.S. Food and Drug Administration (FDA). In certain embodiments, the information included in the kits is prescribing information. In certain embodiments, the kits and instructions provide for treating a disease, disorder, or condition in a subject in need thereof. In certain embodiments, the kits and instructions provide for preventing a disease, disorder, or condition in a subject in need thereof. In certain embodiments, the kits and instructions provide for reducing the risk of developing a disease in a subject in need thereof. A kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition. Methods of Use [00317] Provided herein are methods and uses of the compounds provided herein, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers,
140/200
stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and pharmaceutical compositions thereof. [00318] In one aspect, provided herein is a method of treating a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof. [00319] In another aspect, provided herein is a method of preventing a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof. [00320] In another aspect, provided herein is a method of treating a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof. [00321] In another aspect, provided herein is a method of preventing a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof. [00322] In another aspect, the present disclosure provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, in the manufacture of a medicament for treating a disease, disorder, or condition in a subject. [00323] In another aspect, the present disclosure provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, in the manufacture of a medicament for preventing a disease, disorder, or condition in a subject. [00324] In another aspect, the present disclosure provides the use of a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, in the manufacture of a medicament for treating a disease, disorder, or condition in a subject.
141/200
[00325] In another aspect, the present disclosure provides the use of a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, in the manufacture of a medicament for preventing a disease, disorder, or condition in a subject. [00326] In another aspect, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in treating a disease, disorder, or condition in a subject. [00327] In another aspect, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in preventing a disease, disorder, or condition in a subject. [00328] In another aspect, the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in treating a disease, disorder, or condition in a subject. [00329] In another aspect, the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in preventing a disease, disorder, or condition in a subject. [00330] In certain embodiments, the disease, disorder, or condition is a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition, a psychiatric disorder, an immune disorder, or a spleen disease. In some embodiments, the disease is a neurological disease, ophthalmic disease, liver disease, metabolic disease, cardiovascular disease, cancer, pulmonary disease, or genetic disease. In some embodiments, the disease is a neurological disease, ophthalmic disease, liver disease, metabolic disease, cardiovascular disease, or cancer. In certain embodiments, the disease, disorder, or condition is a liver disease, a neurological disease, an ophthalmic disease, metabolic disorder, pulmonary disease, or genetic disease. In certain embodiments, the disease, disorder, or condition is a liver disease, a neurological disease, an ophthalmic disease, or a metabolic disorder. In some embodiments, the disease, disorder, or condition is a neurological disease, an ophthalmic disease, a pulmonary disease, or a genetic
142/200
disease. In some embodiments, the disease, disorder, or condition is a neurological disease or an ophthalmic disease. In certain embodiments, the disease, disorder, or condition is an ophthalmic disease. In some embodiments, the disease is a peroxisomal disorder. [00331] In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a congenital disorder. In some embodiments, the disease is a leukodystrophy. In some embodiments, the disease is Zellweger syndrome, neonatal adrenoleukodystrophy (NALD), or infantile Refsum disease. In some embodiments, the disease is Zellweger syndrome. In some embodiments, the disease is neonatal adrenoleukodystrophy (NALD). In some embodiments, the disease is infantile Refsum disease. [00332] In certain embodiments, the disease, disorder, or condition is a pulmonary disease. In some embodiments, the pulmonary disease is bronchiectasis, bronchitis, bronchopulmonary dysplasia, interstitial lung disease, occupational lung disease, emphysema, cystic fibrosis, acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, bronchopulmonary dysplasia, asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, interstitial lung disease, sarcoidosis, asbestosis, aspergilloma, aspergillosis, pneumonia, pulmonary fibrosis, pulmonary tuberculosis, rheumatoid lung disease, pulmonary embolism, or lung cancer. In certain embodiments, the pulmonary disease is acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, or bronchopulmonary dysplasia. In some embodiments, the pulmonary disease is respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, or bronchopulmonary dysplasia. In certain embodiments, the pulmonary disease is acute respiratory distress syndrome (ARDS). In certain embodiments, the pulmonary disease is severe acute respiratory syndrome (SARS). In certain embodiments, the pulmonary disease is respiratory distress syndrome. In certain embodiments, the pulmonary disease is neonatal respiratory distress syndrome (NRDS). In certain embodiments, the pulmonary disease is infant respiratory distress syndrome (IRDS). In certain embodiments, the pulmonary disease is hyaline membrane disease. In certain embodiments, the pulmonary disease is surfactant deficiency. In certain embodiments, the pulmonary disease is surfactant
143/200
protein-B deficiency. In certain embodiments, the pulmonary disease is bronchopulmonary dysplasia. [00333] In some embodiments, the disease, disorder, or condition is a neurological disease. In certain embodiments, the neurological disease is a neurodegenerative disease. In some embodiments, the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV-related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supranuclear palsy, vascular dementia, progressive multifocal leukoencephalopathy, dementia with Lewy bodies, lacunar syndromes, hydrocephalus, Wernicke-Korsakoff’s syndrome, post-encephalitic dementia, cancer and chemotherapy-associated cognitive impairment and dementia, or depression-induced dementia and pseudodementia. In some embodiments, the disease is a synuclienopathy. In some embodiments, the disease is Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy. In certain embodiments, the disease is dementia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, a prion disease, amyotrophic lateral sclerosis, or multiple sclerosis. In some embodiments, the disease is dementia, or Alzheimer’s disease. In certain embodiments, the disease is Alzheimer’s disease. In some embodiments, the disease is an advanced neurological disease. In certain embodiments, the disease is an advanced neurodegenerative disease. In some embodiments, the disease is advanced Alzheimer’s disease. In some embodiments, the disease is a neurological disease in the early stages. In certain embodiments, the disease is a neurodegenerative disease in the early stages. In some embodiments, the disease is Alzheimer’s disease in the early stages. In certain embodiments, treating and/or preventing the early-stage disease leads to reversal. [00334] In certain embodiments, the disease is a neurological disease, and treating and/or preventing the disease improves cognitive function. In some embodiments, the disease is a neurological disease, and treating and/or preventing the disease delays disease progression. In certain embodiments, the disease is a neurological disease, and treating and/or preventing the
144/200
disease corrects issues with neurological function. In certain embodiments, the disease is a neurodegenerative disease, and treating and/or preventing the disease improves cognitive function. In some embodiments, the disease is a neurodegenerative disease, and treating and/or preventing the disease delays disease progression. In certain embodiments, the disease is a neurodegenerative disease, and treating and/or preventing the disease corrects issues with neurological function. [00335] In some embodiments, the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV- related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supranuclear palsy, vascular dementia, progressive multifocal leukoencephalopathy, dementia with Lewy bodies, lacunar syndromes, hydrocephalus, Wernicke-Korsakoff’s syndrome, post-encephalitic dementia, cancer and chemotherapy- associated cognitive impairment and dementia, or depression-induced dementia and pseudodementia, and treating and/or preventing the disease improves cognitive function. In certain embodiments, the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV-related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supranuclear palsy, vascular dementia, progressive multifocal leukoencephalopathy, dementia with Lewy bodies, lacunar syndromes, hydrocephalus, Wernicke-Korsakoff’s syndrome, post-encephalitic dementia, cancer and chemotherapy-associated cognitive impairment and
145/200
dementia, or depression-induced dementia and pseudodementia, and treating and/or preventing the disease delays disease progression. In some embodiments, the disease is dementia, Alzheimer’s disease, Parkinson’s disease, a Parkinson’s disease-related disorder, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), a prion disease, corticobasal degeneration, frontotemporal dementia, HIV-related cognitive impairment, mild cognitive impairment, a motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich’s ataxia, Lewy body disease, Alpers’ disease, Batten disease, cerebro-oculo-facio- skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheinker disease, Kuru, Leigh’s disease, monomelic amyotrophy, multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager syndrome), multiple sclerosis (MS), neurodegeneration with brain iron accumulation, opsoclonus myoclonus, posterior cortical atrophy, primary progressive aphasia, progressive supranuclear palsy, vascular dementia, progressive multifocal leukoencephalopathy, dementia with Lewy bodies, lacunar syndromes, hydrocephalus, Wernicke-Korsakoff's syndrome, post-encephalitic dementia, cancer and chemotherapy-associated cognitive impairment and dementia, or depression-induced dementia and pseudodementia, and treating and/or preventing the disease corrects issues with neurological function. [00336] In certain embodiments, the neurodegenerative disease is dementia. In some embodiments, the neurodegenerative disease is mild cognitive impairment, Creutzfeldt-Jakob disease, dementia with Lewy bodies, vascular dementia, mixed dementia, young-onset dementia, alcohol-related dementia, HIV-associated neurocognitive disorder, frontotemporal lobar dementia, or Alzheimer’s disease. In some embodiments, the neurodegenerative disease is mild cognitive impairment. In some embodiments, the neurodegenerative disease is Creutzfeldt-Jakob disease. In some embodiments, the neurodegenerative disease is dementia with Lewy bodies. In some embodiments, the neurodegenerative disease is vascular dementia. In some embodiments, the neurodegenerative disease is mixed dementia. In some embodiments, the neurodegenerative disease is young-onset dementia. In some embodiments, the neurodegenerative disease is alcohol-related dementia. In some embodiments, the neurodegenerative disease is HIV-associated neurocognitive disorder. In some embodiments, the neurodegenerative disease is frontotemporal lobar dementia. In some embodiments, the neurodegenerative disease is neuronal ceroid lipofuscinosis. In some embodiments, the neurodegenerative disease is associated with cerebral ischemia reperfusion injury. In some embodiments, the disease is Alzheimer’s disease or Parkinson’s disease.
146/200
[00337] In some embodiments, the disease is Alzheimer’s disease. In certain embodiments, the disease is Alzheimer’s disease, and treating and/or preventing the disease improves cognitive function. In some embodiments, the disease is Alzheimer’s disease, and treating and/or preventing the disease delays disease progression. In certain embodiments, the disease is Alzheimer’s disease, and treating and/or preventing the disease corrects issues with neurological function. In certain embodiments, the Alzheimer’s disease is early stage. In some embodiments, the Alzheimer’s disease is late stage. In certain embodiments, the Alzheimer’s disease is familial Alzheimer’s disease. In certain embodiments, the Alzheimer’s disease is early-onset Alzheimer’s disease. In certain embodiments, the Alzheimer’s disease is inflammatory, non-inflammatory, or cortical Alzheimer’s disease. In some embodiments, the Alzheimer’s disease is inflammatory Alzheimer’s disease. In certain embodiments, the Alzheimer’s disease is non-inflammatory Alzheimer’s disease. In some embodiments, the Alzheimer’s disease is cortical Alzheimer’s disease. In some embodiments, the Alzheimer’s disease is mild, moderate, or severe. In certain embodiments, the Alzheimer’s disease is mild. In some embodiments, the Alzheimer’s disease is moderate. In certain embodiments, the Alzheimer’s disease is severe. [00338] In some embodiments, the disease is Parkinson’s disease. In certain embodiments, the disease is Parkinson’s disease, and treating and/or preventing the disease improves cognitive function. In some embodiments, the disease is Parkinson’s disease, and treating and/or preventing the disease delays disease progression. In certain embodiments, the disease is Parkinson’s disease, and treating and/or preventing the disease corrects issues with neurological function. [00339] In certain embodiments, the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof, is administered orally. In some embodiments, the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof, is administered once daily. In certain embodiments, the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof, is administered orally once daily. [00340] In another aspect, provided herein is a method of transporting a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, across the blood-
147/200
brain barrier or blood-retinal barrier comprising administering to a subject the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00341] In another aspect, provided herein is a method of transporting a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, across the blood- brain barrier or blood-retinal barrier comprising administering to a subject the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00342] In another aspect, provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport across the blood-brain barrier or blood-retinal barrier comprising administering to a subject the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00343] In another aspect, provided herein is a compound of Formula (II) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport across the blood-brain barrier or blood-retinal barrier comprising administering to a subject the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00344] In certain embodiments, transport is across the blood-brain barrier. In some embodiments, transport is across the blood-retinal barrier. In some embodiments, the compound accumulates in the blood-brain barrier. In certain embodiments, the compound accumulates in the brain. In some embodiments, the compound accumulates in the blood retinal barrier. In certain embodiments, the compound accumulates in the eye. In some embodiments, transport across the blood-brain barrier or blood-retinal barrier occurs via the Mfsd2a protein. [00345] In another aspect, provided herein is a method of transporting a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal,
148/200
tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, via the Mfsd2a protein in a subject, biological sample, tissue, or cell comprising administering to the subject or contacting the biological sample, tissue, or cell with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In some embodiments, the method comprises administering to a subject the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, and Mfsd2a transports the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. In some embodiments, the method comprises contacting a cell, tissue, or biological sample with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In some embodiments, the method comprises contacting a cell or biological sample with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00346] In another aspect, provided herein is a method of transporting a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, via the Mfsd2a protein in a subject, biological sample, tissue, or cell comprising administering to the subject or contacting the biological sample, tissue, or cell with the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In some embodiments, the method comprises administering to a subject the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, and Mfsd2a transports the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. In some embodiments, the method comprises contacting a cell, tissue, or biological sample with the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In some embodiments, the method comprises contacting a cell or biological sample with the compound of Formula (II), or a
149/200
pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00347] In another aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport via the Mfsd2a protein in a subject, biological sample, tissue, or cell. In another aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport via the Mfsd2a protein comprising administering to a subject the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In another aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport via the Mfsd2a protein comprising contacting a biological sample, tissue, or cell with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00348] In another aspect, provided herein is a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport via the Mfsd2a protein in a subject, biological sample, tissue, or cell. In another aspect, provided herein is a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport via the Mfsd2a protein comprising administering to a subject the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In another aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for transport via the Mfsd2a protein comprising contacting a biological sample, tissue, or cell with the compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof.
150/200
[00349] In another aspect, provided herein is a method of increasing plasmalogen levels in a subject, biological sample, tissue, or cell, comprising administering to the subject or contacting the biological sample, tissue, or cell with a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In another aspect, provided herein is a method of increasing plasmalogen levels in the brain or central nervous system of a subject, comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00350] In another aspect, provided herein is a method of increasing plasmalogen levels in a subject, biological sample, tissue, or cell, comprising administering to the subject or contacting the biological sample, tissue, or cell with a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. In another aspect, provided herein is a method of increasing plasmalogen levels in the brain or central nervous system of a subject, comprising administering to the subject a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof. [00351] In another aspect, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in increasing plasmalogen levels in a subject, biological sample, tissue, or cell. In another aspect, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in increasing plasmalogen levels in the brain or central nervous system of a subject. [00352] In another aspect, the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in increasing plasmalogen levels in a subject, biological sample, tissue, or cell. In another aspect, the present disclosure provides a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer,
151/200
stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition thereof, for use in increasing plasmalogen levels in the brain or central nervous system of a subject. [00353] In another aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, for increasing plasmalogen levels in a subject, biological sample, tissue, or cell. In another aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, for increasing plasmalogen levels in the brain or central nervous system of a subject. [00354] In another aspect, provided herein is a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, for increasing plasmalogen levels in a subject, biological sample, tissue, or cell. In another aspect, provided herein is a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof, for increasing plasmalogen levels in the brain or central nervous system of a subject. [00355] In some embodiments, plasmalogen levels are increased in a subject. In some embodiments, the method comprises administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof to a subject. In some embodiments, the method comprises administering a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof to a subject. [00356] In some embodiments, plasmalogen levels are increased in a biological sample, tissue, or cell. In some embodiments, the method comprises contacting a biological sample, tissue, or cell with a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof to a subject. In some embodiments, the method comprises contacting a biological sample, tissue, or cell with a compound of Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer,
152/200
stereoisomer, isotopically labeled derivative, or prodrug thereof, or a composition thereof to a subject. [00357] In some embodiments, the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or the composition is transported by the Mfsd2a protein. [00358] In some embodiments, plasmalogen levels are increased in the blood, brain, central nervous system, heart, kidney, muscle, and/or liver. In some embodiments, plasmalogen levels increase in the blood, brain, central nervous system, muscle, and/or heart. In some embodiments, plasmalogen levels increase in the brain and/or central nervous system. In some embodiments, plasmalogen levels in the brain increase. In some embodiments, plasmalogen levels in the CNS increase. In some embodiments, plasmalogen levels increase in the blood. In some embodiments, plasmalogen levels increase in plasma. In some embodiments, plasmalogen levels increase in serum. In some embodiments, plasmalogen levels increase in the heart. In some embodiments, plasmalogen levels increase in the kidney. In some embodiments, plasmalogen levels increase in the muscle. In some embodiments, plasmalogen levels increase in the liver. In some embodiments, levels of one or more docosahexaenoic acid (DHA)-containing plasmalogens increase. [00359] In some embodiments, plasmalogen levels increase by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%,90%, 100%, 125%, 150%, 200%, 300%, 400%, or 500%. In some embodiments, plasmalogen levels increase by at least 5%, 10%, 15%, or 20%. In some embodiments, plasmalogen levels increase by at least 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, plasmalogen levels increase by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. In some embodiments, plasmalogen levels increase by at least 100%, 125%, 150%, or 200%. In some embodiments, plasmalogen levels increase by at least 200%, 300%, 400%, or 500%. In some embodiments, plasmalogen levels increase by about 5-25%, about 10-40%, about 25-50%, about 40-60%, about 50-75%, about 60-80%, about 75-100%, or greater than about 100%. [00360] In some embodiments, transport via the Mfsd2a protein occurs across the blood- brain barrier or blood-retinal barrier. In certain embodiments, transport via the Mfsd2a protein occurs across the blood-brain barrier. In some embodiments, transport via the Mfsd2a protein occurs across the blood-retinal barrier. In some embodiments, the compound accumulates in the blood-brain barrier. In certain embodiments, the compound accumulates in the brain. In some embodiments, the compound accumulates in the blood retinal barrier. In certain embodiments, the compound accumulates in the eye.
153/200
[00361] In certain embodiments, the method is in vivo. In some embodiments, in vivo methods provided herein comprise administering to a subject an effective amount of a compound provided herein, or a composition thereof. In certain embodiments, the subject is a mammal. In some embodiments, the subject is a human. In certain embodiments, the subject is mouse. In some embodiments, the subject is a wild type mouse. In certain embodiments, the subject is a genetically modified mouse. In some embodiments, the genetically modified mouse comprises in its genome a homozygous disruption of the Mfsd2a gene. [00362] In certain embodiments, the method is in vitro. In some embodiments, in vitro methods provided herein can be carried out, e.g., in an assay, cell culture, or biological sample. In certain embodiments, the cell comprises a human wild type Mfsd2a cDNA or mutant human Mfsd2a cDNA. In some embodiments, the cell comprises a human wild type Mfsd2a cDNA. In certain embodiments, the cell comprises a mutant human Mfsd2a cDNA. In some embodiments, the cell is HEK 293. In some embodiments, the mutant human Mfsd2a cDNA comprises a mutation at a position corresponding to D93 or D97 in the human Mfsd2a protein sequence. EXAMPLES [00363] In order that the present disclosure may be more fully understood, the following examples are set forth. The synthetic and biological examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting in their scope. Synthesis [00364] Compounds of Formula (I) may be synthesized according to the following synthetic scheme.
154/200
EQUIVALENTS AND SCOPE [00365] In the claims, articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The present disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The present disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. [00366] Furthermore, the present disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the present disclosure, or aspects of the present disclosure, is/are referred to as comprising particular elements and/or features, certain embodiments of the present disclosure or aspects of the present disclosure consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub–range within the stated ranges in different embodiments of the present disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. [00367] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made
155/200
without departing from the spirit or scope of the present disclosure, as defined in the following claims.
156/200
Claims
CLAIMS What is claimed is: 1. A compound of Formula (I):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted
, optionally substituted carbocyclylene, or optionally substituted heterocyclylene; X is selected from
and
R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl, or R5 is absent when
L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene; provided that the compound is not:
,
157/200
,
2. The compound of claim 1, wherein the compound is of Formula (I-A):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted
, optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene.
158/200
3. The compound of claim 1, wherein the compound is of Formula (I-B):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; L1 is optionally substituted , optionally substituted carbocyclylene, or optionally substituted heterocyclylene; R3 and R4 are each independently hydrogen or optionally substituted C1-6 alkyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene. 4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is optionally substituted carbocyclylene. 5. The compound of claim 4, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is selected from the group consisting of:
6. The compound of claim 4, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is optionally substituted bicyclic carbocyclylene.
159/200
7. The compound of claim 6, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is selected from the group consisting of:
8. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is optionally substituted heterocyclylene. 9. The compound of claim 8, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is selected from the group consisting of:
10. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is optionally substituted . 11. The compound of claim 10, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is unsubstituted
. 12. The compound of claim 10, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L1 is substituted .
160/200
13. The compound of claim 1, wherein the compound is of Formula (I-A-i):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein: R1 is optionally substituted C7-25 alkyl; R2 is optionally substituted
; R3, R4, and R5 are each independently hydrogen or optionally substituted C1-6 alkyl; R6, R7, R8, R9, and R10 are each independently hydrogen, halogen, or C1-6 alkyl, or R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl, or R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl; and L2 is optionally substituted C1-10 alkylene or optionally substituted carbocyclylene; provided that at least one of R6, R7, R8, R9, and R10 is not hydrogen. 14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is optionally substituted C12-20 alkyl. 15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is unsubstituted C12-20 alkyl. 16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is selected from the group consisting of:
.
161/200
17. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is C12-20 haloalkyl. 18. The compound of claim 17, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is C12-20 fluoroalkyl. 19. The compound of claim 18, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is selected from the group consisting of:
. 20. The compound of claim 18, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is selected from the group consisting of:
. 21. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is substituted with at least one deuterium.
162/200
22. The compound of claim 21, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is selected from the group consisting of:
. 23. The compound of claim 21, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1 is selected from the group consisting of:
. 24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2 is unsubstituted
. 25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2 is
substituted with at least one fluorine.
163/200
26. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2 is
substituted with at least one deuterium. 27. The compound of claim 26, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2 is selected from the group consisting of:
. 28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R3 and R4 are each hydrogen. 29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R5 is hydrogen. 30. The compound of any one of claims 1-27 or 29, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein at least one of R3 and R4 is optionally substituted C1-6 alkyl. 31. The compound of claim 30, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R3 is hydrogen, and R4 is optionally substituted C1-6 alkyl. 32. The compound of claim 30, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R3 and R4 are each independently optionally substituted C1-6 alkyl.
164/200
33. The compound of claim 32, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R3 and R4 are each methyl. 34. The compound of claim 30, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein at least one of R3 and R4 is C1-6 fluoroalkyl. 35. The compound of claim 34, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein at least one of R3 and R4 is -CH2F, -CHF2, or -CF3. 36. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R3 and R4 are joined together with the intervening atoms to form optionally substituted heterocyclyl. 37. The compound of any one of claims 1-28 or 30-36, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R5 is optionally substituted C1-6 alkyl. 38. The compound of claim 37, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R5 is methyl. 39. The compound of claim 37, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R5 is C1-6 fluoroalkyl. 40. The compound of claim 39, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R5 is -CH2F, -CHF2, or -CF3.
165/200
41. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled
. 42. The compound of any one of claims 13-41, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein at least two of R6, R7, R8, R9, and R10 are not hydrogen. 43. The compound of any one of claims 13-42, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R6 and R7 are each methyl. 44. The compound of any one of claims 13-41, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R6 and R7 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. 45. The compound of claim 44, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R6 and R7 are joined together with the intervening carbon atom to form an unsubstituted carbocyclyl. 46. The compound of claim 45, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R6 and R7 are joined together with the intervening carbon atom to form an unsubstituted cyclopropyl or unsubstituted cyclobutyl.
166/200
47. The compound of any one of claims 13-46, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R8, R9, and R10 are each hydrogen. 48. The compound of any one of claims 13-46, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R9 and R10 are joined together with the intervening carbon atom to form an optionally substituted carbocyclyl. 49. The compound of claim 48, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R9 and R10 are joined together with the intervening carbon atom to form an unsubstituted carbocyclyl. 50. The compound of claim 49, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R9 and R10 are joined together with the intervening carbon atom to form an unsubstituted cyclopropyl or an unsubstituted cyclobutyl. 51. The compound of any one of claims 42 or 48-50, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R6, R7, and R8 are each hydrogen. 52. The compound of any one of claims 13-51, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein at least one of R6, R7, R8, R9, and R10 is halogen. 53. The compound of claim 52, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein one of R6, R7, R8, R9, and R10 is fluorine; and the others are hydrogen.
167/200
54. The compound of claim 53, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R6 is fluorine, and R7, R8, R9, and R10 are hydrogen. 55. The compound of claim 53, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R8 is fluorine, and R6, R7, R9, and R10 are hydrogen. 56. The compound of claim 53, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R10 is fluorine, and R6, R7, R8, and R9 are hydrogen. 57. The compound of any one of claims 13-42, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R6 and R9 are joined together with the intervening carbon atoms to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl. 58. The compound of any one of claims 1-57, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L2 is optionally substituted C1-6 alkylene. 59. The compound of claim 58, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L2 is optionally substituted ethylene, propylene, or butylene. 60. The compound of claim 59, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L2 is selected from the group consisting of:
168/200
61. The compound of claim 58 or 59, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L2 is substituted with fluorine. 62. The compound of claim 61, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L2 is selected from the group consisting of:
63. The compound of any one of claims 1-57, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L2 comprises optionally substituted carbocyclylene. 64. The compound of claim 63, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein L2 is selected from the group consisting of: , ,
,
169/200
170/200
171/200
172/200
173/200
, , , , , ,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof.
174/200
175/200
176/200
177/200
178/200
179/200
180/200
181/200
182/200
, , , , ,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof. ,
,
183/200
184/200
185/200
186/200
69. The compound of claim 1, wherein the compound is: ,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof. 70. The compound of claim 1, wherein the compound is: ,
, or a pharmaceutically acceptable salt thereof. 71. A compound of Formula (II):
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein: R1' is optionally substituted C7-25 alkyl; R2' is optionally substituted C7-25 alkenyl; R3' and R4' are each independently hydrogen or optionally substituted C1-6 alkyl;
187/200
n is 0, 1, 2, or 3; * designates a point of attachment at one of positions X, Y, and Z; and the other two of positions X, Y, and Z are each independently hydrogen, halogen, or C1-6 alkyl. 72. The compound of claim 71, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is optionally substituted C12-20 alkyl. 73. The compound of claim 71 or 72, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is unsubstituted C12-20 alkyl. 74. The compound of any one of claims 71-73, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is selected from the group consisting of:
. 75. The compound of claim 71 or 72, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is C12-20 haloalkyl. 76. The compound of claim 75, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is C12-20 fluoroalkyl. 77. The compound of claim 76, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is selected from the group consisting of:
188/200
. 78. The compound of claim 76, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is selected from the group consisting of:
. 79. The compound of 71 or 72, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is substituted with at least one deuterium. 80. The compound of claim 79, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is selected from the group consisting of:
. 81. The compound of claim 79, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R1' is selected from the group consisting of:
189/200
. 82. The compound of any one of claims 71-81, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2' is optionally substituted
. 83. The compound of any one of claims 71-82, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2' is unsubstituted
. 84. The compound of any one of claims 71-82, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2' is
substituted with at least one fluorine. 85. The compound of any one of claims 71-82, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2' is
. 86. The compound of claim 85, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R2' is selected from the group consisting of:
.
190/200
87. The compound of any one of claims 71-86, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R3' and R4' are each independently optionally substituted C1-6 alkyl. 88. The compound of claim 87, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein R3' and R4' are methyl. 89. The compound of any one of claims 71-88, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein two of positions X, Y, and Z are hydrogen. 90. The compound of any one of claims 71-89, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein * designates a point of attachment at position X; and Y and Z are hydrogen. 91. The compound of any one of claims 71-89, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein * designates a point of attachment at position Y; and X and Z are hydrogen. 92. The compound of any one of claims 71-89, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein * designates a point of attachment at position Z; and X and Y are hydrogen. 93. The compound of any one of claims 71-92, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein n is 0 or 1.
191/200
94. The compound of claim 93, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein n is 0. 95. The compound of claim 93, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, wherein n is 1. 96. The compound of claim 71, wherein the compound is: , , ,
,
192/200
,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof. 97. The compound of claim 79, wherein the compound is: , ,
,
193/200
, ,
, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof. 98. The compound of any one of claims 1-97, or a pharmaceutically acceptable salt thereof. 99. A composition comprising a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, and a pharmaceutically acceptable excipient. 100. A composition comprising a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, and a pharmaceutically acceptable excipient.
194/200
101. The composition of claim 99 or 100, wherein the composition is a pharmaceutical composition. 102. The composition of claim 99 or 100, wherein the composition is a nutraceutical composition. 103. The composition of any one of claims 99-102, wherein the composition is formulated for oral administration. 104. The composition of claim 103, wherein the composition is a soft gel capsule. 105. A method of treating or preventing a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 99. 106. A method of treating or preventing a disease, disorder, or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 100. 107. The method of claim 105 or 106, wherein the disease, disorder, or condition is a liver disease, a neurological disease, an ophthalmic disease, a metabolic disorder, a mitochondrial disease, a cardiovascular disease, an infectious disease, a pulmonary disease, a skin disease, a genetic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a hematological disease, a painful condition, a psychiatric disorder, an immune disorder, or a spleen disease. 108. The method of any one of claims 105-107, wherein the disease is a neurological disease.
195/200
109. The method of claim 108, wherein the neurological disease is a neurodegenerative disease. 110. The method of claim 109, wherein the neurodegenerative disease is dementia. 111. The method of claim 109, wherein the neurodegenerative disease is mild cognitive impairment, Creutzfeldt-Jakob disease, dementia with Lewy bodies, vascular dementia, mixed dementia, young-onset dementia, alcohol-related dementia, HIV-associated neurocognitive disorder, frontotemporal lobar dementia, Alzheimer’s disease, or Parkinson’s disease. 112. The method of any one of claims 109-111, wherein the neurodegenerative disease is Alzheimer’s disease. 113. The method of claim 109 or 111, wherein the neurodegenerative disease is Parkinson’s disease. 114. The method of any one of claims 105-113, wherein the method prevents disease progression. 115. The method of any one of claims 105-114, wherein the method improves cognitive function. 116. The method of any one of claims 105-107, wherein the disease is a pulmonary disease. 117. The method of claim 116, wherein the pulmonary disease is respiratory distress syndrome, neonatal respiratory distress syndrome (NRDS), infant respiratory distress syndrome (IRDS), hyaline membrane disease, surfactant deficiency, surfactant protein-B deficiency, or bronchopulmonary dysplasia. 118. The method of claim 117, wherein the pulmonary disease is NRDS. 119. The method of any one of claims 105-107, wherein the disease is a genetic disease.
196/200
120. The method of claim 119, wherein the genetic disease is Zellweger syndrome. 121. The method of any one of claims 105-107, wherein the disease is a peroxisomal disorder. 122. Use of a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 99, in the manufacture of a medicament for treating or preventing a disease, disorder, or condition in a subject. 123. Use of a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 100, in the manufacture of a medicament for treating or preventing a disease, disorder, or condition in a subject. 124. A compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 99, for use in treating or preventing a disease, disorder, or condition in a subject. 125. A compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 100, for use in treating or preventing a disease, disorder, or condition in a subject. 126. A method of transporting a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, via the Mfsd2a protein, comprising administering to a subject a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 99.
197/200
127. A method of transporting a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, via the Mfsd2a protein, comprising administering to a subject a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 100. 128. A method of transporting a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, via the Mfsd2a protein, comprising contacting a cell, tissue, or biological sample with a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 99. 129. A method of transporting a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, via the Mfsd2a protein, comprising contacting a cell, tissue, or biological sample with a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 100. 130. A method of increasing plasmalogen levels in the brain or central nervous system of a subject, comprising administering to the subject a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 99. 131. A method of increasing plasmalogen levels in the brain or central nervous system of a subject, comprising administering to the subject a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer,
198/200
stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 100. 132. The method of claim 129 or 130, wherein the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or the composition is transported by the Mfsd2a protein. 133. The method of any one of claims 130-132, wherein the method increases plasmalogen levels in the brain. 134. The method of any one of claims 130-133, wherein the method increases plasmalogen levels in the central nervous system. 135. A kit comprising: a compound of any one of claims 1-70, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 99; and instructions for using the compound, or pharmaceutically acceptable salt, tautomer, or isotopically labeled derivative thereof, or composition. 136. A kit comprising: a compound of any one of claims 71-97, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labelled compound, or prodrug thereof, or a composition of claim 100; and instructions for using the compound, or pharmaceutically acceptable salt, tautomer, or isotopically labeled derivative thereof, or composition.
199/200
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163212034P | 2021-06-17 | 2021-06-17 | |
US63/212,034 | 2021-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022263927A2 true WO2022263927A2 (en) | 2022-12-22 |
WO2022263927A3 WO2022263927A3 (en) | 2023-03-23 |
Family
ID=82748498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/000336 WO2022263927A2 (en) | 2021-06-17 | 2022-06-16 | Plasmalogen derivatives and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022263927A2 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322531A3 (en) * | 2006-02-28 | 2011-09-07 | Phenomenome Discoveries Inc. | Methods for the diagnosis of dementia and other neurological disorders |
AU2012321073B2 (en) * | 2011-11-17 | 2015-02-26 | Med-Life Discoveries Lp | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof |
US9006472B2 (en) * | 2011-11-17 | 2015-04-14 | Phenomenome Discoveries Inc. | Methods for the synthesis of 13C labeled plasmalogen |
-
2022
- 2022-06-16 WO PCT/IB2022/000336 patent/WO2022263927A2/en active Application Filing
Non-Patent Citations (12)
Title |
---|
"Diagnostic and Statistical Manual of Mental Disorders", AMERICAN PSYCHIATRIC ASSOCIATION |
BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 |
BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24 |
CARRUTHERS: "Some Modern Methods of Organic Synthesis", 1987, CAMBRIDGE UNIVERSITY PRESS |
ELIEL, E.L.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL |
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE |
MICHAEL B. SMITH: "March's Advanced Organic Chemistry", 2013, JOHN WILEY & SONS, INC. |
RICHARD C. LAROCK: "Comprehensive Organic Transformations", 2018, JOHN WILEY & SONS, INC. |
T. W. GREENEP. G. M. WUTS: "Protecting Groups in Organic Synthesis", 1999, UNIVERSITY SCIENCE BOOKS |
WALKER: "Cambridge Dictionary of Biology", 1990, CAMBRIDGE UNIVERSITY PRESS |
WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725 |
WILEN, S.H.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268 |
Also Published As
Publication number | Publication date |
---|---|
WO2022263927A3 (en) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7472026B2 (en) | Small molecules for inducing selective protein degradation and methods of use thereof - Patents.com | |
US10975055B2 (en) | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | |
AU2017252460B2 (en) | EZH2 inhibitors and uses thereof | |
US10765651B2 (en) | Co-crystals of substituted glycine and uses thereof | |
US11731928B2 (en) | Co-crystals of sodium benzoate and uses thereof | |
US11739046B2 (en) | Co-crystals of lithium benzoate and uses thereof | |
US20220395509A1 (en) | A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases | |
WO2017127528A1 (en) | Peptoid agonists of fibroblast growth receptors | |
US20230117680A1 (en) | Cyclophilin d inhibitors and uses thereof | |
WO2022263927A2 (en) | Plasmalogen derivatives and uses thereof | |
US11793823B2 (en) | Compounds and pharmaceutical uses thereof | |
EP4110773A1 (en) | Map kinase kinase (mkk7) inhibitors and uses thereof | |
WO2024077023A2 (en) | Cereblon-recruiting bcl-xl/bcl-2 dual degraders | |
US11130764B2 (en) | Analogs of vincamine and uses thereof | |
US20210069082A1 (en) | Spiroketals and uses thereof | |
US20200062776A1 (en) | Hedgehog acyltransferase inhibitors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22748422 Country of ref document: EP Kind code of ref document: A2 |